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SUM M ARY
An estimation of the average value of pharmacokinetic parameters in a 
group of animals provides limited information if there is no good measure of the 
variability of each of the parameters. The traditional approach used in the analysis 
of animal pharmacokinetic data obtained from studies involving the use of small 
laboratory animals (rats or mice) in which each animal supplies only one concen­
tration - time point does not provide this, nor can it assess the influence of physi­
ology (or pathology) on pharmacokinetics. The consideration of variability within 
the same species during interspecies scaling has been advocated (Vocci & Farber, 
1988). Thus, provision should be made for the estimation of variability inherent 
in an animal population in analysing data obtained by "destructive sampling". The 
NONMEM approach does, however, provide estimates of both average values of 
pharmacokinetic parameters and their statistical distribution within the popula­
tion. In this thesis data were generated by simulation (assuming no covariance), 
and analysed using the NONMEM program. The efficiency of this approach is 
the focus of this thesis.
Experimental error, number of samples taken, and the arrangement of 
samples in time are factors which must be taken into account in designing 
experiments for efficient parameter estimation. In addition, appropriate methods 
of data analysis must be used to extract the required information from the data. 
Simulated data sets were used to investigate the effect of various design features 
on the efficiency of parameter estimation using the one observation per animal 
design. In addition, the efficiency with which parameters could be estimated 
given a range of parameter values and variability was investigated.
Several methods were used to determine the efficiency of parameter 
estimation. Prediction error (bias and precision) was useful in assessing the 
efficiency with which individual parameters were estimated. In addition, the 99% 
individual and joint confidence intervals containing the true parameter 95% of the
2
time for all parameters were introduced as aids to judging the efficiency of 
estimation of individual and all parameters of a model, considered as a set. 
Confidence interval tables were constructed to reveal the influence of bias and 
standard error on parameter estimation.
Also, the design number, a new statistic which combines the contributions 
of bias and precision in judging the efficiency of parameter estimation, was 
introduced to complement bias and precision, and confidence intervals methods 
of analysis. The design number also allowed the efficiency with which all param­
eters of a model were estimated as a set to be judged. The incidence of high pair­
wise correlations of parameter estimates was also taken into account in assessing 
the acceptability of estimates and the adequacy of model parameterization.
Assuming IV bolus injection with the monoexponential pharmacokinetic 
model, simulation studies were carried out to investigate the influence of inter­
animal variability on the estimation of population pharmacokinetic parameters 
and their variances. The range of variability investigated was similar to that 
expected in real studies, and sampling was done at set times. The efficiency of 
estimation of the structural model parameters (Cl and V) was good, on average, 
irrespective of the variability in Cl and V. However, the estimation of these 
parameters was associated with negative bias which was attributed to the nature 
of the NONMEM program (i.e. estimation error since negative bias was also 
observed in subsequent studies in which a£ was set to 0%). The variance 
parameters were mostly inefficiently estimated in this study and all other studies 
using the one observation per animal design. This was attributable to the lack of 
information in the data set about a£ .
When the effect of the arrangem ent of concentrations in time on 
parameter estimation was studied with the two sample point design, efficient 
parameter estimates were obtained when the first sample was obtained as early as
3
possible (5 min.) and the second sample was located at £ 1.4 times the simulated 
H jl min-) of the drug. When three or four sample points were used the exact 
location of the third or fourth sample was not critical to efficient parameter 
estimation.
The efficiency of parameter estimation was investigated given a range of 
parameter values, concentration measurement error, and sampling schedules with 
the two compartment model parameterized as A, a , B, p and assuming IV bolus 
injection with animals sampled at set times. The parameters, considered as a set, 
were efficiently estimated when a  was in the range of 2.0 to 4.0 h” and the A:B 
ratio in the range of 2.5 to 30.0. These results were attributed to the distribution 
of data points between the distribution and elimination phases of the plasma 
concentration - time profile. Concentration measurement error greater than 10% 
yielded variance param eter estim ates with a greater degree of bias and 
imprecision. The inter-animal variability in parameters estimated was a composite 
of inter- and intra-animal variability. Some sampling schedules gave rise to more 
efficient parameter estimates than others. High correlation between some 
parameters led to instability in the estimates, and reparameterization of the model 
in terms of Cl, V j, and &21 t0 more stable estimates.
The need for keeping the number of animals used in any study to a 
minimum, and the necessity for efficient parameter estimation led to the 
investigation of the effect of sample size on parameter estimation. With the 
monoexponential model (assuming IV bolus injection with one observation per 
animal) and sampling at ten time points, it was found that parameters of the 
model were estimated with equal efficiency when 6 to 15 animals were sampled 
per time. Since there was no loss in efficiency when 6 animals are sampled per 
time (i.e., a sample size of 60), the cost involved in such studies could be greatly 
reduced. However, similar results could be obtained with at least 30 animals 
sampled twice with the same traditional sampling strategy. Sampling an animal at
4
least twice allows the partitioning of inter- and intra-animal variability, almost 
eliminating bias in the estimation of the variance parameters.
Using the two compartment model, efficient parameter estimates were 
obtained when 15 observations were made at each of 10 time points (i.e., a 
sample size of 150), but there was no loss in efficiency when 10 animals were 
used at each time point. The use of the numbers of animals with the design 
specifications considered in this thesis would strike a good balance between cost 
and good science.
Given the results of the simulation studies, NONMEM was used to 
analyse data with the one observation per animal design for a drug under 
development. NONMEM permitted some explanation of variability in terms of 
sex, but efficient partitioning between inter- and intra-animal variability would 
have required an increase in the number of samples per animal.
Thus, inefficient estimates of inter-animal variability were obtained with 
the one observation per animal design, but sampling an animal at least twice 
significantly improved the efficiency of parameter estimation. The structural 
model parameters, on the other hand, were efficiently estimated. The individual 
and joint confidence intervals for parameter estimates, design number, incidence 
of high pair-wise correlations in addition to bias and precision were useful in 
judging the efficiency of parameter estimation.
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CHAPTER 1
INTRODUCTION
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1.1 SUMMARY
This chapter contains an overview of pharmacokinetics in drug research 
and development in the preclinical setting. The importance of pharmacokinetics 
in toxicity testing and drug safety evaluation is discussed , and the various 
methods used in the estimation of population pharmacokinetic parameters in the 
preclinical animal setting are examined. Variability has been reported to occur, 
even in homogeneous strains of animals, and the need to account for this in the 
estimation of population pharmacokinetic parameters is stressed. The need for the 
appropriate design of pharmacokinetic experiments for the efficient estimation of 
population pharmacokinetic parameters is highlighted.
1.2 INTRODUCTION
Preclinical testing of new xenobiotics in animals to predict their safety and 
efficacy in man is a very large industry. It has reached its present level of activity 
because of the growth in the number of compounds which have to be tested, the 
expansion of testing requirements which has occurred over the past few years, 
and the increase in data required from any one study. The fact that thousands of 
animals are used can only be justified if it ensures that life is made safer for 
humans who are subsequently exposed to these xenobiotics. However, if the 
testing explosion is to be controlled and the effort worthwhile, then urgent 
attention must be given to increase its scientific content.
The main purpose for conducting extensive animal studies is to help in 
predicting what will happen when xenobiotics are given to humans. These studies
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encom pass tox ic ity , efficacy , m etabolism , pharm acokinetics and 
biopharmaceutics, and are done to accumulate information in the preclinical 
phase of drug development.
The 1964 Helsinki Declaration which was revised in 1975 states that 
sufficient well conducted and controlled animal studies should be performed prior 
to undertaking human studies, and that positive data are essential before 
subjecting humans to a drug (or procedure). In accordance with this, international 
regulatory authorities demand a dossier containing considerable amounts of data 
from animals before they will authorise the administration of new xenobiotics to 
man.
Many of the techniques and procedures used in conventional animal 
toxicity testing are empirically based. For example, the proper relationship 
between the duration of toxicity tests and the length of permitted treatment is a 
matter of opinion. Similarly, the selection of dose levels in toxicity tests often 
appears to be arbitrary. On the other hand, there are disquietening voices which 
even question the validity of animal testing to predict safety for man (Rowan & 
Andrutis, 1990).
Given the Helsinki Declaration, however, there is no doubt that new 
xenobiotics cannot be administered to man until sufficient evidence has been 
collected to indicate that there is no obvious risk. For example, understanding the 
pharmacodynamics of a new drug is very important, particularly from the point of 
view of anticipating the effects of overdosage. In the particular case of a new 
opiate analgesic, it would be vital to know whether or not any potential 
respiratory depressant effect could be reversed by an opiate antagonist such as 
naloxone. The development of new medicines and the use of animals in 
preclinical drug evaluation is therefore inextricably linked.
1.3 PHARMACOKINETICS IN DRUG RESEARCH AND 
DEVELOPMENT
Pharmacokinetics is an applied scientific discipline that achieves its 
greatest potential when considered during the early stages of drug development. It 
encompasses the relationships between the physicochemical properties of a drug 
and both its physiological disposition by the organism and its pharmacological 
response (Kaplan & Jack, 1980). The value of pharmacokinetic studies during 
early stages of drug research and development is to enable critical decisions to be 
made as to which form of active compound should be recommended for the time 
- consuming and costly animal toxicology, formulation design, and clinical 
studies.
1.3.1 Structure - Pharmacokinetic Relationship and Drug Design
The search for new drug molecules basically involves two steps: the 
setting up of a working hypothesis and the screening of molecules resulting from 
application of the hypothesis. A working hypothesis may be formulated in 
different ways (Balant, Roseboom, & Gundert-Remy, 1990):
(a) It may be postulated that the systematic synthesis of compounds 
differing progressively in their chemical structure and physicochemical 
properties will eventually lead to the discovery of novel and useful drugs.
(b) One may also start from known drugs and optimise their 
pharmacological properties by relying on receptor - binding studies.
(c) A more basic approach consists in the study of physiological
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mechanisms and structure - activity analysis of specific enzyme activators 
or inhibitors.
Inherent in all of these hypotheses is the application of quantitative structure - 
pharmacokinetics relationships. Many an in vivo quantitative structure - activity 
relationship (QSAR) study of a series of compounds has related the dose required 
to produce a defined response, such as the dose required to produce 50% of 
m axim al response ( E D ^ q ) at some p redeterm ined  tim e, to m olecular 
modification. But these dose - effect relationships encompass not only the 
structure - effect relationship but also that between the dose administered and the 
unbound concentration of compound at the receptor sites which produces the 
pharmacologic response. Thus, pharmacokinetic events (the processes of and 
kinetics of absorption, distribution and elimination) determine the concentration 
of drug at receptor sites. Any movement from an empirical to a more rational 
design of drug molecules intended to be used in vivo, therefore, requires the 
application of pharmacokinetic principles (Tozer, 1981; Rowland, 1983).
The knowledge of pharmacokinetic parameters is essential for the 
calculation of effective doses, dosing intervals, estimation of bioavailability and 
correlation to pharmacodynamic effects. Pharmacokinetic parameters are, 
however, also an extremely valuable tool with which to derive quantitative 
structure - pharmacokinetic relationships. Variation in different pharmacokinetic 
parameters is explained mainly by lipophilicity, ionisation (pKa) and in some 
cases also by steric influences of substituents within various classes of drugs 
(Seydel, 1983). At least five pharmacokinetic consequences can be expected as a 
result of structural changes. These are: rate and order of absorption, volume of 
distribution, rate and type of metabolism, affinity constant for binding to serum 
proteins and other "unspecific" biopolymeric binding sites, and rate and type of 
elimination (clearance) (Seydel, 1983). Many examples of QSAR analysis used to 
describe variation in rate of absorption have been published (Seydel & Schaper,
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1979; Lien, 1981; Schaper, 1982) showing in most cases nonlinear dependence on 
lipophilicity and on pKa.
Protein binding per se generally does influence many pharmacokinetic 
characteristics of a drug. This influence may be a positive or negative one, 
depending on the drug class and upon the pharmacokinetic process under 
investigation. For example the blood compartment (if one considers the body to 
be made of compartments and blood as one of them) is responsible for drug 
transport and distribution. Although serum protein binding increases the capacity 
of the blood compartment, at the same time it decreases the free unbound fraction 
which can diffuse to receptor sites. Protein binding and also partitioning in red 
blood cells can therefore influence the therapeutic dose, volume of distribution, 
rate and type of metabolism, rate and type of excretion (only unbound drug is 
glomerularly filtered), and serum protein binding of other drugs administered 
simultaneously (capacity limitation, competition). Therefore, knowledge about 
quantitative relationships between structure and "non-specific" binding is impor­
tant in drug design. It is essential not only for understanding, but also for plan­
ning changes in pharmacokinetics. This is because of the restrictive influence of 
protein binding on capillary transport, glomerular filtration and membrane trans­
port (Seydel, 1983).
Volume of distribution has been shown to be dependent on lipophilicity, 
degree of ionisation of drug molecules, and the degree of binding to serum and 
tissue constituents in a series of p - blockers (Ritschel, 1980). Elimination rate 
constant and clearance are not only very important pharmacokinetic parameters 
but, as they can be accurately and precisely determined are very valuable for 
QSAR analysis and drug design. The predictive power of such analysis is 
considerable. This has been demonstrated with a series of sulphapyridines (highly 
protein bound drugs) given to rats intravenously (Seydel et al., 1980). A high
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correlation between clearance and protein - binding constant (i.e. BmQV) was
111 CIA
demonstrated.
Another aspect of QSAR analysis in pharmacokinetics is interspecies 
scaling. This would be useful for a better transform ation of results from 
experimental animal species to humans and for appropriate selection of animal 
species for screening. In comparing QSARs for clearance of sulphonamides in 
rats, goats and humans it was found that the regression coefficients from models 
relating elimination rate constant to high performance liquid chromatography 
(HPLC) retention index (a function of the structure of a compound) were surpris­
ingly similar, only the intercepts were different, indicating differences in the 
capacity of the clearing organ, but no significant differences in dependence on 
lipophilicity (Seydel et al., 1980). Thus QSAR analysis coupled with well 
designed pharmacokinetic studies can be used for a more rational drug design.
1.3.2 Pharmacokinetics in Toxicity Testing
Over the years a great deal of work has been performed on the kinetics of 
drug absorption, metabolism, and excretion. These studies have led to the 
development of a number of general pharmacokinetic principles and to an 
appreciation of the central role played by kinetic relationships in pharmacological 
responses (Levy, 1964; Levy & Nelson, 1965; Levy, 1966; Wagner, 1968; 
Gibaldi & Perrier, 1975). The application of these principles in the assessment of 
pharmacological activity in animals in the drug development process , and in the 
optimisation of therapy in man is becoming increasingly common. In contrast, 
much less use seems to have been made of pharmacokinetic principles in the 
design and interpretation of toxicological tests (Jollow et al., 1982).
Preclinical animal pharmacokinetic and metabolic studies are essential to 
a better understanding of the subsequent clinical pharmacology and toxicology of
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new drugs. Acute and sub-chronic animal studies are designed to determine the 
safety  of a new drug com pound by charac teris ing  its d isposition  and 
physiological effects, both therapeutic and toxic. Specifically of interest are the 
dose range over which the pharmacologically desired effect occurs, the dose level 
at which toxic effects are induced, the scope of toxic effects from gross physical 
changes (dehydration, lassitude) to biochemical and physiological effects (renal 
dam age, enzym e changes), and the e ffect o f a m ultip le  dose regim en 
(accumulation, enzyme induction). Correct design and interpretation of animal 
toxicity experiments is necessary to ensure that human trials will be safely 
conducted. Determination of pharmacokinetic parameters, such as rates of 
absorption and elimination, bioavailability, maximal blood concentration (Cmax), 
time to Cmax (tmax), area under the concentration - time curve (AUC), renal, 
metabolic and / or total body clearance, provides a quantitative description of a 
drug’s disposition profile and can be used to compare profiles across species. 
Pharmacokinetic data from single exposures can be used to help determine 
appropriate dosing regimens for sub-chronic and chronic studies. Correlating 
observed toxicity with appropriate pharmacokinetic parameters may allow the 
investigator to interpret toxicity test data more accurately and even predict at 
what dose toxicity should occur and help in the understanding of the mechanism 
responsible for the effect (Scheuplein, Shoaf, & Brown, 1990).
The complicated and widely varying pharmacokinetics of a drug (in 
animal) may seriously impinge on the very promising properties of a new 
derivative. If there is a choice between different compounds, selection for further 
development is based on both the pharmacokinetic profile (bioavailability, 
half-life, clearance, volume of distribution), and the metabolic profile. Indeed, the 
role of metabolism in the evaluation of safety of new drugs is of great impor­
tance. Understanding the metabolic profile of a new drug in several animal
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species can be of predictive value to the clinical pharmacologist, helping him to 
understand the potential pharmacological effects of a xenobiotic in man. Compar­
ative metabolic and kinetic studies in different species may provide an insight 
into mechanisms of toxicity perhaps due to over-exposure within a particular 
species or because of the formation of toxic or reactive products. This provides a 
basis for a species dependent metabolic effect, and its relevance for the human 
situation can then be assessed more readily. Accurate and precise determination 
of pharmacokinetic parameters and better characterisation of drug disposition 
may allow the investigator to design safer human studies. In Phase I studies, 
results from animal studies may be used to adjust the intervals between dose 
levels in dose escalation studies (Collins, 1987). For example, if the ratio between 
pharmacologically active and toxic doses is small or there is an abrupt increase in 
the dose response curve in animals, then the initial dose escalation studies in 
humans should use smaller increases between doses. Tracer pharmacokinetic 
studies in a number of animal species yield information about the tissue distribu­
tion of the drug, and this is of predictive value in Phase I clinical studies (Colburn 
& Matthews, 1979; Hammer & Bozler, 1977).
1.3.3 Commonly Used Animals in Preclinical Drug Evaluation
It would be desirable if animals used for toxicity testing were selected so 
that they were sim ilar to humans in both their in trinsic sensitiv ity  and 
pharmacokinetic handling of the test compound. However, more often than not, 
the selection of an animal model is based on considerations of cost, size and 
availability of the animal, housing requirements and lifespan. In the absence of 
pharmacokinetic and metabolism data, animal selection has tended toward the use 
of animal test species that are most sensitive and / or for which there is an
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availability of historical controls (Hill, 1987; Huff et al., 1988).
Only four anim al species are com m only used and accepted for 
pharmacokinetic, metabolic, and long - term toxicological studies, namely mouse, 
rat, dog, and monkey. From a review of the literature it has been observed that rat 
and mouse are the animal species most commonly used in toxicological studies 
with the dog a distant second while the monkey is used least. This is a reverse of 
the order of metabolic similarities of these animals to man (Smith & Caldwell, 
1977). Pharmacokinetics is a tool that can be used to further our understanding of 
the biology of laboratory animals and improve our interpretation of toxicity data.
1.3.4 Role of Metabolic and Pharmacokinetic Studies in Preclinical Drug 
Evaluation
Metabolic and pharmacokinetic studies are essential for gaining an insight 
into the behaviour of a new drug and as an adjunct to preclinical (and clinical) 
safety studies. The main objectives of such studies are (Annex IV ,1983; 
Chasseaud, 1988; Smith, 1988; Tse, 1988):
(a) the assessment of drug and metabolite(s) concentrations and kinetics in 
blood, body fluids and organs;
(b) the gathering of information on the relationship between target organ 
toxicity and blood, or body fluids or organ concentrations;
(c) the assessment of possible enzyme induction and drug accumulation 
upon repeated administration;
(d) the choice, when feasible, of the animal species to be used in 
toxicological studies on the basis of their similarity to man in the handling 
of the drug. This determines, in part, the human relevance of these studies.
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(e) the development of appropriate dosage schemes to be used in Phase I 
clinical studies.
(f) determination of the relationship between the age and sex of the 
animal and the kinetics of the test drug;
(g) support for the pharmacology of the drug;
(h) screening of new dosage forms and formulations.
A major objective of animal metabolic studies - bearing in mind human metabolic 
studies - is the assessment of the validity of the animal model in qualitative, 
quantitative and kinetic terms. Ideally, the qualitative pattern of metabolism of the 
test drug in animal species should resemble that occurring in man so that both 
species are broadly exposed to a similar array of metabolites.
The prediction of species differences in the qualitative pattern of 
metabolism of drugs is far from being an exact science, and the best that can be 
achieved at present is described as a "forecast". Indeed, by taking into account 
chemical structure, metabolic pathways, species patterns and deficiencies it is 
often possible to arrive at a quite reasonable forecast as to what would be 
anticipated in terms of metabolic pattern in humans (Smith, 1988).
Most helpful in this predictive context is the knowledge that has been 
acquired concerning species defects with respect to particular metabolic pathways 
and certain substrates. Also of value is the recognition that, occasionally, species 
may exhibit uncommon reactions, particularly unusual conjugation reactions. 
Their occurrence is relatively unpredictable and arises from a particular 
combination of species and substrates.
Potential confounding factors such as dose and duration of exposure 
which may alter metabolic patterns have to be taken into account in the 
interpretation of animal metabolic studies. Dose size is particularly important as it 
is now known that high dose exposure may saturate detoxification pathways and 
result in an alternative pathway of metabolism or "metabolic switching". This can
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result in the formation of a different array of metabolites, or at least in a change in 
the relative proportions of metabolites compared with that seen in low dose 
exposure conditions (Zangouras et a l , 1981; Sangster et a l , 1983; Sutton et a l , 
1985).
Moreover, the interpretation of long - term toxicity studies is hampered by 
lack of pharmacokinetic data. The need for detailed pharmacokinetic studies to 
aid in the design and interpretation of toxicity tests has been emphasised (Mellet, 
1969; Clark & Smith, 1984; Jollow et a l,  1982). Pharmacokinetic data should 
usually be developed in correlation with acute and sub-chronic testing of a xeno- 
biotic before the initiation of chronic studies. Evidence of possible absorption 
problems, unusual toxic dose relationships, or notable species differences in the 
early toxicity studies suggest that additional pharmacokinetic experiments are 
useful in developing protocols for further short - or long - term toxicity studies 
(Glocklin, 1982). Questions which arise from effects observed from a particular 
xenobiotic during sub-chronic or chronic toxicity studies may warrant additional 
pharm acokinetic  studies and / or re trospective  reassessm ent of 
pharmacokinetic/toxicology correlates. This might, for example, include compre­
hensive characterisation of metabolite identity and reactivity (Glocklin, 1982; 
Levy, Galinsky, & Lin, 1982). Hottendorf et al (1976) have pointed out the 
inadequacy of safety extrapolations based upon the daily dose and suggested that 
comparative peak blood levels, AUCs, duration of dosing, clearance, were of 
equal or greater importance. Pharmacokinetic and metabolic data are therefore 
important in virtually every aspect of drug safety evaluation.
Most toxicological studies are conducted according to standard guidelines, 
and no effort is made to optimise experimental protocols on the basis of sound 
pharmacokinetic and metabolic knowledge (Zbinden, 1984). Some pitfalls of 
traditional toxicity testing methods (Rentsch, 1974) are as follows:
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(a) The methods are qualitative and empirical.
(b) Complete absorption is assumed in data interpretation.
(c) Animals are assumed to handle high and low doses of drug similarly.
(d) Dosing conditions are different from those intended to be used 
clinically.
(e) Differences among species are usually ignored.
(f) A test compound is usually abandoned when an unusual toxicity is 
observed, without attempts to understand the fundamental reasons for 
toxicity.
One has to assume complete absorption of a drug in the interpretation of safety 
data when pharm acokinetic  inform ation is not availab le. S im ilarly , 
pharmacokinetic linearity between doses being evaluated must be assumed. 
Unless tested, these assumptions are groundless because the kinetics of 
absorption, distribution, and elimination of large doses of a drug as given in 
toxicity (safety evaluation) studies can be completely different from the kinetics 
of smaller doses for therapeutic purposes. A serious disadvantage of traditional 
toxicity testing is that when an unusual toxicity is observed, further development 
of the compound is generally stopped with no attempts made to understand the 
mechanism of its toxicity. In many cases, the toxicity is simply due to selection of 
a very high dose or the formation of a toxic metabolite that may be specific to the 
test species, with no relation to human beings at all (Batra & Yacobi, 1989). A 
knowledge of the concentrations of the parent compound and metabolites in 
plasma and tissue, allied to the accumulation of the drug on further dosing or the 
rate of elimination after cessation of administration, allows the opportunity to 
rationalise both the species of animal most appropriate for the testing of a 
compound and the extrapolation of any toxicity observed in animals to the likely 
risk for man (Anderson, Hoel, & Kaplan, 1980; Batra & Yacobi, 1989).
Observance of nonlinear pharmacokinetics of absorption, elimination, or
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both is very common in toxicity studies because of the very high doses (relative 
to therapeutic doses) used in such studies. This has become a rule rather than an 
exception (Batra & Yacobi, 1989). Pharmacokinetics incorporated in dose rang­
ing studies would help establish a dose range in which linear relationship between 
blood concentration and dosage exists. This relationship would introduce a quan­
titative measure in the study relating response to an accurate estimate of the 
amount of drug absorbed rather than the dose administered. The knowledge 
gained could be useful in correlating toxicity with blood concentrations and 
elucidating whether toxicity observed at any point during the short - or long - 
term toxicity studies was drug related.
It is well established that drug metabolising capacity generally diminishes 
with age (Yacobi, Kamath, & Lai, 1982). Whereas age - dependent metabolism is 
unlikely to be of consequence in shorter - term toxicity studies, it may be of 
importance in lifespan studies in rodents, particularly as the dose levels for such 
studies are often chosen on the basis of data obtained from younger animals in 
shorter - term studies. An obvious consequence of such age - dependent 
metabolisms is that the impact of a selected dose alters as the study progresses: 
what was a suitable dose at the start of the study may become less appropriate 
towards its conclusion. Consequently, doses should be selected for lifespan 
studies by making allowances for age - dependent metabolism. Whether this 
actually occurs can be evaluated by determining the kinetics of the test compound 
at appropriate intervals during the course of the study (e.g. at 3 and 6 months, 1 
year and 2 years (Chasseaud, 1988)). During maturation, for instance, the 
developmental profiles of different drug metabolising enzymes are dissimilar 
(Gibson & Skett, 1986), and it is not unreasonable to suppose that there are 
differences in senescence. The amount of the important endogenous protective 
agent, glutathione, in the heart, liver and kidneys of mice has been shown to
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diminish gradually by some 20 - 30% with increasing age (Hazelton & Lang, 
1980). This would be of importance for compounds detoxified by reaction with 
glutathione. Since age - or sex - dependent alterations in drug disposition is 
important in humans (Schmucker, 1985) because of the variable manner in which 
individuals metabolise xenobiotics, these factors must be considered as pharma­
cokinetics’ input in the design and interpretation of toxicity studies.
It has been a long recognised fact that the intensity and duration of the 
pharmacological effect of a systemically acting drug are functions not only of its 
in trinsic  activity  but also of its pharm acokinetic characteristics. Thus, 
pharmacokinetic data obtained from the pharmacological test species are often 
useful in the interpretation of drug effects. A typical example is a drug that is 
active following intravenous administration but is considerably less active after 
comparable oral dose. Possession of the appropriate pharmacokinetic data could 
reveal whether the drug is poorly absorbed to yield subtherapeutic circulating 
levels or is subject to presystemic biotransformation to an inactive metabolite. 
Such information would be invaluable in subsequent decisions, for example to 
improve drug absorption by altering the salt form or formulation, to investigate 
the possibility of making prodrugs, or to abandon the oral route of administration.
For many drugs there is a direct correlation between drug concentration at 
site of action and pharmacological effect. For instance, present knowledge 
suggests that the bactericidal action of antibiotics is directly related to drug levels 
at the site of infection, and the bactericidal effect is lost when antibiotic levels fall 
below the minimum inhibitory concentration for the invading micro-organisms. 
Also, the time course of drug - induced hypothermia in cold - room acclimatised 
rats parallel plasma bromocriptine concentrations but not total radioactivity levels 
following an intravenous dose of - labelled bromocriptine (Schran, Tse, & 
Bhuta, 1985).
Knowledge of the effective blood or plasma concentration in animals can
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be used as a guide for later studies in humans as the drug trial progresses into the 
clinical phase. A drug should not be considered as inefficacious unless circulating 
levels approaching the effective concentrations in the pharmacological test 
species are achieved in man (Tse, 1988). Consequently, potentially valuable 
therapeutic agents will not fall into unw arranted disrepute because of 
underdosing.
There is sometimes a more complicated relationship in the time course of 
plasma levels and the pharmacological effect for drugs with an extravascular site 
of pharmacodynamic action. Simultaneous modelling of the pharmacokinetics 
and pharmacodynamics of such drugs is relatively complex, and numerous 
integrated models have been have been introduced (Dahlstrom et al., 1978; 
Colburn, 1981; H olford & Sheiner, 1981). A lthough there is a greater 
accessibility of tissue drug concentration data in small laboratory animals which 
should render them attractive models for testing the applicability of this 
modelling approach, this type of elaborate analysis is usually not attempted 
during the preclinical phase of drug development.
In the process of developing a final drug product, the formulation scientist 
develops one or more formulations that demonstrate desirable disintegration and 
dissolution characteristics in vitro. The in vivo release pattern of the drug based 
on the resulting blood level curves in humans is studied, and the dosage form is 
accepted if an adequate blood level profile is obtained. With some sophisticated 
formulation designs, such as those used in controlled release drug delivery sys­
tems, repeated trial and error may be needed before an acceptable product is 
identified. Such a development pattern is not only costly but also time consuming, 
since a typical human bioavailability study requires the coordination of personnel 
from the various units involved in drug research and development (Tse, 1988).
A more direct and simpler approach is to perform in vivo screening tests
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in animals. As a result, formulations with a desirable release pattern in vitro are 
submitted for definitive bioavailability or bioequivalence testing in humans only 
after yielding a favourable blood level profile in an animal model.
A proper model is the key to the successful use of animal data in this 
manner. The beagle dog has proven to be a useful indicator of potential human 
absorption and formulation problems when the animal studies are conducted 
under appropriate conditions for the following reasons (Smyth et al., 1983; Tse, 
1988):
(a) Generally, oral dosage forms intended for man can be administered 
intact to dogs.
(b) It is relatively easy to handle and maintain the beagle dog. Its body 
weight is sufficiently stable over time to allow repeated studies using the 
crossover study design. The normal physiology of a 10 kg beagle dog is 
not affected by the withdrawal of approximately 100 ml of blood weekly 
for 6 weeks.
(c) Although interspecies differences in metabolism (Mellet, 1969), 
protein binding (Vallner, 1977), and drug clearance (Boxenbaum, 1980) 
preclude absolute correlation of dog and human pharmacokinetics, 
similarities in anatomy and physiology (Hamilton, 1957; Anderson, 1970; 
Wilson, 1962) provide a basis for the use of the dog in relative 
bioavailability studies. Formulation - related absorption problems in the 
dog usually also exist in the human (Crouthamel & Bekersky, 1983).
The need to apply the know ledge of pharm acokinetics and
biopharmaceutics in the design and interpretation of toxicological studies cannot 
be overemphasised. The advantages are as follows (Smyth & Hottendorf, 1980; 
Hawkins & Chasseaud, 1985; Bolt & Filser, 1987):
(a) Effect of changing formulations on bioavailability by different routes 
can be established.
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(b) Data on the extent of absorption, achieved plasma concentrations and 
rates of elimination over the range of doses selected for toxicity studies 
become available.
(c) Any likelihood of accumulation of the parent compound and or its 
metabolites is identified prior to commencing chronic toxicity studies.
(d) The relative and / or actual exposure to test compound can be 
determined (i.e. a bioavailability of 1.0 is not assumed).
Proper characterisation of kinetic behaviour is a prerequisite for the selection of 
appropriate dosages in long - term studies, and is also useful for interpretation of 
dose - response relationships, especially when toxicity is mediated by metabolites 
rather than the parent compound. It is therefore appropriate to investigate the 
pharmacokinetic behaviour of xenobiotics over the range of dosages used for 
animal toxicity tests as well as at dosages approximating "in use" exposure for 
humans. Pharmacokinetic data are essential if there is to be better and more 
rational interpretation of information obtained from toxicity studies. In fact, 
without pharmacokinetic data, the actual or relative dose levels to which animals 
are exposed systemically during toxicity studies cannot be determined, and the 
assessment of safety margins based on administered doses alone becomes pure 
guess work. Thus, adequate and proper characterisation of the pharmacokinetics 
of a drug is important for prediction from one animal species to another, and most 
importantly man.
1.4 Parameter Estimation in Preclinical Pharmacokinetic Studies
Small laboratory animals (rats and mice) have been the animals of choice 
for pharm acokinetic and tox ico log ical studies because o f econom ic 
considerations and ease of handling. The collection of samples (blood or tissues)
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from these animals usually involves "destructive" sampling at specified times.
The most commonly used method of analysing pharmacokinetic data 
obtained from small laboratory animals is the Naive Pooled Data (NPD) 
approach. This is best illustrated by example. Suppose that 10 animals are 
sacrificed at each of 10 time points and the concentration measured (i.e. 100 
animals), the data at each time point are averaged to give 10 (averaged) 
concentration - time points. These are then used for the estimation of model 
parameters (Fig. 1.1).
However, the averaging procedure, in general, may mask the most 
appropriate model, and allow a different model to be justified. No estimate of 
intra- or inter-animal variability is possible. Estimates of parameter errors bear no 
relationship to the variability of these parameters within the population of animal 
under test. In fact, variability (physiological, anatomical, and biochemical) within 
the study population can be considerable, and when considered in terms of 
clearance and volume of distribution can be expressed as coefficients of variation 
of the order of 50% (Lindstrom & Birkes, 1984). The NPD approach cannot, 
therefore, be recommended as a reliable method of kinetic data analysis, either for 
modelling or parameter estimation.
There are instances where animal pharmacokinetic data are obtained from 
large animals (such as dogs) by serial sampling in each animal, and these are 
analysed by the Standard Two Stage (STS) method. This method is, in a sense , 
the opposite of the NPD approach. It involves estimating individual animal 
parameters in the first stage with simple nonlinear regression, and combining 
these estimates in the second. Estimates of average parameters are then computed 
as means and their variances.
The STS method provides reasonable estimates of average population 
parameters, but the standard deviation of these parameter estimates will, in 
general, overestimate variability (Sheiner & Beal, 1980a; 1981; Sheiner, 1984).
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Fig. 1.1 An example of concentration - time plot from a typical animal 
pharmacokinetic study in which one observation is taken per animal. The 
parameters of the model are obtained by averaging concentrations at each time 
point and fitting a model to the averaged data (the NPD approach). The 
continuous line is the model fitted line.
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This is because each parameter is estimated from the original drug level - time 
profile, which itself contains some measurement error and possibly model 
misspecification. This error adds variability to the parameter estimates that is not 
of biological origin. Hence random inter - animal variability will be over 
estimated.
Not only are the estimates of variability obtained with the STS method 
biased, but the use of this method is also not possible when the data from study 
animals are too few to permit the calculation of individual animal parameter 
estimates. Because of these reasons, the STS method, like the NPD method, 
cannot be regarded as ideal for population pharmacokinetic parameter estimation
Where data are not analysed by either the NPD or STS approaches, 
parameter estimates are obtained by the use of statistical moments analysis. 
Again, the estimates of AUCs obtained are devoid of estimates of error, and no 
information on variability is provided. Accuracy and precision at this stage of 
drug development is crucial, and these objectives are jeopardised by inefficient 
data analytical techniques.
There is a great need to incorporate in the analysis of data obtained from 
pharmacokinetic studies involving "destructive sampling" the fact that the data 
came from a population with more variability than the traditional experimental 
error. Once this provision is made the data should be analysed with a method 
which takes into account the inherent variability in the population sample. The 
precision of the parameter estimates is then a function of the underlying structural 
model and the sampling strategy (Balant etal,, 1990).
1.4.1 Variability
Comparison of pharmacokinetic data obtained from different animals
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given the same dose of drug will indicate the degree of population variability in 
drug disposition; it may also indicate the source of variability. For example, 
comparison of the total amount of drug excreted unchanged into the urine can 
indicate whether metabolism or excretion is extremely variable. If the total 
amount of drug excreted is very different then this would indicate that the amount 
of drug metabolised was variable. If the total amount of drug excreted unchanged 
was the same but the rate at which it was excreted was different, then this would 
indicate variability in the excretion process. Brodie (1962) pointed out that 
different inbred strains of rats oxidise antipyrine at widely different rates (as 
much as a factor of 3). Vocci and Farber (1988) have advocated the consideration 
of pharmacokinetic differences within the same species in interspecies scaling. If 
population variability  for a drug is high in laboratory anim als, usually 
homogeneous and inbred populations, then even larger variations in response 
would be expected for humans (Scheuplein et al., 1990). A large degree of 
unexplained inter-animal variability may suggest that other factors, as yet 
undetermined, may be affecting the pharmacokinetics of the drug.
Inter - animal variation in pharmacokinetics can be attributed to various 
factors. Some of these involve easily measurable animal characteristics (for 
example, weight, sex, age, protein binding). On the other hand, intra - animal 
pharmacokinetic variability involves the change in response of animal to drug 
treatment with time. Examples include inhibition or induction of metabolic elimi­
nation (changes in clearance), variable absorption due to intestinal flora or gut 
wall metabolism, and diurnal variation due to circadian rhythms. It is highly 
pertinent to accurate and precise pharmacokinetic parameter estimation that these 
variabilities be accounted for.
In contrast to the NPD, STS and statistical moments analysis approaches it 
is necessary to use the nonlinear mixed effects regression model approach (Beal
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& Sheiner, 1979 - 1989) in estimating population mean parameters and their varia­
bility from data obtained from animal pharmacokinetic studies. This data analysis 
approach is usually carried out with the exportable software program NONMEM 
(Nonlinear Mixed Effects Model, Beal & Sheiner, 1979 - 1989). The statistical 
model used in NONMEM is based on the premise that individual (animal) 
pharmacokinetic parameters of a study (animal) population arise from a distribu­
tion which can be described by the population mean and inter-individual (animal) 
variance. Thus, each individual’s (animal’s) pharmacokinetic parameter can be 
expressed as a population mean and a deviation from the population mean, typical 
of that individual (animal). NONMEM is designed to handle relatively sparse 
data, in that it permits the use of unsystematically sampled plasma concentrations 
and few measurements per subject (animal), to determine population parameters 
and their variability. The strength of this approach, therefore, is the fact that a 
data set can be analysed at once to yield average values of pharmacokinetic 
parameters and their variances.
The NONMEM approach has proved itself in the human clinical setting 
(Vozeh et al., 1982; Grasela et al., 1983; Grasela & Sheiner, 1984; Grasela & 
Donn, 1985; Grasela et al., 1986; Thomson & Whiting, 1987; Grevel, Thomas, & 
Whiting, 1989), and there is a need for the application of the NONMEM 
approach in the animal preclinical setting (Rahamani et al, 1988; Balant et al, 
1990).
1.5 Experimental Design for the Estimation of Population Pharmacokinetic 
Parameters
The design of experiments is crucial in the analysis of a system under 
investigation. The design of pharmacokinetic experiments is usually based on
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the immediate objective of the investigation, i.e., model discrimination or 
param eter estim ation. Determ ining the correct structural model among 
alternatives (e.g., single versus multicompartmental) yields valuable insights into 
pharmacokinetic mechanisms, and estimating model parameters is the key to 
quantifying population variability. Pharm acokinetic analysis of data is 
informative only if the data themselves are informative, and that informative data 
could best be assured by appropriately designing the experiments from which the 
data are collected.
Animal pharmacokinetic experiments typically consist of administration 
of a test compound and measurement of the changing drug concentration in timed 
blood samples from either individual animals or groups of animals. It is 
established (Box, 1970; Landaw, 1985) that design decisions in human 
pharmacokinetic experiments can be at several levels:
1. the route of drug administration
2. the dose to be used (e.g., tracer versus large, single versus multiple, IV
bolus versus continuous infusion)
3. sites, metabolites, or "pools" to be sampled
4. the number of samples to be collected
5. the spacing of sampling times
These decisions also apply to animal pharmacokinetic studies. Although "input" 
design can be quite important (Endrenyi, 1981; Mannervik, 1981), the route and 
dose of drug are often determined by the biopharmaceutical properties of the drug 
(Smyth & Hottendorf, 1980). Likewise the number of samples to collect may be 
lim ited to a large extent by the sample size in "destructive" anim al 
pharmacokinetic studies in which one animal supplies only one observation. In 
situations which allow for serial sampling the total amount of blood that can be 
withdrawn is limited. The balance, particularly in small animals, between
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providing realistic pharmacokinetic data and increasing the sample size to 
unmanageable proportions is narrow. Although items 4 and 5 are the most easily 
controlled aspects of animal pharmacokinetic studies examples abound in the 
literature of poor sampling strategy in animal pharmacokinetic studies designed 
for parameter estimation (Zbinden, 1984; Smith, Humphrey, & Charuel, 1990).
The inform ation that can be derived from experim ental data of 
pharmacokinetic studies is determined by three factors (Suverkrup, 1982):
(1) accuracy, specificity and sensitivity of the assay, (2) number of samples taken, 
and (3) arrangement of samples in time.
The observations made in a pharmacokinetic study are subject to two 
types of error - errors due to analysis and errors due to biological variation during 
the course of the experiment. Both will contribute to the error of the parameters 
being estimated. The number of sample points taken and their timing will affect 
the errors in parameter estimation, hence it is important that sufficient samples are 
taken.
As with statistical estimations the larger the sample size, the better are the 
parameter estimates in the sense that the variances will be smaller. However, in 
animal and most pharmacokinetic studies the sample size is usually fixed so that 
the arrangement of samples in time should be given adequate consideration.
Generally, sampling times can be manipulated to improve the information 
content of the available concentration - time data. The benefits of attempting to 
obtain measurements at certain key time points which will contain the maximum 
pharmacokinetic information about model parameters have been highlighted by a 
number of authors (D’Argenio, 1981; DiStefano, 1981; Endrenyi, 1981; Endrenyi& 
Dingle, 1982; Landaw, 1985; Suvekrup, 1982). Theory suggests that two 
sampling times are needed for the efficient estimation of model parameters, 
clearance and volume of distribution, of the one compartment model (Box & 
Lucas, 1959). Using Monte Carlo simulation, D’Argenio (1981) found that a
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repeating p point design led to a reduction in the parameter estimate variability 
when data were collected at optimal sequential sampling times from a group of 10 
subjects. Using this simulation technique in population pharmacokinetic studies 
involving multiple sampling of subjects, Al-Banna, Kelman, and Whiting (1990) 
examined the impact of two sampling times (an early and a late sampling time) 
and three sampling times (where the first and the last samples were obtained at 
early and late times and the third time varied between the two) on parameter 
estimation. They concluded that variability was better estimated with the three 
point sampling strategy, and the exact location of the middle (third) sampling 
time was not critical. In animal pharmacokinetic studies involving the one 
observation per animal study design the situation is not so clear.
Even when sample size and the arrangement of samples in time are 
adequate, the parameterization of the model of choice may be crucial to efficient 
parameter estimation. Using the two compartment model with oral administration, 
Westlake (1971) pointed out that parameter estimates can be unreliable when the 
constants in the exponential terms (e.g., a  and p) are nearly equal. He also noted 
that even when the parameter estimates are satisfactory for limited prediction 
purposes, they can be quite unreliable. Boxenbaum, Riegelman, and Elashoff 
(1974) noted the instability of regression parameter estimates and related this to 
high correlation between the estimates. In this type of model, reparameterization 
has been suggested to reduce correlation between parameter estimates, leading to 
more stable estimation (Boxenbaum et al., 1974; Metzler, 1981; Laskerzewski, 
Weiner, & Ott, 1982). Reparameterization results in a transformation of the 
parameter space.
The philosophy behind this approach has been stated quite succinctly by 
Box (1980); ’Known facts (data) suggest a tentative model, implicit or explicit, 
which in turn suggests a particular analysis of data / or the need to acquire further
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data; analysis may then suggest a modified model that may require further 
practical illumination and so on.’ This is also the philosophy behind data driven 
linear regression transformations of the target variable (Box and Cox, 1964).
1.6 STUDY OBJECTIVES
The aim of the work described in this thesis is to investigate the efficiency 
with which NONMEM can estimate population pharmacokinetic parameters and 
their variances, using experimental design normally applicable to small laboratory 
animals. The effects of parameter variability, arrangement of samples in time, 
sample size, experimental error, and a range of parameter values are investigated.
1.7 OUTLINE OF THESIS
The chapters that follow have the following features:- 
Chapter 2: methods of data acquisition and analysis;
Chapter 3: influence of inter-animal variability on parameter estimation; 
Chapter 4: effect of sampling designs on parameter estimation;
Chapter 5: efficiency of parameter estimation given a range of parameter 
values of the 2 compartment model with an intravenous bolus 
administration, sample size, concentration measurement error, and 
sampling schedules;
Chapter 6: effect of reparameterization of the model used in Chapter 5 on 
parameter estimation;
Chapter 7: application of NONMEM to the analysis of real data from 
animal pharmacokinetic study;
Chapter 8: effect of sample size, error in concentration measurement,
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sampling an animal twice on the efficiency of estimation of 
population pharmacokinetic estimates; and 
Chapter 9: general discussion and conclusion.
With the exceptions of Chapters 5 to 7, all other experimental chapters deal with 
the one compartment model with intravenous bolus dose administration. All, but 
one, of the experimental chapters (Chapter 7) deal with simulated data sets.
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CHAPTER 2
METHODS
34
2.1 SUMMARY
Pharmacokinetic principles, methods of estimation of pharmacokinetic 
parameters, population pharmacokinetic methods and data analysis methods used 
in this thesis are discussed in this chapter. The efficiency of parameter estimation 
is examined in terms of accuracy and precision (mean and SD of percent 
prediction error) and design number (a new statistic introduced). While the 
percent prediction error can be used to judge the efficiency with which an 
individual parameter is estimated, it cannot be used to determine the efficiency 
with which all parameters are estimated when different designs within a study are 
compared. The design number, on the other hand, not only measures the 
efficiency with which individual parameters are estimated but may measure that 
for all model parameters estimated as a set.
Since NONMEM, which is used throughout the course of this thesis, 
produces standard error estimates, individual and joint confidence intervals for 
parameter estimates were computed as measures of efficiency of parameter 
estimation. Also, incidence of pair-wise correlations were computed as an aid to 
judging the adequacy of the parameterization of a model.
2.2 INTRODUCTION
2.2.1 Parmacokinetics
Pharmacokinetics is concerned with the study and characterisation of the 
time course of drug absorption, distribution, metabolism and excretion, and the 
relationship of these processes to the intensity and time course of therapeutic and 
adverse effects of drugs. It involves the application of mathematical and
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biochemical techniques in a physiological context (Gibaldi & Levy, 1976). In the 
preclinical setting the appropriate pharmacokinetic characterisation of a new 
xenobiotic is indispensable in the drug development process.
The pharmacokinetic behaviour of a drug is readily summarised with 
parameters which relate concentration to dose and time, and the two most useful 
parameters are clearance (Cl) and volume of distribution. Cl is defined as the 
volume of blood , plasma or serum (containing drug) which is cleared of drug per 
unit of time. In this thesis it is measured in units of m illilitres per minute 
(ml/min).
The volume of distribution (V) of a drug corresponds generally to an 
apparent space, which may be defined as the volume it would occupy at a 
concentration equal to that at the site of measurement, often peripheral plasma 
(Gillete, 1973). In this thesis it is measured in millilitres (ml). Knowledge of 
volume enables calculation of the concentration of drug immediately after an 
intravenous bolus dose.
The elimination rate constant (Ke) is the fractional rate of removal of drug 
and is defined as the ratio of Cl to V (Eq. (2.1)).
Ke = Cl/V (2.1)
1 1It is measured in units of either per minute or hour (min"A or h"A).
2.2.2 Compartment Models
Generally, a compartment has no physiological or anatomical counterpart. 
Occasionally it does, such as circulating plasma, extravascular fluid space and
36
total body water space. A compartment may also correspond to a perfusion 
volume of tissue (Bischoff et al., 1971). It can be defined as an ideal volume in 
which each molecule or particle of a substance (drug) has equal probability of 
leaving (Segre, 1986). Implied in this definition is the fact that the concentration 
of the material present in a compartment is uniform and that the rate of mixing 
within the compartment is rapid compared with transfer into or out of it (Segre, 
1986). This definition emphasises the statement of Wagner (1971), that a 
compartmentalised system is an approximation of a biological system, being an 
"average" rather than an exact state.
Many biological systems can be modelled as a collection of homogeneous 
compartments, with material moving according to specified rate laws. In 
pharmacokinetics, an attempt is made to quantify the kinetics of absorption, 
distribution, metabolism and excretion of a drug. Quantification calls for a 
mathematical model, and "compartment models" have been extensively used in 
pharmaceutical and clinical pharmacology research. By modelling the body as a 
set of separate compartments and measuring the amount of drug in one or more of 
these over time, the parameters governing the movement of drug in the system 
can be estimated. The concentration of drug is assumed to be the same throughout 
all compartments at equilibrium, and the rates of transfer of drug between 
compartments are assumed to obey first order kinetics. The mathematical 
formulation of compartment models is a set of differential equations with
constant coefficients.
The one compartment model is the simplest model which depicts the body 
as a single, kinetically homogeneous unit from which drug elimination is first 
order. This is a particularly useful model for the pharmacokinetic analysis of 
drugs that distribute relatively rapidly throughout the body. The schematic 
representation of this model is shown in Fig. 2.1.
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Fig. 2.1 A diagrammatic representation of one compartment model assuming 
instantaneous IV input with first order elimination
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Assuming instantaneous input (IV bolus injection) the mathematical 
description of drug disposition with this model is given by the following 
differential equation:
dA/dt = -KeA (2.2)
where A is the amount of drug in the body at time t after injection. Ke is the 
apparent first - order elimination rate constant for the drug. Eq. (2.2) can be 
solved by Laplace transformation (Gibaldi & Perrier, 1975) to give Eq. (2.3).
A = Ao.exp(-Ke.t) (2.3)
Assuming that the relative binding of a drug to components of tissues and fluids 
is essentially  independent of drug concentration, then the ratio  of drug 
concentrations in various tissues and fluids is constant. Thus, there will exist a 
constant relationship between drug concentration in (for example) plasma, C, and 
the amount of drug in the body:
A = VC (2.4)
Thus, Eq. (2.3) can be expressed as
C = Co.exp(-Ke.t) (2.5)
where Co is the drug concentration in plasma immediately after injection, and C 
is the drug concentration in the plasma at time t.
The two compartment model (Metzler, 1971) for drug kinetics is depicted
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in Fig. 2.2. Com partm ent one is called the "central com partm ent" and 
incorporates circulating plasma from which the drug distributes into a second 
compartment which is sometimes referred to as the "tissue" or peripheral 
compartment. For a drug exhibiting two compartment kinetics the concentration - 
time profile shows an initial rapid decline in concentration which represents both 
distribution and elimination followed by a second slower decline.
Assuming all exchanges between compartments are first order processes, 
the mathematical description of this model is given by the following set of 
differential equations:
dAj/dt = "(k^2 kio)Af + ^21^2  (2*6)
dA2/dt = ■ ^21^2 (2*7)
where and A2 are the amounts of drug in compartments 1 and 2, respectively. 
The rate constants k^Q, k^*  and k2 i represent the rate of elimination from the 
central compartment, the rate of transfer from the central compartment to the 
peripheral compartment, and the rate of transfer from the peripheral to central 
compartment, respectively. These equations can also be solved by Laplace 
transformation to give:
C = [Dose/Vi(a - p)][(cx - k21)EA + (k21 - p)EB] (2.8)
where EA= exp(-at), EB = exp(-pt)
and a, p = l/2{k12 + k2j + k10 + [(k12 + k21 + k10)2 - 4k2 ik 1Q]1/2} 
a  and p are hybrid rate constants describing distribution and elimination, and V j 
is the volume of the central compartment.
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Fig. 2.2 A diagrammatic representation of the two compartment open model 
assuming instantaneous IV input with first order transfer and elimination 
processes.
41
2.2.3 Nonlinear Regression
Nonlinear regression methods are used in the analysis of data generated 
during the course of a pharmacokinetic study to estimate the parameters of the 
model. There is no unique solution for the model parameters. Initial parameter 
estimates are progressively altered until the best set of parameters is obtained 
corresponding to the minimisation of the sum of squared deviations between the 
observed and model predicted values.
For example, at each time tj, i = 1, N, the expected drug concentration C  ^
will be given by an equation
where 0  represents the structural model pharmacokinetic parameters (e.g., Cl and 
V) for the individual (or animal). The observed concentration, q  may be 
represented by
where the e j is a small random error. The distribution of the e j has zero mean 
and variance <?.
The probability density function of observing q  at tj is given by the
C*i = f(0, tp (2.9)
(2 .10)
normal distribution with a mean of C  ^and variance, v-,
i.e. p(Cp = ( l^ f lv p  exp. -(q -C*p2 /2vj (2.11)
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The joint probability density function (pdf) that all of the observations (C) occur, 
is given by p(C), where
p(C) = p(C1).p(C2) p(Cn) (2.12)
and each p(Cp is as given above. Eq. (2.12) represents the probability function 
for obtaining the values of C, given the values of the parameters 0.
The probability function can also be used to define the "likelihood" (L*) 
function for the parameters, 0 , given the observations of C, so that
L '(0) a  p(C) or L '(0) = k.p(C) = k.L(0)
where k is a constant, but L(0) is not a probability density function. L(0) can be 
used to obtain the most likely estimates (MLE) or estimators of 0 . These will be 
the set of parameter values which maximises L(0). Thus, by substituting for 
p(C), the problem reduces to maximising the product
L(0) = [(l//2I1vj)exp -(Cj - C*1)^/2v1] [(l//'2nv2)exp -(C2 - C*2)2/2v2]...
 (2.13)
The logarithm of both sides gives
ln(L(©» = -{(Cj - C*j)2/2vj + l/21n(2nvj)) - ((C2-C*2)2/2v2 + l/21n(2nv2))
....(2.14)
Thus maximising ln(L(0)) is equivalent to maximising L (0), or minimising 
-ln(L(0)), i.e.
-ln(L(0)) = I ( q  - C*i)2/2vj + l/21n(2IIv;) (2.15)
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where -ln(L(0)) is called the negative log likelihood. Multiplying Eq. 2.15 by 2, 
and also removing the 211 term reduces to minimising Eq. 2.15 to obtain the MLE 
of the parameters.
i.e. Objective function = E(C| - C*p^/vj + ln(vp (2.16)
This objective function is called the Extended Least Squares (ELS) objective 
function.
The interest in the ELS regression method is due to the fact that the 
variance or weighting scheme can be included as part of the model for the data, 
and the parameters of the variance model may be estimated simultaneously. 
Consequently, a variance model or weighting scheme need not be chosen 
explicitly before the data are fitted. However, the form of the model used to 
describe the variance must be selected.
The most frequently used variance model is
where the value of <p is estimated along with other model parameters. Eq. (2.17) 
gives the general variance model in which various weighting schemes can be 
incorporated. When (p = 0, Eq. (2.17) yields the constant variance model and the 
objective function in Eq. (2,16) reduces to the Ordinary Least Squares (OLS) 
objective function which is given by
The assumption of a constant variance may be unjustifiable in cases in which 
concentration is measured over a large range of values (e.g. 0.01 to 100 {Xg/ml).
V: a  C*:<P (2.17)
OLSq b j  = KC; - c y (2.18)
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As the variance of each point is rarely known, there are several weighting 
schemes which are commonly used. Examples of these occur in the radioactive 
decay and dilution processes. In the former, a  Vj a  C and in the latter Wj a
if; OVj a  C . Thus, cp = 1 and 2 for the respective processes (i.e. W ja C  j or C j , 
respectively) and the objective function in Eq. (2.16) reduces to the Weighted 
Least Squares (WLS) objective function. Thus,
WLS0BJ = SWi (Cr C*i)2 (2.19)
The contribution of each point to the WLSq ^ j  is weighted by a function which 
reflects the certainty of the observation. More weight is placed on the data points 
about which there is the greatest confidence and vice versa.
2.3 POPULATION PHARMACOKINETICS
All drugs exh ib it pharm acokinetic variab ility . Population  
pharmacokinetics describes this variability in terms of fixed and random effects. 
"The fixed effects are the population average values of pharmacokinetic 
parameters which may in turn be a function of various patient characteristics such 
as: (a) age, weight, height and sex; (b) underlying pathology such as renal or 
hepatic impairment; and (c) other influences on drug disposition such as 
concomitant drug therapy, smoking habits and alcohol intake. The random effects 
quantify the amount of pharmacokinetic variability which is not explained by the 
fixed effects, i.e., inter- and intrasubject variability" (Whiting, Kelman, & Grevel, 
1986). In animals fixed effects are similarly a function of those characteristics 
listed for humans.
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Thus inter-animal random effect parameters measure the magnitude of the 
random individual animal variability in relation to the fixed effects. Intra-animal 
variation includes measurement errors involved in quantifying drug concentration 
or response and random changes in an animal’s parameter values over time. It 
also includes model misspecification errors which arise because all mathematical 
calculations of parameter values are simplifications of reality.
2.3.1 Population Methods
There are two standard approaches to estim ating  population  
pharmacokinetic parameters : the NPD and the STS approaches (Sheiner & Beal, 
1980a). These approaches have been traditionally used in the estimation of 
population pharmacokinetic parameters from animal data. The NPD approach 
tends to ignore individual animal pharmacokinetic differences. The usual 
approach when an animal (e.g., rat or mouse) can be measured only once is to 
sample more than one animal at each of several time points and to treat the 
sample means as a time series of measurements from a "typical" animal. This 
procedure only gives estimates of population parameter means and ignores inter­
animal variability in the parameters.
When animals are sampled serially all data are pooled at each time point 
to yield an arithmetic mean plasma concentration curve (Eq. 2.20) of all 
individual animal curves and a pharmacokinetic model fitted to the mean data as 
if it came from a "super" animal.
jl(C(t)} = l /n IC i(t) (2.20)
Thus the NPD approach has several drawbacks:
(1) It totally ignores individual animal pharmacokinetic characteristics
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and, by doing so, obscures important information on how xenobiotic 
substances are handled.
(2) The average concentration curve derived by the NPD approach, does 
not necessarily follow the individual model function. A wrong model may 
be obtained (Martin et al, 1984). Undefined statistical uncertainties and 
large "unknown" animal variations might smooth the average response 
curve in an unpredictable manner.
The STS method is, in a sense, the exact opposite of the NPD method. At 
first it regards each animal as completely distinct from all others and estimates 
each animal’s pharmacokinetic parameters from its data alone. In the second 
stage, the individual animal pharmacokinetic parameter estimates are often 
pooled to obtain population parameter estimates. If Cl, for instance, is to be 
related to physiology, linear regression is used. This, however, has only been 
used in human studies although it could be applied to animal studies. For inter­
animal random effect parameters, the standard deviations of the individual animal 
parameters about the regression line ( or the mean value) are used. When the 
residual error random effect parameter is estimated (which is rare) the square root 
of the sum of the pooled, squared residuals of the initial, nonlinear fits divided by 
the (pooled) residual degrees of freedom is usually used (Sheiner & Beal, 1980a).
When standard errors of the fixed effect parameter estimates are obtained 
with the STS approach they are usually taken to be the standard deviations of 
each animal’s parameter estimates divided by the square root of the number of 
sampled animals. The standard errors of the inter-animal random effect parameter 
estimates are not computed.
The manner in which the random inter-animal effect parameters is 
estimated is a fundamental problem associated with the STS approach. They tend 
to be upward biased because each parameter is estimated from the original drug
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concentration - time data with some error, and this error adds variability to the 
parameter estimates that is not of biological origin (Sheiner, 1984; Martin et al., 
1984). Accurate variance estimates can be achieved only through well designed 
and performed pharmacokinetic studies. In addition, this method cannot be used 
when data from some animals are too few to permit individual animal parameter 
estimates.
The statistical problems of pharmacokinetic data analysis are now being 
appreciated more often than formerly and alternative population - based methods 
of estimating population pharmacokinetic parameters have been elaborated. These 
methods focus on central tendency in response across a study population and the 
variability in response between individual members of the population studied. 
This difference in point of view requires a dramatically different approach to 
modelling and parameter estimation. A variety of approaches have been proposed 
(Steimer et al., 1984), but the nonlinear mixed effects model has been studied in 
detail, and it is applied throughout the course of this thesis. Traditional 
compartmental pharm acokinetic models invariably assume that error or 
unexplained deviation from expected response is simply added to the predicted 
response. Such an error structure can be satisfactorily dealt with using simple 
least squares nonlinear regression. Population based methods assume a more 
complex error structure and are generally expressed as mixed effect models, 
indicating that complex interactions and effects are responsible for an observed 
response (Beal & Sheiner, 1984).
Expression of a population model in a form that lends itself to extended 
least squares analysis allows explicit estimation of components of variance as 
well as estim ation of central tendencies. At the heart of population  
pharmacokinetic analysis is the explicit estimation of inter- and intra-individual 
(inter- and intra-animal) variability and the exploration of factors that account for 
this variability (Sheiner, Rosenberg, & Marathe, 1977; 1980a & b; 1981; 1983;
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Beal & Sheiner, 1982,1984).
2.3.2 Population Data Analysis Using NONMEM
The formal expression of a population based model for parameter 
estimation is accomplished through application of the basic principles of analysis 
of variance. The similarities between traditional analysis of variance (ANOVA) 
or, more accurately, analysis of covariance (ANCOVA) and nonlinear mixed 
effects modelling underscores the importance of variance in population modelling 
(Colburn & Olson, 1988).
In common with simple nonlinear regression models (OLS and WLS), 
mixed effects nonlinear regression models estimate a central tendency for 
parameters that predict average response. The principal difference between 
simple nonlinear regression and mixed effects nonlinear regression is the level of 
complexity allowed in the subsequent expression of variability. Simple nonlinear 
regression allows a single component of random error about the predicted 
response. This error is added to the predicted response to account for deviations 
from prediction and may or may not arise from a distribution of a constant 
variance. A more complex expression of variance models based on principles 
firmly established for traditional ANOVA is accomplished with mixed effects 
nonlinear regression (Beal & Sheiner, 1982).
Nonlinear mixed effects regression recognises two sources of deviation 
from a predicted response. Assuming that the central tendency in a population 
model represents the response of an average animal, any particular animal 
response will be different for the simple reason that the particular animal is not 
average. This is the source of inter-animal variability. The second source of 
variability (residual error) arises from deviations from predicted response after
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accounting for inter-animal variability. The residual error is the same as that 
estimated in simple nonlinear regression. This analysis approach allows a 
generally correlated error structure, with varying error magnitude as a function of 
observable data (e.g., sex, weight, time of sample after dose, etc) and the fixed 
effect parameters.
Fewer samples are needed from each animal because the individual 
animal is no longer of central interest; this procedure should lend itself to the 
sparse data obtained with the one observation per animal study design. 
Observations are pooled to characterise a central tendency for the population 
rather than the individual animal. The characterisation of inter-animal variability 
preserves the fact that individual animal response is different from the population 
mean response. Each animal’s contribution to the characterisation of this variance 
is adequately  defined with few er sam ples than are required  for the 
characterisation of each animal’s parameters.
The NONMEM program (Beal & Sheiner, 1979 - 1989) uses the ELS 
method to estimate population pharmacokinetic parameters and is designed to 
handle relatively sparse data from a large number of subjects. This feature makes 
it applicable in the analysis of data collected during animal pharmacokinetic 
studies in which as few as one observation is obtained  per anim al. It 
simultaneously analyses data from all animals in a study, provides estimates of 
average population parameters and partitions all sources of error into that arising 
from inter-animal variability and that arising from residual error. When 
analysing experimental data the ability to state a general parametric model for the 
error structure frees the analyst from the task of specifying weights for the data 
analysis. NONMEM provides estimates of standard errors for all parameters 
estimated and these can be used to construct confidence intervals for true 
parameter values, thereby allowing hypothesis tests for these. Under the
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assumption of normality for the distributions of the random variables, NONMEM 
provides yet another possibly preferable method of testing hypotheses, the 
likelihood ratio test (Rao, 1965) which is used in comparing models.
Three input files are required to run NONMEM. These are: (1) the data 
file which contains the concentration - time data, (2) the "PRED" file, a 
FORTRAN subroutine which defines the structural and variance models, and (3) 
the control file which details information on the organisation of data in the data 
file, initial estimates of parameters with upper and lower limits, and instruction 
for presentation of results, tables and graphs. The PRED files used in this thesis 
are shown in Appendix I.
The param eters of the structural model, ( 0 ^ )  for any animal are 
represented by the population mean, (0^), plus the deviation from the mean 
which is relevant to the particular animal t^-  (where represents inter-animal 
variability), i.e.
e ki = ® k+1^d <2*21)
values are often assumed to be normally distributed with zero mean and 
variance o?^. The inter-animal variability expressed in this form is additive to the 
population mean, and < \ approximates the inter-animal standard deviation for 
associated parameters. Alternatively, the inter-animal variability can be assumed 
to be proportional to the value of 0^, i.e.
ln(0jQ)= lnC©^) (2*22)
The statistical model given in Eq. (2.21) is used throughout this thesis.
The residual error quantifies deviations of the plasma concentration 
measured in each animal, Cj, from the overall predicted concentration, C*j. The
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predicted concentration is a function of structural model parameters
c * = f(0ki»D’ t) (2.23)
and Cj = fCe^, D, t) + 6 j = C*j + e j (2.24)
The error is assumed to be normally distributed with zero mean and variance <?. 
This corresponds to a "constant or additive error" model. The "proportional error" 
(error proportional to concentration), a realistic assumption in pharmacokinetics, 
is an alternative model which can be obtained by assuming a log normal 
distribution of concentration, i.e.
ln(Cj) = In D,t) + e j (2.25)
Fig. 2.3 is an example of the PRED (for a drug which is administered by 
intravenous (IV) bolus dose injection and exhibits one compartment kinetics) 
used in the 1985 version of NONMEM (Beal & Sheiner, 1979 - 1989). It requires 
the provision of both the structural (pharmacokinetic) model (F) and the 
derivatives of the function with respect to each i^(G array) by the user. The 
statistical nature of the inter-animal variability is defined by the G functions. The 
"H" function defines the statistical nature of the concentration error model. 
Appendix I contains examples of other PRED’s and control files used in 
NONMEM analysis during the course of this thesis.
2.3.3 Model Comparison
NONMEM models are compared on the basis of the objective function
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SUBROUTINE PRED(ICALL,NEWIND,THETA,D ATRECJNDXS ,F,G,H)
C
C
C 1 COMP IV, 1ST DOSE, CL, V 
C 
C 
C
DIMENSION THETA(2),DATREC(3),H(1),G(2),INDXS(1)
DOUBLE PRECISION THETA,F,G,H,T,DOSE,CL,V,EKT,XKE,EXPWCH 
CL=THETA(1)
V=THETA(2)
x k e =cl / v
T=DATREC(2)
DOSE=3000.
EKT=EXPWCH(-XKE*T)
F=DOSE*EKT/V
G(1)=-T*F/V
G(2)=(F/V)*(XKE*T-1)
C H(1)=F 
RETURN 
END
DOUBLE PRECISION FUNCTION EXPWCH(XX)
DOUBLE PRECISION XX 
IF(XX.LE.-50.) XX=-50.
IF(XX.GE.50.) XX=50.
EXPWCH=DEXP(XX)
RETURN
END
Fig. 2.3 The PRED subroutine used for parameter estimation with the one 
compartment model (IV bolus injection). Note that when more than one 
observation is obtained per animal "H" is included in the subroutine.
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(twice negative log likelihood function). Hierarchical models can be compared 
using a chi- squared test with degrees of freedom equal to difference in the 
number of parameters (Sheiner, Rosenberg, & Marathe, 1977). Non-hierarchical 
models (where all models have the same number of parameters, see chapter 7) are 
compared by an examination of the objective function, the variances associated 
with each parameter, and the weighted residuals plot.
2.4 SIMULATION
Monte Carlo sim ulation is a num erical technique for conducting 
experiments with certain types of mathematical models describing the behaviour 
of the system  under study (N aylor, B urdick, & Sasser, 1966). In a 
pharmacokinetic simulation study, it is assumed that both the form of the 
deterministic and the stochastic components (structural model parameters and 
error structures, respectively) of the pharmacokinetic model are known, and the 
sampling strategy specified.
Thus, simulation was carried out as described by Bard (1974). For studies 
involving the use of the one compartment model with IV bolus injection 
(Chapters 3, 4, and 8) population parameters of a drug having the characteristics 
of avicin, a cytotoxic agent (McGovern et al., 1988) were used for the simulation. 
The parameter values were Cl = 1.3 ml/min.; V = 162.5 ml, C q , G y, and oe were 
set to give coefficients of variation of 15%.
The half-life ( ty 2) °f simulated drug (using Cl and V) was 84 min., 
and ten sampling times were specified between 5 and 240 min. (i.e. 5 , 15, 30, 60, 
90, 120, 150, 180, 210, and 240 min.). The first two time points were fixed in all 
cases while the other time points were sampled uniformly from a range of 15
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min. about the stated times. This was considered to mimic a real study, and in 
parameter estimation with NONMEM the exact times were used. One observation 
was made on each animal. Variations of this sampling design are specified in 
chapters 4 and 8.
Individual Cl values (C lj’s) were obtained by sampling from the 
population distribution (Cl, c?q ) using a random number generator. Vj’s were 
similarly generated. Using the appropriate sampling time (tj) sampled from the 
uniform distribution (tj ± 7.5 min.), apart from the first two points, the expected 
concentration C j was computed. A random error, proportional to C j was then 
added to C j to give the final observation. This was repeated for each animal 
comprising a data set.
For each study design, 30 such sets of data were generated and analysed 
assuming zero covariance between any two parameters. A similar procedure was 
used to simulate data for the two compartment open model with IV bolus injec­
tion using the parameters and variances specified in Chapters 5 and 6.
Simulation was carried out using the ICL main frame (ICL 3980). Appen­
dix II contains the simulation programs used in this thesis. The data thus simulat­
ed were analysed with the NONMEM program.
2.5 DATA ANALYSIS
2.5.1 Prediction Error
Given that the "true" parameter values were known, the efficiency with
$
which each model parameter is estimated could be judged. Let 0  represent the 
"true" value of the parameter 0 . Intuitively an estimate is "better" the closer it is 
to the "true" value.
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This notion was formalised by defining the error (bias) of an estimate 0  as
*
0 - 0  .In  order to express the accuracy and precision for all parameters on the 
same scale, percentage errors were computed. For each run and for each parame­
ter, the difference between the "true" value and the "estimated" value was ex­
pressed as a percentage of the "true" value (i.e., percent prediction error, %PE). 
Thus,
%PE = (0j - & * / & * )  * 100 (2.26)
The mean of %PE for each of 30 replicates of data was used as a measure of the 
accuracy with which each parameter was estimated.
An estimate of the precision with which each parameter was estimated 
was obtained from the standard deviation of %PE, denoted SD of %PE. Bias and 
precision are illustrated in Fig. 2.4. The first estimate (I) of the parameter 0  is 
unbiased and precise, the second estimate (II) is unbiased and imprecise, the third 
estimate (III) is positively biased but precise, and the fourth estimate (IV) is posi­
tively biased and imprecise. In deciding on the acceptability of precision of 
estimates, an SD of %PE of 25% was used as the cut off. Statistical significance 
of nonzero %PE’s was tested using the two - tailed t test.
In some studies reported in the course of this thesis some data sets gave 
rise to totally implausible estimates. Since these would be rejected from further 
analysis, criteria had to be adopted with which to judge acceptability. Thus, any 
parameter estimate which was smaller than l/100th of the "true" value or larger 
than 10 times the "true" value was rejected. Also, if the estimated standard error 
of a parameter was greater than 10 times the "true" value, the result was rejected. 
This is similar to the criteria used by White et al (1991) in a simulation study with 
a drug exhibiting one compartment open model kinetics. These criteria were 
applied in Chapters 3, 5, and 8.
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Fig. 2.4 Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for a parameter, 0 . The first estimate (I) of © is unbiased and 
precise, the second estimate (II) is unbiased and imprecise, the third estimate (IQ) 
is positively biased but precise, and the fourth estimate (IV) is positively biased 
and imprecise.
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2.5.2 Confidence Intervals
The reliability of estimates is important in parameter estimation. The usual 
way to approach this statistical problem is through the construction of a "confi­
dence interval" for the parameter estimate. Briefly a 95% confidence interval is a 
region in the parameter space that is so constructed that in repeated trials the true 
parameter will lie in the confidence region (interval) in 95% of the cases.
The standard errors (SE) of parameter estimates (0^) produced by 
NONMEM can be used for the construction of confidence intervals (Sheiner & 
Beal, 1980a). The approximate 95% confidence interval is given by ± 
1.96(SE) for 0 . Efficient parameter estimation requires low standard errors for 
parameters. From preliminary experiments it was found that for any given 
amount of data, the variance parameters were estimated with considerably less 
precision than were the structural model parameters. Thus, a cut off rule was 
established as an aid to determining the impact of SE on confidence interval 
coverage for a parameter estimate, hence the efficiency with which such a 
parameter was estimated. For efficient estimation of Cl and V the "coefficient of 
variation" (i.e. S E (0 j)/0^) associated with any estim ate of any of these 
parameters for any given run had to be < 20% while that for the variance 
parameters had to be <50%. Confidence intervals were calculated to determine 
the runs in a simulated data set which covered the "true" values. In addition, the 
99% univariate confidence interval was used as suggested by Sheiner & Beal 
(1987) as a reasonable approximation for confidence interval estimates to contain 
95% of the estimates produced using the ELS estimation procedure.
Bias in estimates production, and standard error of estimates are some of 
the factors that affect confidence interval coverage. Thus, there are three sections 
in confidence interval tables presented throughout the course of this thesis (e.g., 
Table 2.1). Section I, indicated by the ratio "success /  total", shows confidence
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intervals coverage for parameter estimates when the cut off rule is not applied. 
Section II, denoted by the ratio "success - excluded /  total - excluded", shows 
interval estimates when the cut off rule is applied to both the numerator and 
denominator during confidence interval coverage computation. The estimates not 
used for the construction of these confidence intervals are herein referred to as 
"catastrophic" estimates. Thus, this section gives an indication of how good the 
coverage is if catastrophic estimates were deleted from the results. The last 
section of the table (Section III) shows the coverage when the catastrophic 
estimates are included in the denominator but discounted in the numerator for the 
computation of confidence interval coverage. With Section in  the acceptability of 
an estimate can be judged in combination with the accuracy with which such an 
estimate is produced. From Fig. 2.5, for instance, the estimate of oq  obtained 
with sampling time specification at 240 min. in a study in which the effect of the 
arrangement of sampling times on parameter estimation was studied, is almost 
unbiased. However, an examination of the confidence interval coverage (Table 
2.1, Section III) which was computed from the results of the experiment present­
ed in Fig. 2.5 shows that 70 NONMEM runs yielded catastrophic estimates of this 
parameter. Thus, Section III is helpful in determining the reliability of an esti­
mate.
Parameters of a model are not estimated individually, and consideration 
should be given to this in results interpretation. Thus, the "joint confidence 
interval" for all parameter estimates was computed as an aid to the interpretation 
of the efficiency with which all parameters were estimated. The approximate 99% 
joint confidence interval for all parameter estimates was computed from the 
number of runs containing true parameter values for all parameters of the model. 
99% individual and joint confidence intervals coverage for parameter estimates is 
used throughout the course of this thesis.
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Fig. 2.5 Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for Cjnj. The horizontal axis represents the different sampling times 
for the two sampling times design. The first sampling time was fixed at 5 min. 
while the second time was varied. Each vertical bar expresses the bias and 
precision of the population parameter estimate for each design. Significant (p < 
0.05) biases are indicated by asterisks.
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The chi - squared test (p < 0.01) was used to determine whether the indi­
vidual or joint confidence intervals coverage for parameter estimates was signifi­
cantly different from the expected values (e.g., 0.95 and 0.81 (4 parameters only), 
for individual and joint confidence intervals coverage, respectively, for the 
parameters of the one compartment model with IV bolus injection).
2.5.3 Design Number
Most pharmacokinetic studies are carried out to obtain estimates of 
parameters which define an assumed pharmacokinetic model. Parameter estima­
tion procedures (such as NONMEM which is used throughout the course of this 
thesis) produce sets of interrelated estimates. However, in the interpretation of the 
results, relationships between parameters are usually ignored. Thus, in the com­
parison of study designs used in parameter estimation, there is a need for an 
examination of the efficiency with which all model parameters are estimated 
singly and jointly from a design.
In Section 2.5.1 of this chapter the usual approach to judging accuracy 
and precision was presented. However, this method of analysis allows the 
investigator to judge the efficiency of estimation of only one parameter at a time. 
In the previous section the joint confidence interval was introduced as an aid to 
judging the efficiency with which all population pharmacokinetic parameters 
were estimated. Sometimes it may be difficult to choose the best sampling design, 
for instance, from a series of designs for the estimation of a parameter of interest. 
In addition, it was pointed out in the previous section that the reliability of a 
parameter estimate had to be judged with its SE taken into account. The %PE 
approach ignores the fact that NONMEM produces parameter estimates with
SE’s.
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To this end, a new statistic was proposed with which the efficiency of 
parameter estimation from a study design could be measured. In it the elements of 
accuracy and precision in parameter estimation are combined. The statistic, a 
"design number", <J>j for each parameter was defined:
<t>j = ( ( 0 r  © i*)/^*}2 * SEC©;)/©;* (2.27)
has two desirable properties which are useful for determining the most
jjj{
efficient parameter estimate. It should be recalled that 0^ - 0 j measures the bias 
in the estimation of a parameter. SE, of course measures precision. The two terms 
on the right hand side of Eq. (2.27) are normalised to allow the comparison of 
different estimates of a parameter from different designs within a study.
Since accuracy is improved as 0 j approaches 0^ , the first term on the 
right hand side of Eq. (2.27) will approach 0 as this happens. This term is squared 
so that all computed values of d>j remain positive. As the parameter estimate 
becomes more precise, SE(0p becomes smaller. As the two right hand terms in 
Eq. (2.27) tend towards 0, approaches 0 indicating greater efficiency with 
which the parameter is estimated. If a reasonably symmetrical distribution for 0 j 
is assumed, then the distribution of d>j is skewed right. 95% confidence intervals 
can be calculated for different designs within a study.
From Eq. (2.27), d>^  defines a design number for each parameter viewed 
independently. As earlier discussed, model parameters are estimated as a set, and 
an investigator may be interested in choosing a study design which produces the 
most efficient parameter estimates. This can be done by combining all design 
numbers to give the "overall design number". Thus,
<D = £{[(©; - ©i*)/©i*]2 * SECQj)/©;*) / n (2.28)
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where n is the number of estimated parameters. The power and efficiency of 
and 0  are outside the scope of this thesis.
A preliminary study was carried out in order to apply <J>^ (<b) in determin­
ing the efficiency with which parameters were estimated with different sampling 
schedules using the two sampling times design.
Parameters of the drug, avicin (Section 2.4) were used to simulate data 
with the first sampling time fixed at 5 min. and the second sampling time speci­
fied at either 90, 150, 210, or 240 min. With the one observation per animal study 
design a sample size of 48 was used for each sampling strategy. 180 replicates of 
data were generated for each of the sampling schedules. Table 2.2 is a summary 
of the 95% confidence intervals for and d> for the different sampling schedules 
of this two sampling times design. It can be seen that Oj values for the variance 
parameters had more influence in O computed.
To give equal weighting to all parameters, d>- was rescaled as follows:
Oir = {(©i - 0i*)/0i*)2 * SE(0j)/0j* / Max [{(©i - ©i*)/©;*}2 * SECQj)/©^]
(2.29)
Therefore, the overall design number was computed as follows:
<J>r = l/n 2 ((0 i - 0 i*)/0i*)2 *SE(0i)/0 i* /M ax [{ (0 i - 0 i*)/0i*)2 *
SE(0j)/0j*] (2.30)
Oir, <I>r calculated using Eq. (2.29) and (2.30) were then used to compare the 
efficiency of parameter estimation from the different sampling schedules.
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Table 2.3 summarises the 95% confidence intervals for <J>^ . and Or obtained with 
the different sampling schedules for comparison with Table 2.2. The rescaling 
resulted in changes in Oj and d>, therefore, giving equal weighting to all 
parameters. The Kruskal Wallis test (p < 0.05) with multiple comparisons was 
used to compare the efficiency with which parameters were estimated with the 
different sampling schedules. Thus, the most efficient parameter estimate(s) is 
obtained with the study design yielding the lowest average rank of (<E>r).
The results of the multiple comparisons in this example are summarised in 
Fig. 2.6. The design numbers for the sampling times are ranked in increasing 
order from left to right, and this format is used in the presentation of results 
obtained using (Or) throughout the course of this thesis. The design yielding 
the least efficient parameter estimate has the highest rank order. Where two 
sampling times in the Fig.2.6, for instance, are connected with a line it indicates 
that there was no significant difference in the efficiency with which a parameter 
was estimated with the designs considered. When two sampling times are not 
connected with each other by a line, it indicates that there was a significant 
difference in the efficiencies with which the parameters considered were 
estimated using the different sampling designs.
Thus, from Fig.2.6a Cl was most efficiently estimated with the specifica­
tion of the second sampling time at 150 min., but this was not significantly 
different from the estimate obtained with the second sampling time specified at 
210 min. However, the efficiency of Cl estimation with this two sampling times 
schedule was significantly better than the efficiency with which it was estimated 
when the second sample was at 90 or 240 min. The results obtained with the 
second sample at 90 min. yielded the most inefficient estimate of Cl. Although V 
was most efficiently estimated with the second sample at 90 min. (Fig.2.6b), this 
was not significantly better than results obtained with the other sampling
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(a) Estimation of Cl 
150 210 240 90 Sampling Times (min)
(b) Estimation of V
90 210 240 150 Sampling Times (min)
(c) Estimation of Gq  
240 210 150 90 Sampling Times (min)
(d) Estimation of Oy 
90 210 240 150 Sampling Times (min)
(e) Overall Design Efficiency 
210 150 240 90 Sampling Times (min)
Fig. 2.6 aSummary of significant differences in the efficiency with which 
parameters were estimated using the two sampling times design, 
a - Rank order of design numbers increasing from left to right.
* - Efficiency measured with design number.
The connecting of sampling times with a line indicates a lack of significant 
difference between the designs.
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schedules.
Cq  was "best estimated" with the second sample at 240 min. (Fig.2.6c), 
but this was not significantly better than when the second sample was at 210 min. 
These two sampling schedules produced more efficient estimates of this 
parameter than the design with the second sample at 90 min.
As with V, the efficiency with which Oy was estimated was similar for all 
the study designs although the design with the lowest average rank of <D^ . was the 
one with the second sampling time specified at 90 min. (Fig.2.6d).
Fig.2.6e gives the overall efficiency with which param eters were 
estimated. The parameters were estimated with a similar efficiency when the 
second sample was at 150, 210, or 240 min. More efficient parameter estimates 
were obtained with these sampling schedules than with the design having the 
second sample at 90min. Specifying the second sample at 210 min. yielded the 
most efficient parameter estimates. 0^r and <E>r were applied in the analysis of 
data in Chapters 4,5, 6, and 8 of this thesis.
2.5.3 Correlation Analysis
Model parameters are not estimated independently but as an interrelated 
set giving rise to the generation of a correlation matrix for parameters. The 
interpretation of this should be considered in the overall interpretation of the 
results of a study. In the course of this thesis, the incidence of "high" correlation 
between parameter estimates is used to examine the reliability of parameter 
estimates. Two parameters are judged to be highly correlated if the pair-wise 
correlation coefficient is > 0.75. otherwise, it is termed low. Thus, the study 
reported in Section 5.3 yielded 0% incidence of high pair-wise correlations for 
the different parameter combinations (Table 2.4). When the incidence of high
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pair-wise correlations between most parameters is high it is an indication of a 
"poor" fit of the model to the data since the data in the studies reported in this 
thesis were generated with the assumption that all model parameters were inde­
pendent.
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CHAPTER 3
INFLUENCE OF INTER-ANIMAL VARIABILITY ON THE 
ESTIMATION OF POPULATION PHARMACOKINETIC PARAMETERS
72
3.1 SUMMARY
Simulation studies were carried out to investigate the influence of inter­
animal variability on the estimation of population fixed and random effects 
parameters. Data were simulated according to a monoexponential model with the 
one observation per animal study design and a range of inter-animal variability in 
Cl and V.
The efficiency with which the fixed effect parameters were estimated was 
good, on average, irrespective of the inter-animal variability in Cl and V. The 
estimates of the random effect parameters were sometimes imprecise and often 
inaccurate.
3.2 INTRODUCTION
Variability in pharmacokinetic parameters among homogeneous strains of 
small laboratory animals has been claimed to be between 30 and 50% in some 
cases (Lindstrom & Birkes, 1984; McArthur, 1988). There is need to investigate 
the effect of this wide range of variability on the estimation of population 
pharmacokinetic parameters in a setting where each animal supplies only one 
concentration time point as is often the case in preclinical studies involving the 
use of small laboratory animals. The goal of this simulation - based study was to 
evaluate the influence of inter-animal variability on the estimation of population 
pharmacokinetic parameters using the one observation per animal study design. 
Specifically, the accuracy and precision with which these parameters were 
estimated, the "normality" of their sampling distributions, single and joint 
confidence intervals coverage of parameters estimates, and the incidence of high 
correlation between pairs of parameter estimates were examined.
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3.3 METHODS
Parallel simulations were performed for two different studies. In the first 
study, three observations were obtained from 3 different animals at each time 
point. In the second study, 5 observations were obtained from 5 animals at each 
time point. In both studies only one observation was taken per animal. An 
intravenous bolus dose and sampling design previously described in Chapter 2 
(Section 2.4) was used in these studies. Cl and V for the jth animal were sampled 
as previously described in Chapter 2 (Section 2.4), and the respective variances 
were selected to yield coefficients of variation of 15, 30, 45, and 60%. There 
were 4 * 4  com binations of variab ility  in Cl and V (Table 3.1). These 
combinations of variability were chosen to cover the range of inter-animal varia­
bility likely to be encountered in real life (Lindstrom & Birkes, 1984; McArthur 
1988). A 15% error was added to concentration measurements as previously 
described (Chapter 2, Section 4.1). 30 data sets were generated for each combina­
tion of C£i and Oy for each study. Thus, 480 data sets were generated for each 
study, and 960 data sets in all.
The chi - squared test (p < 0.05) was used to determine the normality of 
the distribution of the estimates obtained for the fixed and random effects 
parameters. When the assumption of normality was rejected further testing 
showed that the distributions were significantly positively skewed (p < 0.05), but 
tests of kurtosis were not appropriate since the test is only valid on sample sizes 
of greater than 50.
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3.4 RESULTS
3.4.1 Acceptable NONMEM Runs
Using the outlier criteria stipulated in Chapter 2 (Section 2.5.1) the 
number of times over 30 replications in each simulation that NONMEM produced 
acceptable estimates and corresponding standard errors was determined. All Cl 
and V estimates were acceptable (Chapter 2, Section 2.5.1). Estimates of and 
G y  were acceptable (90 to 100%) in most of the combinations of inter-animal 
variability except for the 45% * 60% and 60% * 60% combinations of Gq[ and Oy 
where the acceptable estimates dropped to 86.7% (Table 3.3). Runs with 
unacceptable estimates were deleted, and the results presented are based on runs 
with acceptable estimates.
3.4.2 Bias and Precision
Three dimensional plots are used to summarise the relationships between 
the various com binations of O q  and G y  and the mean %PE w hile two 
dimensional plots are used to show both bias and precision for various values of 
at a specified value of G y. Thus, in the presentation that follows the bias and 
precision in parameter estimation are considered for each level of O y and at 
various levels of c^j for each study. With three observations per time point, and 
setting Oy at 15% while was varied between 15 and 60%, all estimates of Cl 
were negatively biased. The most biased estimate was obtained when C q  was 
specified at 60% while the least biased estimate was obtained with specified
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Fig. 3.1 Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the 
different values of with a specified value of Oy (15%). Each vertical bar 
expresses the bias and precision of the population parameter estimate. 3 
observations were made at each time point, and only one observation was made 
on each animal. Significant (p < 0.05) biases are indicated by asterisks.
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at 15%. The bias ranged from -0.5% (c ^  (oy )  = 15%) to -18.7% (c ^  = 60%, G y  
= 15%) (Fig. 3.1a). All estimates of Cl were precise for all combinations of 
and G y  (Fig. 3.1a). The SD of %PE ranged from 4.2% ( c q ,  G y  =  15%) to 9.6% 
(c^j and G y  = 60 and 15%, respectively).
The bias in Cl estimates obtained when 5 observations were made at each 
time point ranged from -1.2% (Cq, G y  = 15%) to -13.9% (c^j = 60%, G y  = 15%) 
(Fig. 3.2a), and all the estimates were more precise than those obtained when 
three observations were made per time point. The SD of %PE ranged from 2.7% 
(eft (Oy) = 15%) to 8.9% (cfcj = 60%, Oy = 15%).
When Oy was 15% and G q  varied between 15 and 60% relatively 
unbiased and precise estim ates of V were obtained (Fig. 3.1b) when 3 
observations were made per time point. The %PE ranged from -0.2 ± 5.4% (c ^  
(cfy) = 15%) to 1.4 ± 9.0% (C£i = 60%, O y = 15%). Similar results were obtained 
when 5 observations were made per time point. All estimates of V were relatively 
unbiased and precise (Fig. 3.2b). The SD of %PE ranged from 5.2% (Cq (O y) = 
15%) to 6.6% (C£i = 60%, O y = 15%).
Varying c^j from 15 to 60% and fixing O y at 15% yielded estimates of 
C£i at the different combinations of variability which were positively biased with 
3 observations made per time point. As with Cl estimates there was a trend in the 
degree of bias associated with c^j estimates. While Cl estimates showed a trend 
of bias from O q and Oy combination of 15% * 15% yielding the least biased 
estimate to the 60% * 15% combination yielding the most biased estimate (Fig. 
3.1a), the reverse was the case for estimates of (Fig. 3.1c). The 15% * 15% 
combination of inter-animal variability yielded the most biased and least precise 
estimate of while the 60% * 15% combination yielded the least biased and 
most precise estimate of this parameter (Fig. 3.1c). The %PE ranged from 2.44 ± 
16.4% for the 60% * 15% combination to 24.4 ± 39.2% for the 15% * 15% 
combination. A similar trend was observed in the bias associated with the
80
estimation of q ^  when 5 observations were made per time point. The least biased 
estimate was observed with q-^ and Oy set at 60 and 15%, respectively, and the 
most biased was obtained with q ^  and O y fixed at 15% (Fig. 3.2c). There was no 
clear cut pattern in the precision of the estimates (Fig. 3.2c). The SD of %PE 
ranged from 16.0% (q ^  = 60%, O y = 15%) to 28.9% (q ^  = 30%, O y = 15%).
Estimates of O y obtained by varying q^j from 15 to 60% while setting O y 
at 15% were relatively stable across the different values of when 3 obser­
vations were made per time point. All the estimates were significantly positively 
biased and imprecise (Fig. 3.Id). Also, when 5 observations were made per time 
point all O y estimates were significantly positively biased and imprecise (Fig. 
3.2d).
When O y was set at 30% and q-^ varied from 15 to 60% estimates of Cl 
which were biased with a positive to negative trend were obtained; positive at 
15% and negative at q ^  of 60% when 3 observations were made per time point. 
The most biased estimate of Cl was obtained when q ^  was specified at 60% (Fig. 
3.3a). All Cl estimates were precise (Fig. 3.3a). The SD of %PE ranged from 
4.9% (q^jj = 15%, O y = 30%) to 10.9% (q ^  = 60%, O y = 30%). Similarly, the 
most biased estimate of Cl was obtained in the 5 observations per time point 
study with q ^  and O y specified at 60 and 30%, respectively (Fig. 3.4a). The bias 
ranged from 1.7% (q ^  = 15%, O y = 30%) to -12.7% (q^j = 60%, O y = 30%). 
These estimates were precise with the SD of %PE ranging from 4.0% (C q = 
15%, O y = 30%) to 10.0% (q:i = 45%, 60%; O y = 30%).
All estimates of V were significantly negatively biased, relatively stable, 
but precise at all levels of q ^  when Oy was 30% and 3 observations were made 
at each time point (Fig. 3.3b). The least precise estimate was obtained when q ^  
and O y were 60 and 30%, respectively. In addition, similar results were obtained 
for V estimates when 5 observations were made at each time point.
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All estimates of this parameter were significantly negatively biased and precise 
(Fig. 3.3b). Setting q ^  and O y at 15 and 30%, respectively, produced the least 
biased estimate of V while the 60% * 30% combination produced the least precise 
estimate of this parameter.
All c^j estimates were positively biased irrespective of the value of C q 
used in combination with G y of 30% when 3 observations were made per time 
point. When and O y were fixed at 15 and 30%, respectively, estimate was 
significantly biased and imprecise (%PE = 23.2 ± 53.0%; Fig. 3.3c). The least 
biased estimate (%PE = 2.7 ± 22.1%) was obtained with and G y set at 60 and 
30%, respectively. At the latter combination of inter-animal variability the 
estimate was acceptably precise (Chapter 2, Section 5.1). All other estimates of 
°C1 were im precise (Fig. 3.3c). Sim ilar, results were obtained when 5 
observations were made per time point. A 15% (o^j) * 30% (O y ) combination 
yielded the most biased estimate and 60% (O q) * 30% (O y ) combination 
produced the least biased estimate (Fig. 3.4c). Only the 60% * 30% inter-animal 
variability combination produced an acceptably precise estimate (SD of %PE = 
25.2%; Fig. 3.4c) since the SD of %PE is only 0.2% greater then 25%.
Significantly positively biased and imprecise estimates of O y were 
obtained at all levels of when Gy was 30% and 3 observations were made per 
time point (Fig. 3.3d). The mean of %PE ranged from 15.8% (q ^  = 15%, G y = 
30%) to 25.6% (<£j = 60%, G y = 30%) while the SD of %PE ranged from 32.1%
(C£l = 15%, O y = 30%) to 46.4% = 45%, O y = 30%). Taking 5 observations
per time point yielded similarly biased and imprecise estimates of O y (Fig. 3.4d).
When G y was 45% and was in the range of 15 to 60% the estimates 
of Cl obtained in the 3 observations per time point study were biased but precise.
The estimates were significantly positively biased when was set at 15%, 
almost unbiased at 30%, and significantly negatively biased at 45 and 60% (Fig. 
3.5a). The most biased estimate was obtained with the 60% * 45% combination of q-jj
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and Oy. The SD of %PE ranged from 8.5% to 15.0%. For the 5 observations per 
time point study there was a trend in the bias from positive to the negative 
direction as q^j was varied from 15 to 60%. The most biased estimate was 
obtained when q^j and O y were specified at 60 and 45%, respectively (Fig. 3.6a). 
The SD of %PE ranged from 4.5% (q ^  = 15%, Oy = 45%) to 10.6% (q ^  = 60%, 
O y =  45%).
V estimates obtained when 3 observations were made at each time point 
were significantly negatively biased at all levels of with Oy fixed at 45% 
(Fig. 3.5b). The estimates were precise for each of the combinations of inter­
animal variability with the SD of %PE ranging from 13.3 to 17.4% (Fig. 3.5b). 
When 5 observations were made per time point V estimates were significantly 
negatively biased and precise (Fig. 3.6b). The least biased estimate was obtained 
with the 15% (q-*j) * 45% (O y) combination.
With O y set at 45% the estimates of q-ij were positively biased when 3 
observations were made at each time point. The most biased estimate was 
obtained when q ^  was specified at 15% and the least biased estimate when q ^  
was fixed at 60% (Fig. 3.5c). All estimates of this parameter were imprecise (Fig. 
3.5c). At this 45% level of O y all estimates of O y were significantly positively 
biased and imprecise (Fig. 3.5d). In addition, the estimates of O q when 5 
observations were made per time point were imprecise and significantly positive­
ly biased (Fig. 3.6c). The estimates of O y obtained for this 5 observations per 
time point study at the different levels of G q with O y  fixed at 45% were 
significantly positively biased and imprecise (Fig. 3.6d).
When O y was 60% and c^j varied, estimates of Cl were positively biased 
when q^j was set at either 15 or 30% and negatively biased when q-^ was set at 
either 45 or 60% with 3 observations made at each time point. The most biased 
and least precise estimate of this parameter was obtained with q ^  fixed at 60% 
(Fig. 3. 7a). All estimates of Cl were precise with SD of %PE ranging from
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6.0% (q ^  = 15%, Oy = 60%) to 17.1% (q ^  (Oy) = 60%; Fig. 3.7a). All estimates 
of V were significantly biased and precise at these specified values of and Oy 
(Fig. 3.7b). The SD of %PE ranged from 13.0 to 21.3%. The most biased and 
least precise estimate of this parameter was obtained when q ^  and O y were set 
at 60%.
Making 5 observations at each time point when Oy was 60% and C q 
varied between 15 and 60% yielded some estimates of Cl which were positively 
biased but precise (Fig. 3.8a). The %PE ranged from -2.4 ± 14.1% (c q , O y = 
60%) to 9.6 ± 5.9% (q^j = 15%, cy = 60%). Most of the estimates of V obtained 
with the various settings of Oq when cy  was fixed at 60% were significantly 
negatively biased (Fig. 3.8b). The mean of %PE ranged from -3.3% (Cq  = 15%, 
cy  = 60%) to -13.6% (C£i (cy) = 60%). All the estimates were acceptably precise 
with the SD of %PE ranging from 13.1 to 22.1%.
Most of the Oq[ estimates obtained when 3 observations were made at 
each time point with <y at 60% and C q  varied between 15 and 60% were 
significantly positively biased with poor precision (Fig. 3.7c). Similar findings 
were obtained when 5 observations were made per time point (Fig. 3.8c). The 
estim ates of Oy at these com binations of inter-anim al variab ility  were 
significantly positively biased and imprecise (Fig. 3.8d) when 5 observations 
were made per time point, but only positively biased and imprecise when 3 
observations were made at each time point (Fig. 3.7d).
Overall, as the values of Cq  and cy  were increased the bias in the 
estimation of Cl increased in both studies (Fig. 3.9a (3 observations per time 
point); Fig. 3.10a (5 observations per time point)). However, the bias in the 
estimates of V were relatively stable irrespective of the study considered (Fig. 
3.9b (3 observations per time point); Fig. 3.10b (5 observations per time point)). 
In contrast to the results obtained with the estimation of Cl, the bias in the
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estimation of decreased as the values of and O y were increased (Fig. 3.9c 
(3 observations per time point); Fig. 3.10c (5 observations per time point)). As 
with the estimation of V, Oy were relatively stable and positively biased (Fig. 
3.9d (3 observations per time point); Fig. 3.10d (5 observations per time point)).
3.4.3 Distribution of Estimates
The validity of the confidence interval coverage of parameter estimates is based 
on the assumption that parameter estimates follow a normal distribution. This 
assumption was validated for each of the estimates using the chi - squared test (p 
< 0.05). Accordingly, estimates of Cl and V for the 3 observations per time point 
study were normally distributed (Tables 3.4). 18.8 and 6.3% estimates of Cl and 
V, respectively, for the 5 observations per time point study were not normally 
distributed . Also, 12.5% (3 observations per time point) and 25.0% (5 
observations per time point) of estimates were not normally distributed. 37.5 
and 43.8% of Oy estimates obtained in the 3 and 5 observations per time point 
studies, respectively, were not normally distributed. These estimates were 
significantly positively skewed (Tables 3.4 & 3.5).
3.4.4 Individual and Joint Confidence Intervals Coverage for Parameter Estimates
Individual and joint coverage for 99% interval estimates containing the 
true parameter value 95% of the time for all parameters are presented in Tables 
3.6 to 3.9 for the 3 observations per time point study and Tables 3.10 to 3.13 for 
the 5 observations per time point study. The coverage for Cl and V was good for 
all combinations of Gq \ and Oy irrespective of the manner in which the coverage 
was computed and the study considered (Tables 3.6 - 3.9 & 3.10 -13). For these 
two parameters the biases in the estimates were generally low (< 19%) and the
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"coefficient of variation” was generally less than 20%.
When catastrophic estimates were either included or excluded in the 
computation of coverage for all data sets good coverage was obtained for and 
O y (Tables 3.6 - 3.9 & 3.10 - 3.13, Section I & II). However, when catastrophic 
estimates were excluded from the numerator during the computation of coverage 
for all data sets, a reasonable coverage was obtained for C q, but significantly 
reduced coverage (less than the expected value of 0.95) was obtained for O y 
when Oqi was varied between 15 and 45% and Gy set at 60% for the 5 
observations per time point study (Table 3.13, Section III). This also occurred 
when either O q  was 60% and O y , 45% or O q (O y )  was 60% for the 3 
observations per time point study (Tables 3.8 & 3.9, Section IE).
The influence of bias in the estimation of confidence interval coverage 
was not marked for either or O y. Standard errors appeared to be the primary 
determinants of interval coverage for these parameters. As the values of the 
combinations of and O y became larger the coverage for these parameters was 
reduced irrespective of the sample size (Tables 3.6 - 3.9 & 3.10 - 3.13, Section 
IE).
When catastrophic estimates were considered in the numerator in 
computing coverage for all data sets the joint coverage was reduced as the values 
for Cqy * combinations became larger (Tables 3.6 - 3.9 & 3.10 - 3.13, Section 
III). The setting of O y at 45 and 60% for the 3 observations per time point study 
and O y at 60% for the 5 observations per time point study led to the production of 
joint confidence intervals coverage for all parameter estimates which were 
significantly lower than the expected value of 0.81.
3.4.5 Incidence of High Correlation between Parameter Estimates
The incidence of high correlation between parameter estimates was
110
relatively low when O y was 15% and Cq  varied between 15 and 60% for either 
study. The incidence of high correlation ranged from 0 to 20% when 3 
observations were made per time point (Table 3.14), with the upper limit of this 
range being for the correlation between Oy and V. On the contrary, incidence of 
high correlation when 5 observations were made per time point ranged from 0 to 
10% (Table 3.15). The highest incidence occurred with the correlation between 
Oy and V.
When was varied between 15 and 60% and O y was specified at 30% 
the incidence of high correlation ranged from 0 to 26.7% for the 3 observations 
per time point study (Table 3.16), and 0 to 16.7% for the 5 observations per time 
point study (Table 3.17).
With O y  at 45%, varying C q resulted in incidence of high correlation 
ranging from 0 to 27.6% when 3 observations were made per time point (Table
3.18), and 0 to 22.2% when 5 observations were made per time point (Table
3.19). In both cases the upper limit of the ranges was for the correlation between 
O y and V.
When 3 observations were made per time point with O y at 60% and Cq  
varied between 15 and 60% the highest incidence (34.5%) of high correlation was 
obtained with the O y versus V pair (Table 3.20). Similarly, the highest incidence 
(46.7%) of high correlation was obtained for this pair when 5 observations were 
made at each time point (Table 3.21).
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3.5 Discussion
The ranges of inter-animal variability used in these studies were based on 
their occurrence in preclinical situations (Lindstrom & Birkes, 1984; McArthur; 
1988). Most Cl estimates were negatively biased irrespective of the values of 
and O y  used to generate the data. This may be either due to estimation error or the 
nature of the NONMEM program because the fixed effect parameters enter the 
regression model nonlinearly and the random effect parameters linearly. This 
negative bias has been noted in the simulation studies reported in the literature 
which involved the use of a monoexponential pharmacokinetic model with 
multiple sampling (Sheiner & Beal, 1983; Al-Banna, Kelman & Whiting, 1990; 
White et al., 1991) with no explanation. There was a tendency for the bias in Cl 
to increase as the value of o ^  was increased, irrespective of the values of O y. 
The relatively larger negative bias at higher values of compared with those 
obtained at smaller values of q ^  for any given value of O y  was indicative of the 
fact that Cl was underestimated as q ^  was increased. This underestimation of Cl 
was coupled with the estimation of with either positive, minimally positive, 
or negligible bias in some cases. It is possible that the estimation error associated 
with Cl was partitioned to q ^ ,  hence the negative bias in Cl estimation and the 
positive bias associated with estimation. This may also be a consequence of 
the one observation per animal study design since this opposite trend in biases 
associated with the fixed and random effects parameters has not been reported 
with multiple sampling involving different combinations of variability using the 
monoexponential pharmacokinetic model (White et al., 1991). Although most 
estimates of were minimally biased, they were mostly imprecise. This was 
possibly a consequence of the number of animals used in each study. Estimates of 
variability associated with structural model parameters are considerably less 
precise, given a fixed number of experimental units, than are estimates of their
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means (Chapter 2, Section 5.3; Sheiner & Beal, 1981: Grasela etal., 1986).
The negatively biased estimates of V were counterbalanced with 
positively biased estim ates of O y . Most of the runs deleted were due to 
NONMEM yielding spurious estimates of Oy and the associated standard error. 
The reasons for NONMEM producing negatively biased estimates of V and 
positively biased estimates of O y are probably the same as those advanced for the 
estimation of Cl and o^j. It is pertinent to note that residual error was not 
estim ated since there was no inform ation in the data sets about error in 
concentration measurements. Thus, NONMEM was estimating composite inter­
animal variability with error in concentration measurements incorporated since it 
had no information on o£ .
Confidence interval estimates are a function of three factors: bias, 
standard error estimates, and the distribution of parameter estimates. Good 
confidence interval coverage was obtained for Cl and V because of the small 
biases and high precision associated with the estimation of these parameters. 
There were no catastrophic estimates with these parameters even though the cut 
off criterion for the "coefficient of variation" was 20% as opposed to 50% for the 
for the variance parameters. For the variance parameters, the interplay of the three 
factors produced confidence intervals which, on average, were not different from 
the expected value of 0.95 when the cut off rule was not applied. With O y, for 
example, although there were large biases present with large standard errors, the 
nonnormality of some of the distributions brought in the confidence coverage 
back to the expected value of 0.95. A small increase is to be expected for a 
variable with a right-skew distribution. The import of large standard errors in the 
production of good confidence interval coverage could be observed when the 
exclusion criterion for NONMEM runs with large "coefficient of variation" was 
applied. The coverage was reduced when compared with the coverage obtained
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with confidence intervals computed without the application of the exclusion 
criterion. Some of these confidence intervals were significantly different from the 
expected value of 0.95 (Tables 3.8 - 3.9 & 3.13, Section III). The standard error 
factor was also the major determinant in the joint coverage for all parameter 
estimates. However, it is difficult to anticipate what the results of the interplay 
between these three factors will be in any given data set.
The generally low incidence of high correlation between parameter 
estimates was an indication of the adequacy of the parameterization of the model. 
The relatively high correlation between G y  and V at some combinations of Cq 
and G y  possibly contributed to the poor estimates of G y  obtained.
In using NONMEM to analyse data in a realistic preclinical animal 
pharmacokinetic setting simulated in these studies no attempt was made to 
optimise conditions in regard to either experimental design. These results suggest 
that when magnitudes of inter-animal variability are in the range specified in 
these data sets, NONMEM produces estimates of fixed effect parameters which 
were relatively accurate and precise given the one observation per animal design. 
It often produced relatively accurate but imprecise estimates of c^p and mostly 
inaccurate and imprecise estimates of G y. It is worthy to note that when biases in 
CqY and Oy- were large, they were positive and would require a more conservative 
approach to data interpretation. In addition, the usual confidence intervals 
computed may give an erroneous impression of the precision with which the 
random effect parameters were estimated because of the large standard errors 
associated with these parameters.
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CHAPTER 4
EFFICIENT PARAMETER ESTIMATION: COMPARISON OF SAMPLING
DESIGNS WITHIN A STUDY
123
4.1 SUMMARY
Simulation studies were carried out to evaluate the influence of sampling 
design on the efficiency of population pharmacokinetic parameter estimation 
when only one observation was obtained per animal. A finite number of 
observations and number of animals, as is always the case in practice, was used in 
the generation of data sets using the one compartment model with IV bolus 
administration.
The effect of arrangement of observations in time on the efficiency of 
parameter estimation was investigated using three different designs: the two 
sample point design, three sample point design, and four sample point design. 
The efficiency of parameter estimation obtained with the different sampling 
schedules within each design was compared to determine the "best" strategy.
The exact location of the third or fourth sample was not critical to the 
overall efficiency with which model parameters were estimated using either the 
three or four sample designs. However, in studies using the two sample design, 
the location of the second sampling time at approximately 1.4 times the 
elimination half-life of the drug or greater resulted in efficient estimation of 
population pharmacokinetic parameters.
4.2 INTRODUCTION
An optimal sampling strategy for monoexponential pharmacokinetic 
model with instantaneous IV input would require taking the first sample as early 
as possible after the dose (tmin) and the other (tend) as late as possible (Edrenyi, 
1981). The maximal feasible response is associated with tmin while the minimal
124
feasible response is associated with ten(j.
In this chapter, simulated data sets were used to investigate the effect of 
arrangement of observations (drug concentrations) in time on parameter 
estimation. Data were generated assuming one compartment open model kinetics 
and IV bolus administration. Different sampling designs within a study were 
compared to identify the "best" sampling design for efficient param eter 
estimation involving the use of one observation per animal.
4.3 SAMPLING DESIGN
In this study, the optimal sampling strategy was applied in an ad hoc 
manner, and the drug was assumed to be administered by IV bolus injection. 15% 
error was added in the concentration measurements (see Chapter 2, Section 2.4). 
Sampling time ranged from as early as possible after the beginning of the 
experiment ( t j ,^  = 5 min.) to some value (ten(j = 240 min.), the latest time that 
could be contemplated in actual experiment, taking into consideration the 
"average" t j ^  drug* 48 observations corresponding to 48 animals were 
used in each design.
4.4 The Two Sample Point Design
In a series of experiments the first sampling time was fixed at 5 min. 
while the second was allowed to vary at 30 min. intervals from 90 to 240 min. 
after dose. The second sampling time was sampled uniformly within a range of
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Fig. 4.1 Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the 
different samples for the two sample point design. Each vertical bar expresses the 
bias and precision of the population parameter estimate for each design. 
Significant (p < 0.05) biases are indicated by asterisks.
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15 minutes centred on the stated time. This was considered to mimic a real study, 
and in the analysis the exact times were used. The six sampling schedules for this 
design specification are shown in Table 4.1.
4.4.1 Results
4.4. la  Bias and Precision
All designs yielded estimates of Cl which were precise. The SD of %PE 
ranged from 3.3% (180 min.) to 5.9% (90 min.). The bias ranged from 
approximately 0.0% (90 min.) to -2.3% (240 min.). Some of the sampling designs 
yielded estimates of Cl which were negatively biased (Fig. 4.1a).
All V estimates were relatively stable, negatively biased, but precise (Fig. 
4.1b). The least biased estimate was obtained with the sampling design in which 
the second sample time was at 90 min. (mean of %PE = -1.2%) and the most 
biased estimate with the second sample at 180 min. (mean of %PE = -3.1%). The 
SD of %PE ranged from 3.5 to 4.4%.
C£i estimates were highly positively biased when the second sample was 
at early times. As the second time point was specified at late times the bias was 
reduced, and tended to level off at 210 min. giving an almost unbiased estimate 
(Fig. 4.1c). However, the biases associated with most O q estimates were 
significant. The bias in the estimation of c^j ranged from -2.3% (210 min.) to 
56.4% (90 min.) although the precision was acceptable with the different designs. 
On the contrary, all estimates of Oy were significantly positively biased, 
relatively stable, and acceptably precise (Fig. 4. Id).
128
(a) Estimation of Cl
180 150 210 240 120 90 Sampling Times (min)
(b) Estimation of V
90 150 180 240 210 120 Sampling Times (min)
(c) Estimation o f< ti
240 210 180 150 120 90 Sampling Times (min)
(d) Estimation of Cy 
240 210 180 90 150 120 Sampling Times (min)
(e) Overall Design Efficiency 
150 240 180 210 120 90 Sampling Times (min)
£
Fig. 4.2 aSummary of significant differences in the efficiency with which 
parameters were estimated using the two sample point design, 
a - Rank order of design numbers increasing from left to right 
* .  Efficiency measured with design number.
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4.4.1b Design Number
The design with the second sample at 180 min. produced the most 
efficient estimate of Cl (Fig. 4.2a). However, the efficiency with which Cl was 
estimated with this design was not significantly better than those with the second 
sample at 120, 150, 210, or 240 min. Also, the efficiency with which Cl was 
estimated with these designs was significantly better than that obtained when the 
second sample was at 90 min. The latter design produced the least efficient 
estimate of Cl.
V was estimated to a similar degree of efficiency with all sampling 
schedules although the design with the lowest rank order (on average) of d>^ . was 
the one with the second sample at 90 min. (Fig. 4.2b).
C£j was most efficiently estimated when the second sample was at 240 
min. (Fig. 4.2c). The efficiency with which this parameter was estimated with this 
design was not significantly better than that obtained when the second sample 
was at either 150, 180, or 210 min. These designs yielded significantly better 
estimates of than designs having the second time point at either 90 or 120 
min. The least efficient estimate of was obtained with the second sample at 90 
min.
Oy was poorly estimated with all sampling designs (Fig. 4.2d), and all 
produced similar results.
Overall, the most efficient estimates of fixed and random effects 
parameters were obtained with the specification of the second sample at 150 min. 
(Fig. 4.2e). The efficiency of parameter estimation with this design was not 
significantly better than when the parameters were estimated with designs having 
the second sample at 120, 180, 210, or 240 min. These designs ( except when the 
second sample was at 120 min.) produced param eter estim ates w ith a 
significantly better efficiency than the design with second time point at 90 min.
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The least efficient estimates of model parameters and their variances were 
obtained with the second sample at 90 min.
Thus, Cl was best estimated with the second sample at 180 min. although 
this was not significantly better than estimates of this parameter obtained when 
the second sample was at 120, 150, 210, and 240 min., respectively. On the other 
hand, V was best estimated when the second sample was at 90 min., and this was 
not significantly better than the results obtained with the other designs, was 
best estimated with the second sample at 240 min. although not significantly 
better than when the second sample was at 150, 180, or 210 min. Oy was poorly 
estimated at all specifications of the second time point.
The design with the second sample at 150 min. yielded the most efficient 
estimates of all parameters of the model, but this was not significantly better than 
when the second time point was at 120,180, 210, or 240 min.
4.4.1c Individual and Joint Confidence Intervals for Parameter Estimates
Individual and joint confidence intervals for parameter estimates are 
summarised in Table 4.2. All designs produced good coverage for individual and 
joint confidence intervals for parameter estimates whether or not NONMEM runs 
with catastrophic estimates were included. The coverage for individual and joint 
parameter estimates were not significantly different from the expected values of 
0.95 and 0.81, respectively. When NONMEM runs with catastrophic estimates 
were discounted in the numerator during confidence interval coverage 
computation a slightly reduced coverage, though not significantly different from 
the expected value, was obtained for and joint parameter estimates when the 
second sampling time was specified at 240 min. (Table 4.2, Section El).
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4.4. Id Incidence of High Correlation between Parameter Estimates
Generally, 0% incidence of high correlation between parameter estimates 
was produced, except the design with the second sample at 90 min., this having 
an incidence of 3.3% for the correlation between Oy and V (Table 4.3).
4.4.2 Discussion
The accuracy and precision with which fixed effect parameters were 
estimated were good with the bias in Cl and V not exceeding 3%, and the SD of 
%PE not exceeding 6%. However, most of the estimates of these parameters were 
negatively biased. This bias may be due to estimation error as discussed in 
Chapter 3. The best estimates of Cl and V in terms of bias and precision were 
obtained when the second sample was at 180 and 90 min., respectively.
The tendency for improvement in accuracy and precision in the estimation 
of C£j as the second sampling time was specified at late times (150 to 240 min.) 
was due to the fact that information about this parameter was best obtained when 
the second sample was approximately two to three times the t y 2  ° f  the drug. 
Thus, an efficient estimate of C q could be obtained at either 180, 210, or 240 
min.
Oy- was inefficiently estimated with all designs. Thus, all estimates of this 
parameter were biased but acceptably precise to the same extent. The positive 
bias associated with the estimation of Oy with all designs and Gq  for some 
designs, could have been due to the lack of information in the data sets about 
concentration measurement error, since NONMEM was estimating composite 
inter-animal variability and concentration measurement error.
A comparison of d>jr ’s obtained from the different sampling designs
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showed that Cl was best estimated when the second sample was at 180 min. 
although this was not significantly better than when the second sample was at 
120, 150, 210, or 240 min., respectively. Thus, specifying the second sampling 
time between 1.4 and 3 times the t j /2 ° f  the drug would produce efficient 
estimates of this parameter since information on drug elimination is contained in 
the late phase of the plasma concentration - time profile. This also explains why 
Gqy was better estimated at the late sampling times.
V was efficiently estimated when the second sample was at 90 min. 
However, this was not significantly different from the results obtained with the 
other designs. The lack of difference was due to the associated bias and precision 
with which this parameter was estimated with the different designs.
As with the estimation of V, all designs produced estimates of Oy which 
were not different from one another. The reasons for this are as previously stated 
forV.
The design which yielded the most efficient estimates of all parameters 
was that with the second sample at 150 min. However, this was not significantly 
different from those obtained with the second time point at 120, 180, 210, or 240 
min. The design with the second time point at 90 min. was significantly worse 
than others, except the one with the second time point at 120 min., due to the bias 
associated with the estimation of Oq.
Bias and precision are some of the factors which determine the properties 
of interval estimates. The interplay of these factors produce confidence intervals 
for fixed effect parameter estimates which had coverage near the expected value 
of 0.95. The good coverage for the random effect parameters was essentially due 
to the good precision associated with these estimates. Also, the good coverage 
obtained for the joint confidence intervals coverage was due to all designs 
producing precise parameter estimates. The reduced coverage, though not
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significant, obtained when the second sample was at 240 min., was due to 12 
NONMEM runs producing estimates of with "coefficient of variation"
> 50%. Moreover, the good coverage obtained for individual and joint confidence 
intervals for parameter estimates was associated with negligible incidence of high 
correlation.
Given the design specifications considered here, the "best" design for the 
efficient estimation of parameters was the one with the second sample at 150 min. 
However, this sampling time could be either 180, 210, or 240 min. to obtain 
parameters estimated with similar efficiency.
4.5 The Three Sample Point Design
The impact of introducing a third sample on parameter estimation was 
investigated. In this design t ^  and tend were fixed at 5 min. and 240 (± 7.5)
min., respectively, and the third sampling time was at 30, 60,90,.... . or 210 (all ±
7.5) min. after dose, yielding the 7 schedules shown in Table 4.1.
4.5.1 Results
4.5.1a Bias and Precision
The estimates of Cl were mostly negatively biased with the mean of %PE 
ranging from -0.3% to -3.1% (30 min.). These estimates were precise with the SD 
of %PE ranging from 3.0% (150 min.) to 4.0% (60 min.) (Fig. 4.3a).
V estimates were precise and mostly negatively biased (Fig. 4.3b). The
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Fig. 4.3 Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the 
different samples for the three sample point design. Each vertical bar expresses 
the bias and precision of the population parameter estimate for each design. 
Significant (p < 0.05) biases are indicated by asterisks.
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(a) Estimation of Cl
150 120 180 60 90 210 30 Sampling Times (min)
(b) Estimation of V
60 30 150 180 90 120 210 Sampling Times (min)
(c) Estimation of
180 210 150 30 120 60 . 90 Sampling Times (min)
(d) Estimation of Oy 
120 180 210 150 90 30 60 Sampling Times (min)
(e) Overall Design Efficiency 
60 30 150 180 90 120 210 Sampling Times (min)
Fig. 4.4 aSummary of significant differences in the efficiency with which 
parameters were estimated using the three sample point design, 
a - Rank order of design numbers increasing from left to right 
* - Efficiency measured with design number.
1 3 8
least biased estimate occurred with the third sample at 60 min. (mean of %PE = 
0.3%) and the most biased estimate with the third sample at 120 min. (mean of 
%PE = -2.7%). The most precise estimate was obtained with the third sample at 
60 min. (SD of %PE = 3.5%) while the least precise was at 210 min. (SD of %PE 
= 6.4%).
Except for the specification of the third sample at 30 or 60 min. there was 
a general trend for the bias in the estimation of to decrease as the third sample 
was shifted towards 240 min. (Fig. 4.3c). Estimates of G q were acceptably 
precise when the third sample was at > 120 min., while the most imprecise 
estimate was obtained with the third sample at 60 min. (SD of %PE = 49.4%). 
The best estimate of this parameter was obtained with the third sample at 180 
min. followed by sampling at 210 min.
As with the two sample design, Oy estimates were significantly positively 
biased and imprecise (Fig. 4.3d). Specification of the third sample at 30 min. 
yielded acceptably precise estimates Oy. The least biased estimate was obtained at 
120 min. (mean of %PE = 33.8%) and the most biased estimate was obtained at 
60 min. (mean of %PE = 67.2%).
4.5.1b Design Number
There was no significant difference when the efficiency with which Cl 
was estimated was compared for all sampling designs. This not withstanding, the 
design with the lowest rank order (on average) of d>ir was that with the third
sample at 150 min. (Fig. 4.4a).
V was most efficiently estimated with the third sample at 60 min. (Fig. 
4.4b), but this was not significantly better than when this sample was at 30, 90, 
150, and 180 min. However, it was significantly better than the efficiency with
139
which estimates of V were produced with the third sample at 210 min.
The most efficient estimate of was obtained with the third sample at 
180 min. (Fig. 4.4c). This, however, was not significantly better than when the 
third sample was at 30, 60, 120, 150, or 210 min., but was significantly better 
than results obtained with this sample at 90 min. Setting the third sampling time 
at 90 min. yielded the least efficient estimates of Oqj. However, when the 
efficiency with which q^j was estimated with this design was compared with that 
obtained at either 60 or 120 min., there were no significant differences.
Cty was estimated with similar efficiency at 30, 90, 120,150,180, and 210 
min. (Fig. 4.4d). The design with the lowest rank order (on average) of was 
that with the third sample at 120 min. The efficiency of O y estimation at this time 
was significantly better than when the third sample was at 60 min.
Overall, the parameters were estimated with similar efficiency at all 
values of the third sample (Fig. 4.4e). There was no significant difference when 
the d>r ’s of all sampling designs were compared.
Consequently, Cl was efficiently estimated with all designs. However, the 
design with the third sample at 150 min. resulted in the lowest rank order of 
(i.e., least biased and most precise). Although V was efficiently estimated with 
the third sample at 30, 60, 90, 120, 150, or 180 min., the most efficient design 
was obtained when the third sample was at 60 min. Oq was most efficiently 
estimated with the third sample at 180 min. The efficiency of the estimation of 
this parameter with this design was not significantly better than the results 
obtained with other designs, except the one with the third sample at 90 min. O y 
was badly estimated with all designs. Overall, the exact location of the third 
sample was not critical for the efficient estimation of the parameters.
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4.5.1c Individual and Joint Confidence Intervals for Parameter Estimates
When NONMEM runs with catastrophic estimates were included in the 
computation of confidence intervals, good coverage was obtained for all designs 
(Table 4.4, Section I). When catastrophic estimates were excluded in the 
numerator and denominator during the computation of confidence intervals 
coverage (see Chapter 2, Section 2.5.2) no significant effect was observed on the 
coverage (Table 4.4, Section II). However, when catastrophic estimates were 
discounted in the numerator during the computation of confidence intervals , the 
coverage for was reduced for the design with the third sample at 60 min. and 
significantly so with this sample at 30 min. (Table 4.4, Section III). Equally 
reduced coverage was observed for the joint confidence intervals for parameter 
estimates with these two designs compared to other designs. The coverage for Cq  
and joint confidence intervals obtained for the design in which the third sample 
was at 30 min. was significantly different from the expected values of 0.95 and 
0.81, respectively. All other designs yielded estimates with individual and joint 
confidence intervals coverage not significantly different from the expected value 
of 0.95 and 0.81, respectively.
4.5. Id Incidence of High Correlation between Parameter Estimates
The pair-wise correlations between V and Cl, and Cl, and Oy and V 
for some designs yielded incidence of high correlation greater than 0% (Table
4.5). The incidence of high correlation between V and Cl was 3.3% for the design 
with the third sample at 210 min., but 0% for other designs. The incidence of high 
correlation for c w i t h  Cl, and C q with V was 6.7% and 3.3% for the designs 
with the third sample at 90 and 210 min., respectively, but 0% for other designs. 
In the correlation between Oy and V, the designs with the third sample at 30, 120,
143
or 210 min. produced an incidence of high correlation of 0%, while 6.7% was 
obtained with designs which had the third sample at 60 and 90 min. An incidence 
of 16.7% and 3.3% was obtained for designs with the third sample at 150 and 180 
min., respectively.
4.5.2 Discussion
The estimation of Cl and V was associated with low bias and high 
precision for all designs. More precise estimates of Cl and V were obtained with 
the third sample at late and early times, respectively, where more information was 
available for the estimation of these parameters. The negative bias associated with 
the estimation of these parameters might be due to estimation error.
Although the estimates of obtained with the third sample at 30 and 60 
min., respectively, were relatively unbiased, these estimates were associated with 
large "coefficient of variation". The improvement in precision when the third 
sample was obtained late was due to the increased amount of information (data 
points) available for C£j (Cl) estimation. The most precise estimate of G y  was 
obtained with the design having the third sample at 30 min. This was due to 
having more data points in the early times. The positive biases associated with the 
estimation of and Gy were due to the lack of information in the data sets on 
cy as earlier discussed for the two sample design.
The efficiency of Cl estimation was similar for all designs, although the 
lowest rank order (on average) of <I>-r was obtained with the third sample at 150 
min. The design with the highest rank order of <J>ir was the one with the third 
sample at 30 min. However, the exact location of the third sample was not critical 
to the estimation of Cl.
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On the contrary, the location of the third sample at early times (30 to 60 
min.) led to a more efficient estimation of V, with the most efficient estimate 
obtained when the third sample was at 60 min., about two-thirds the drug ty 2 (or 
as early as possible).
Gqi was most efficiently estimated with the third sample at 180 min., 
although the location of this sample at any time greater than 1.4 times the t y 2 °f 
the drug led to efficient estimation of this parameter. The best estimate of O y, 
obtained with the third time at 120 min., was associated with the least bias. The 
poor estimates of O y obtained with all designs could be a characteristic of the one 
observation per animal design.
The similar efficiency of estimation of all parameters with all the three 
sample designs indicated that the exact location of the third sample was not 
critical (Fig. 4.4e). The results obtained with the design number approach were in 
good agreement with those obtained using the bias and precision analysis.
The reduced confidence interval coverage obtained for the estimation of 
Oy with the design with the third sample at 30 min. was due to the associated 
bias. On the other hand, the significantly reduced coverage obtained for Cq  
estimates with designs having the third sample at 30 or 60 min., when NONMEM 
runs with catastrophic estimates were discounted in the numerator during 
confidence intervals computation (to reveal the influence of standard error on 
confidence intervals coverage), indicated that the estimates obtained for this 
parameter were not very reliable. However, the good coverage obtained for 
irrespective of the manner in which the confidence intervals were computed using 
the other designs indicated that those estimates were reliable. Apart from the 
design with the third sample at 30 min., the joint confidence intervals coverage 
for parameter estimates was good. The low incidence of high correlation between 
parameters was an indication of the adequacy of the parameterization of the 
model.
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With the designs considered here, the exact location of the third sample 
was not critical to the efficiency with which the set of population pharmacokinetic 
parameters could be estimated.
4.6 The Four Sample Point Design
In this situation, t j ^  and ten(j were fixed as in the previous case at 5 min. 
and 240 min., respectively. The second time point was fixed at 30 (± 7.5) min. 
and the fourth time point was varied between 60 and 210 (all ± 7.5) min. in steps 
of 30 min. (Table 4.1). The aim was to determine the efficiency with which fixed 
and random effects parameters could be estimated with this strategy.
4.6.1 Results
4.6.1a Bias and Precision
The estimate of Cl was least biased and most precise when the fourth 
sample was at 210 min. (Fig. 4.5a). All estimates of Cl were negatively biased 
ranging from approximately -0.2% to 3.1%, with the SD of %PE from 2.9% (210 
min.) to 4.2% (60 min.).
On the contrary, the least biased and most precise estimate of V was 
obtained with the design in which the fourth sample was at 60 min. (Fig. 4.5b). 
All estimates of this parameter were also negatively biased with the mean of %PE 
ranging from -0.2% (60 min.) to 2.0% (120 min.) The SD of %PE ranged from 
3.5% (60 min.) to 5.2% (180 min.).
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Fig. 4.5 Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the 
different samples for the four sample point design. Each vertical bar expresses the 
bias and precision of the population parameter estimate for each design. 
Significant (p < 0.05) biases are indicated by asterisks.
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(a) Estimation of Cl
210 180 90 150 120 60 Sampling Times (min)
(b) Estimation of V
60 150 210 120 90 180 Sampling Times (min)
(c) Estimation of
180 210 150 120 60 90 Sampling Times (min)
(d) Estimation of Oy 
180 120 150 210 90 60 Sampling Times (min)
(e) Overall Design Efficiency 
210 150 180 90 60 120 Sampling Times (min)
£
Fig. 4.6 aSummary of significant differences in the efficiency with which 
parameters were estimated using the four sample point design, 
a - Rank order of design numbers increasing from left to right 
* - Efficiency measured with design number.
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The estimates of were almost unbiased when the fourth sample was at 
60 and 210 min. (Fig. 4.5c). As was the case with the two and three sample 
designs, there was a general trend of decrease in bias in the estimation of Cq  as 
the fourth sample occurred at later times. The estimates of Cq  were imprecise, 
except for the design with the fourth sample at 180 min. The most imprecise 
estimate was obtained when the fourth sample was at 60 min.
The estimation of Oy was associated with a significant positive bias for all 
designs (Fig. 4.5d). The only acceptably precise estimate was obtained with the 
third sample at 210 min.
4.6.1b Design Number
The most efficient estimate of Cl was obtained with the fourth sample at 
210 min. Cl was significantly better estimated with this design than the other 
designs. The least efficient estimate of Cl was obtained when the fourth sample 
was at 60 min. (Fig. 4.6a).
Although the design with the lowest average rank order of <I>^r for the 
estimation of V was that with the fourth sample specified at 60 min., there was no 
significant difference when the d ^ ’s for all designs were compared (Fig. 3.6b).
G£i was most efficiently estimated with the fourth sample at 180 min. 
However, this was not significantly better than when this sample was at 60, 120, 
150, and 210 min. (Fig. 4.6c). The design with the fourth sample at 90 min. 
produced the least efficient estimate of c^p and this was significantly worse than 
the results obtained with designs having the fourth sample at 180 min and 210 
min., but not significantly worse than when this sample was at 60, 120 or 150 
min.
Oy was estimated with similar efficiency by all designs (Fig. 4.6d). The 
design with the lowest rank order of d>^ (on average) was the one with the fourth
149
sample at 180 min.
Similarly, there was no difference in the overall efficiency with which the 
population pharmacokinetic parameters were estimated (Fig. 4.6e).
Thus, Cl was most efficiently estimated when the fourth sample was at 
210 min. V was efficiently estimated with all designs since there was no 
significant difference in the efficiency with which it was estimated when the 
O ^ ’s were compared. However, the most efficient (least biased and most precise) 
estimate of this parameter was obtained with the fourth sample at 60 min. On the 
other hand, was most efficiently estimated when the fourth sample was at 180 
min. The efficiency with which this parameter was estimated with this design was 
not significantly better than that with which it was estimated when the fourth 
sample was at 60,120,150, and 210 min., respectively. The efficiency of Oy 
estimation obtained with the different designs was indistinguishable.
Equally, there was no significant difference in the overall efficiency with 
which all the parameters were estimated. Again, the results obtained using bias 
and precision were in agreement with those obtained using O ^’s.
4.6.1c Individual and Joint Confidence Intervals Coverage for Parameter
Estimates
The coverage for individual and joint confidence intervals for parameter 
estimates was good for all designs when the influence of bias alone was 
considered (Table 4.6, Section I &II). When the runs with catastrophic estimates 
were discounted in the numerator to examine the influence of standard errors on 
confidence intervals coverage (Table 4.6, Section III) the design with the fourth 
sample at 60 min. was found to yield estimates of c^j with a confidence interval
150
Ta
ble
 4
.6 
In
di
vi
du
al 
and
 
Jo
int
 C
on
fid
en
ce
 
In
ter
va
ls 
Co
ve
ra
ge
 
for
 P
ar
am
ete
r 
Es
tim
ate
s 
Ob
tai
ne
d 
wi
th 
the
 
Fo
ur
 S
am
ple
 
Po
in
t 
D
es
ig
n
•§ COCS CS '
I
C*—(
§•a
I
co•a
8co
&W
(A
{Aou
3CO
CO CO
I
8 1
to
.S
»“ 5  (A  Q< O
co H
c
!S
I £
:§
P
co
NO o
I  Ics cs
£
o
sco
©
§8
o
§CO
O
§8
CO
Scs
o
§
CO
© S
^  2  WO On CS CS
o o
2  2  ©  ©
CO CO
O
S
CO
OSCO
s a
o
§CS
O
Q
8
s i scs
r~ci
COcs
Ongoocsoo
o
2O'cs
o
28
<s
o
§
CO
o
s
CO
5 I*-l ^cs *-< 
o o
s  $cs cs
s  a 
s  a
© s?JO 5
or oCS CO
o
§ I
CO CO
o o
JO JO
r- oo CS cs
o o
2  2 O' OO
CS cs
© sJO JO  
v©cs cs
CO CS
O
28
o
28
©cs
0
1
0
1
o»n
o
28
0
1
a
0
1
o  ©oo*-« CS
1 5 1
p 
< 
0.
01
Ta
ble
 4
.7 
In
cid
en
ce
 o
f 
Co
rre
lat
io
n 
Va
lue
s 
As
so
cia
ted
 
wi
th 
Pa
ra
m
ete
rs 
for
 t
he 
Fo
ur
 S
am
ple
 
Po
int
 D
es
ig
n
I
o
cs
■5
E o o
CO
CO
Ooo
I
r-
vo0\
W>a
*o
CO
CO
©«n
!
■§>s
$
00a
!
$
8 8
*
CO
CO
00
o
S
.5
6
eo
"oba
*
*r-
VO
£
H
00
.5
cx
c/i
0  >  o  >  &
CA tf l> >
152
Co
rre
lat
io
n 
co
ef
fic
ien
t 
< 
0.
75
coverage significantly less than the expected value of 0.95. This design yielded 
23 runs with catastrophic estimates of c ^ .  On the other hand, the design with the 
fourth sample at 210 min. also produced estimates with reduced coverage, but 
this was not significantly different from the expected value of 0.95. In this case 
11 NONMEM runs had catastrophic estimates of this parameter. Apart from the 
design with the fourth sample at 60 min. the other designs produced estimates of 
parameters whose joint coverage was not significantly different from the expected 
value of 0.81.
4.6. Id Incidence of High Pair-Wise Correlations
The incidence of high correlation between Gy and V did not exceed 10% 
for any of the study designs (Table 4.7). With the exception of the correlation of 
G y  and V all designs produced parameter estimates which were not highly 
correlated with one another.
4.6.2 Discussion
The production of the least biased and most precise estimates of Cl and V 
with the designs having the fourth sample at 210 and 60 min., respectively, was 
due to the fact that more information was contained in the data sets for the 
estimation of these parameters at late and early samples, respectively. The 
negative biases associated with the estimation of these fixed effect parameters 
were due to estimation error as earlier discussed.
Also, the production of efficient estimates of with late samples (180 
min. (%PE = -3.6 ± 27.4%), and 210 min. (%PE = 11.3 ± 25.1%)) was due to the
153
same cause. The estimate of obtained with the fourth sample at 60 min., 
although almost unbiased, was associated with very poor precision (%PE = 2.5 ± 
46.2%).
Using the design number approach, Cl was found to be most efficiently 
estimated when the fourth sample was at 210 min. The reason for this was 
previously stated when the result was discussed for bias and precision. The lack 
of difference in the estimation of V was due to the estimates being similarly 
biased and precise. No design produced estimates of V with "coefficient of 
variation" > 20% (Table 4.6).
Cq Y was more efficiently estimated with the fourth sample at > 1.4 times 
11/2 of the drug, since this provided more information on this parameter. The 
efficiency of estim ation with the fourth sample at 60 min., although not 
significantly different from the results with the fourth sample at 120, 150, 180, 
and 210 min., was not acceptable. This was due to this design having 23 runs 
with the "coefficients of variation" > 50%. The similar poor efficiency with 
which all designs estimated Oy could have been a consequence of the one 
observation per animal study design.
The exact location of the fourth sample was not critical in the overall 
estimation of parameters. The specification of two samples at not greater than one 
third the elimination ty 2  °f the drug (Table 4.1) and the fourth sample close to or 
greater than the ty 2  the drug, with the last sample at 240 min., might have 
contributed to this observation.
The influence of bias on confidence interval coverage was negligible. All 
designs produced good coverage for individual and joint parameter estimates 
when NONMEM runs with catastrophic estimates were included in the numerator 
during confidence intervals computation. The predominant factor governing 
confidence intervals coverage in the studies considered here, was standard errors.
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Excluding NONMEM runs with estimates which had "coefficients of variation"
> 50% in the numerator during confidence intervals computation led to reduced 
coverage for for most designs, and Oy for two designs.The reduction in the
coverage for was significant only for the design in which the fourth sample
was at 60 min. With this design also, estimates of the joint confidence intervals 
coverage for parameter estimates was significantly different from the expected 
value because of the significantly reduced coverage for estimates. Setting the 
fourth sample at 210 min. was also associated with reduced coverage when 
NONMEM runs with catastrophic estimates were discounted in the numerator for 
confidence intervals computation. However, this was not significantly different 
from the expected value.
In addition, the estimation of parameters with this design was associated 
with low incidence of high correlation between parameter estimates. This might 
have contributed to the lack of significant difference in the overall efficiency with 
which model parameters were estimated.
Thus, the overall efficiency of parameter estimation obtained with all the 
four sample designs was similar. Although the exact location of this sample was 
not critical, the specification of the fourth sample at > 2.5 times the elimination 
ty 2  of the drug would result in more efficient parameter estimation.
1 5 5
CHAPTER 5
THE TWO COMPARTMENT POPULATION PHARMACOKINETIC 
MODEL: PARAMETER ESTIMATION WITH ONE 
OBSERVATION PER ANIMAL
1 5 6
5.1 SUMMARY
A simulation study was carried out using the two compartment model 
with IV bolus injection of a test drug. The efficiency with which model parame­
ters and their variances were estimated was investigated given a set of parameter 
values, concentration measurement error with different sample sizes and sampling 
schedules. Data were simulated using one observation per animal.
Efficient parameter estimation was obtained when 15 observations were 
made per time point. Concentration measurement error greater than 10% yielded 
variance parameter estimates with greater degree of bias and imprecision. The 
inter-animal variability in parameters estimated was a composite of inter- and 
intra-animal variability.
When a  was in the range of 2.0 and 4.0 h"* and the A:B ratio between 2.5 
and 40.0 efficient estimates of parameters were obtained. Some sampling 
schedules gave more efficient estimates of some parameters than others. High 
correlation between some parameters led to instability in the estimates.
5.2 INTRODUCTION
Equation (5.1) is the general equation for the disposition of a drug exhibit­
ing two compartment open model kinetics and administered by IV bolus injec­
tion.
C = A.exp(-a.t) + B.exp(-p.t) (5.1)
where A and B are regression coefficients; a  and p are hybrid rate constants of 
distribution and elimination, respectively. Using the model expressed in Eq. (5.1)
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the efficiency with which model parameters and their variances could be 
estimated was investigated given a set of parameter values, concentration 
measurement error with different sample sizes and sampling schedules.
5.3 METHODS
5.3.1 SAMPLING DESIGN
The individual values of A and B were randomly selected from normal 
distributions with means of 10000.0 and 500.0 IU/ml, respectively. The values of 
a  and p, were similarly selected from distributions with means of 2.0 and 0.2 h"*, 
respectively. The respective variances were chosen to yield a coefficient of 
variation of 15% for all parameters. A 15% error was added in concentration 
measurements as previously described (see Chapter 2, Section 2.4), except in (b) 
below.
An intravenous bolus dose of 200,000 IU was specified and data were 
sampled at ten time points, viz. 0.083, 0.25,0.50, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, and
6.0 h. The first point was fixed while the others were sampled from a uniform 
range of 0.25 h centred on the stated time. The simulation was carried out as 
previously described in Chapter 2 (Section 2.4) with 30 replicates of data for each 
simulation run.
(a) The effect of varying the number of observations at each time (i.e., 
number of animals used per time point) on the efficiency with which parameters 
were estimated was investigated using either 6, 10, or 15 observations per time 
point, yielding sample sizes of 60,100, and 150, respectively.
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(b) The influence of error in concentration measurements on parameter esti­
mation was investigated by specifying ae to be 0, 1, 5, 10, and 15%. A sample 
size of 150 was used in this study. The values A, a , B, and p were as previously 
stated.
(c) The efficiency with which model parameters were estimated with a  in the 
range of 1.5 to 8.0 h' 1 (i.e. 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, and 8.0 h '1) was 
investigated. As with (b) a sample size of 150 was used in this study.
(d) The efficiency with which the parameters were estimated was investigated 
given a range of A:B ratios: 1.0, 2.5, 5.0, 7.5, 10.0, 20.0, 30.0, and 40.0. The A:B 
ratios were obtained by keeping B at a constant mean value of 500.0 IU/ml while 
the mean value of A was varied.
(e) From (a) and (b) above (a  = 2.0 h"*, p = 0.2 h"*, and A:B ratio = 20.0 ) it 
was observed that the change over from the a  to the p phase occurred after 2.0 h. 
Taking this demarcation of the a  and p phases into consideration, the influence of 
varying sampling times in either the a  or p phase of the plasma concentration 
time curve was examined in two separate studies:-
Study I:
12 sampling times were specified in the a  phase. In this case the first time 
was fixed while the others were varied within a range of 0.033 h on the selected 
time (Table 5.1). The number was then reduced to 7, 5, and 3 (Table 5.1) with the 
total number of sampling times being 15,10, 8, and 6, respectively. Consequent­
ly, the sample sizes were 150,150,152, and 150, respectively.
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Study II:
The number of sampling times in the p phase was increased from 3 to 6, 
and to 8 (Table 5.1), with a resultant total number of sampling times of 10, 13, 
and 15, respectively (i.e., 7 times in the a  phase). The corresponding sample sizes 
were 150, 143, and 150, respectively. In each study, sample sizes were kept as 
close as possible to 150 to allow comparison of the results, oc and the A:B ratio 
were set at 2.0 h’* and 20.0, respectively.
5.4 RESULTS
NONMEM runs with estimates of parameters and /  or their standard errors 
which did not satisfy the outlier criteria outlined in Chapter 2 (Section 2.5.1) were 
deleted. The results presented were based on runs with acceptable estimates.
5.4.1 Effect of Sample Size
The 60, 100, and 150 sample sizes had 27, 27, and 29 successful 
NONMEM runs, respectively. Most estimates of Gp were infinitesimal and 
removing this parameter from the model did not alter the results. Model parame­
ters were associated with minimal bias for the various sample sizes (Fig. 5.1 (a - 
d)). Although the biases in the estimates of A and a  were significant for the 
sample size of 150, these were less than 5% (Fig. 5.1 (a & b)). The estimates of p 
were unbiased irrespective of the sample size (Fig. 5.Id). The estimates of A and 
a  obtained with the different sample sizes were precise (SD of %PE < 9%), while 
the estimates of B (Fig.5.1c) and p (Fig. 5.Id) obtained with the 60 and 100 
sample sizes were imprecise. Only the estimates of these parameters obtained 
with the 150 sample size were precise (SD of %PE < 13%). The estimates of cr ,^
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Fig. 5.1 (a - d) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the number 
of animals used for observations at each time point. Each vertical bar expresses 
the bias and precision of the population parameter estimate. Significant (p < 0.05) 
biases indicated by asterisks.
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(b) Estimation of a
150 60 100 Sample size
(c) Estimation of B
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Fig. 5.2(a - e) aSummary of significant differences in the efficiency with which 
parameters were estimated: effect of varying sample size.
- Rank order of design numbers increasing from left to right.
Efficiency measured with design number
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(h) Overall Design Efficiency 
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Fig. 5.2(f - h) aSummary of significant differences in the efficiency with which 
parameters were estimated: effect of varying sample size.
- Rank order of design numbers increasing from left to right.
Efficiency measured with design number
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an<^  °B were significantly positively biased (Fig. 5.1(e - g)). These estimates 
were associated with poor precision for the 60 and 100 sample sizes. Using the 
150 sample size, acceptably precise estimates were obtained for and aa  while 
an imprecise estimate was obtained for cfg.
The were compared using the Kruskal Wallis test with multiple 
comparisons. The estimate of A produced with a sample size of 150 was signifi­
cantly better than estimates produced with the sample size of 60 but not 100 (Fig. 
5.2a). The most efficient estimate of A was obtained using a sample size of 150 
while the least efficient estimate was obtained with a sample size of 60. Also, the 
most efficient estimate of a  was obtained with the sample size of 150 while the 
least efficient estimate was obtained with a sample size of 100 (Fig. 5.2b). 
However, the efficiency with which a  was estimated using the 100 sample size 
was not worse than that with the sample size of 60.
The best estimate of B was obtained using the 150 sample size. This was 
significantly better than the results obtained with the other two sample sizes 
which were not significantly different to each other (Fig. 5.2c). p was most effi­
ciently estimated when the sample size was 150. This was significantly better 
than when the sample size was 100. Although the least efficient estimate of p was 
obtained with the latter sample size it was similar to that obtained with the 60 
sample size.
(Fig. 5.2e) and oa  (Fig. 5.2f) were most efficiently estimated with the 
150 sample size, and these were significantly better than when the sample size 
was 60. The estimates obtained with a sample size of 100 had efficiencies similar 
to the other sample sizes, was estimated with similar efficiency using the three 
sample sizes (Fig. 5.2g).
Overall, parameters were most efficiently estimated when the 150 sample 
size was used. As expected, the sample size of 60 yielded the least efficient 
estimates of parameters when considered as a set. The results obtained with the
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Table 5.2 Effect of Sample Size on Individual and Joint Confidence Intervals Coverage 
for Parameter Estimates
Section I
Success
Total
Sample Parameter
Size A a  B P °A ^  %  Joint
60 27/27 27/27 27/27 27/27 25/27 27/27 27/27 25/27
100 27/27 27/27 27/27 27/27 26/27 27/27 27/27 26/27
150 29/29 29/29 29/29 29/29 25/29 29/29 29/29 25/29
Section II
(Success - Excluded)
(Total - Excluded)
60 27/27 27/27 27/27 26/26 20/22 9/9 1/1 0/0
100 27/27 27/27 26/26 23/23 26/27 16/16 1/1 0/0
150 29/29 29/29 29/29 29/29 25/29 28/28 0/0 0/0
Section HI 
(Success - Excluded) 
Total
60 27/27 27/27 27/27 26/27 20/27
lie
9/27 1/27* 0/27’
100 27/27 27/27 26/27 23/27 26/27 16/27 1/27* 0/27'
150 29/29 29/29 29/29 29/29 25/29 28/29 0/29* 0/29'
________ _______ —........---------------- -- ----
* - p < 0.01
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sample size of 150 were significantly better than the results obtained with either 
100 or 60 sample sizes.
When catastrophic estimates were included in the computation of individ­
ual and joint confidence intervals coverage for all parameters, good coverage was 
obtained (Table 5.2, Section I). However, when the catastrophic estimates were 
excluded in the computation of coverage, good coverage was obtained for A, a, 
B, p, and for all the sample sizes studied. Although good coverage was ob­
tained for with 150 observations, the coverage obtained with 100 observations
was reduced but not significantly lower than the expected value of 0.95, and poor 
coverage was obtained with 60 observations (Table 5.2, Section II & III). When 
the catastrophic estimates were excluded, very poor coverage was obtained for 
irrespective of the sample size (Table 5.2, Section III). Similar results were ob­
tained for the joint coverage of all parameter estimates.
The incidence of high correlation was 100% for the correlation between P 
and B, but there was generally low incidence (< 30%) of high correlation between 
other parameter estimates (Table 5.3).
Overall, the use of 150 observations (15 animals per sampling time) 
yielded parameter estimates which were acceptably precise and least biased as 
expected.
5.4.2 Varying the Error in Concentration Measurements
With Ge  specified at 0, 1, 5, 10, and 15% there were 29, 28, 28, 29, and 
29, respectively, successful NONMEM runs. As in the previous section Gp was 
removed from the model. Although the estimates of A and a  were significantly 
negatively biased for all values of oe , the magnitude of the bias was very small. 
The mean %PE ranged from -1.3 to -4.0% (Fig. 5.3( a & b). These estimates were
169
%PE
2 0  - (a) A
10-1
0
-10-
-20-
201 
10-
0 -
-10-
-20-
20 1 
10-
0 -
-10
-20
20 7 
10-
0 -
-10-
-20 -
(b )a
(c) B
t
i
t*
i*
15%ct
Fig. 5.3(a - d) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the 
different values of used in the study. Each vertical bar expresses the bias and 
precision of the population parameter estimate. Significant (p < 0.05) biases 
indicated by asterisks.
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Fig. 5.4 aSummaiy of significant differences in the efficiency with which all 
parameters were estimated: effect of error in concentration measurements.
- Rank order of design numbers increasing from left to right.
Efficiency measured with design number.
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Tabic 5.4 Effect of Error in Concentration Measurements on Individual and 
Confidence Intervals Coverage for Parameter Estimates
Section I 
Success_ 
Total
<*= Parameter
(%) A a B P °A <tx % Joint
0.0 29/29 29/29 29/29 29/29 27/29 29/29 29/29 27/29
1.0 28/28 28/28 28/28 28/28 27/28 28/28 28/28 27/28
5.0 28/28 28/28 28/28 28/28 28/28 28/28 28/28 28/28
10.0 29/29 29/29 29/29 29/29 29/29 29/29 29/29 29/29
15.0 29/29 29/29 29/29 29/29 25/29 29/29 29/29 25/29
Section II
ISuccess_- Excluded), 
(Total - Excluded) .ls2
0.0 29/29 29/29 29/29 29/29 27/29 29/29 5/5 5/5
1.0 28/28 28/28 28/28 28/28 27/28 28/28 2/2 2/2
5.0 28/28 28/28 28/28 28/28 28/28 27/27 1/1 0/0
10.0 29/29 29/29 29/29 29/29 29/29 28/29 1/1 0/0
15.0 29/29 29/29 29/29 29/29 25/29 28/29 0/0 0/0
Section in 
(Success - Excluded) 
Total
0.0 29/29 29/29 29/29 29/29 27/29 27/29 5129* 5/29*
1.0 28/28 28/28 28/28 28/28 27/28 28/28 2/28* 2/28*
5.0 28/28 28/28 28/28 28/28 28/28 27/28 1/28* 0/28*
10.0 29/29 29/29 29/29 29/29 29/29 28/29 1/28* 0/28*
15.0 29/29 29/29 29/29 29/29 25/29 28/29 0/29* 0/29*
*-p<0.01
1 7 3
very precise (SD of %PE < 4.5%). All estimates of B were precise but positively 
biased (Fig. 5.3c). |3 estimation was associated with minimal bias and relatively 
good precision (Fig. 5.3d). The highest degree of bias was obtained for aA, c^, 
and Cfc when oe was specified at 15% (Fig. 5.3(e - g)).
Parameter estimation was least efficient when ae was set at 15% (Fig. 
5.4) since Or was significantly higher than when ce was specified at 0, 1, 5, or 
10%. As expected the best parameter estimates were obtained with ce set as 0%, 
but the results obtained were not significantly better than the results obtained with 
ce specified at 1,5 , and 10%.
Good individual and joint confidence intervals coverage was obtained for 
all levels of a€ used in this study (Table 5.4, Section I). However, discounting 
estimates, with "coefficient of variation" greater than 50% in the numerator for 
the computation of confidence intervals coverage, gave poor coverage for Oq and 
joint parameter estimates (Table 5.4, Section IE).
Thus, as the error in concentration measurements increased the efficiency 
with which parameters were estimated decreased as expected.
5.4.3 Varying the Distribution Rate Constant
The distribution rate constant (a) was varied between 1.5 and 8.0 h"1 (i.e. 
1.5 , 2 .0 , 2 .5, 3.0, 3.5, 4 .0 , 6.0, and 8.0 h"1) and the number of successful 
NONMEM runs were 27, 29, 29, 29, 30, 30, 29, and 28, respectively. As in the 
previous studies Ojj was removed from the model. The results show that A and oc 
were associated with good precision and negative bias, irrespective of the value 
of a  (Fig. 5.5 (a & b)). Except when a  was 1.5 h '1, B and p were unbiased and 
precise (Fig. 5.5 (c & d)). All estimates of cA, % , and Cfc were significantly posi­
tively biased (Fig. 5.5 (e - g)). Poor precision was obtained in the estimation of
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respectively) for estimated parameters. The horizontal axis represents the 
different values of a  used in the study. Each vertical bar expresses the bias and 
precision of the population parameter estimate. Significant (p < 0.05) biases 
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(a) Estimation of A
1.5 2.0 2.5 3.0 3.5 4.0 6.0 8.0 a  (If1)
(b) Estimation of a
3.5 2.5 4.0 2.0 3.0 1.5 6.0 8.0 a  (h '1)
(c) Estimation of B
6.0 8.0 3.5 4.0 3.0 2.0 2.5 1.5 a  (If1)
(d) Estimation of p
8.0 6.0 3.5 4.0 3.0 2.0 2.5 1.5 a (h _1)
Fig. 5.6(a-d) aSummary of significant differences in the efficiency with which 
parameters were estimated: effect of different a  values 
a - Average rank of design number increasing from left to right.
* Efficiency measured with design number
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(e) Estimation of cr^
2.0 2.5 4.0 1.5 8.0 3.5 3.0 6.0 a  (If1)
(f) Estimation of
4.0 8.0 6.0 3.0 2.5 2.0 1.5 3.5 a ( h _1)
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(h) Overall Design Efficiency
2.0 2.5 4.0 3.5 3.0 6.0 8.0 1.5 a (h _1)
Fig. 5.6(e - h) aSummary of significant differences in the efficiency with which 
parameters were estimated: effect of different a  values 
- Average rank of design number increasing from left to right.
Efficiency measured with design number
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(SD of %PE ranged from 26.8 to 32.2%) when a  was varied between 3.5 and
8.0 h The estimates of oa  were generally precise while those of Cg were 
mostly imprecise, the most imprecise estimate being when a  was 1.5 h"^.
Using the the best estimate of A was obtained with a  of 1.5 h“* 
(Fig. 5.6a). However, this was not significantly better than the efficiency with 
which A was estimated for a  between 2.0 and 4.0 h"1. The efficiency with which 
A was estimated with a  of 1.5 and 2.0 h“* was significantly better than when a  
was 6.0 or 8.0 h"*. The least efficient estimate of A was obtained when a  was 8.0 
h’ l. a  was estimated with similar efficiency over the range investigated (Fig. 
5.6b).
B was most efficiently estimated when a  was 6.0 h'*, but this was not 
significantly better than the results obtained when a  was 3.5, 4.0, and 8.0 h"^ 
(Fig. 5.6c). However, the B estimates obtained with a  of 6.0 and 8.0 h-* were 
significantly better than those obtained when a  varied between 1.5 and 3.0 h“*. 
Also, p was most efficiently estimated when a  was 8.0 IT* (Fig. 5.6d). The 
efficiency of p estimation when a  equalled 8.0 h'* was not significantly better 
than that when a  varied between 3.0 and 6.0 h~*. However, p estimates obtained 
when a  was 6.0 and 8.0 h“* were significantly better than those obtained when a  
varied between 1.5 and 2.0 h'*.
aA (Fig. 5.6e) and ca  (Fig. 5.6f) were estimated with similar efficiency 
for all values of a. However, the lowest rank order (on average) of d>ir’s was 
obtained when a  was 2.0 h-1 for aA and a  equalled 4.0 h"1 for aa . On the other 
hand, Gq was best estimated when a  was 8.0 IT1 and the worst estimate was 
obtained when a  was 1.5 h' 1 (Fig. 5.6g). The efficiency of cg estimation with a  
of 8.0 h"1 was not significantly better than that when a  varied between 2.5 and
6.0 h"1, but was significantly better than that obtained with a  of 1.5 and 2.0 h"1.
Overall, the parameters were best estimated when a  was 2.0 h-1
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Table 5.5 Effect of Different Values of a  on Individual and Joint Confidence Intervals 
Coverage for Parameter Estimates
Section I
Success
Total
a  1 (h’1) A a B
Parameter
P oA % % Joint
1.5 27/27 27/27 27/27 27/27 21/27 27/27 27/27 21/27
2.0 29/29 29/29 29/29 29/29 25/29 29/29 29/29 25/29
2.5 29/29 29/29 29/29 29/29 27/29 29/29 29/29 27/29
3.0 29/29 29/29 29/29 29/29 28/29 29/29 29/29 28/29
3.5 30/30 30/30 30/30 30/30 29/30 30/30 30/30 29/30
4.0 30/30 30/30 30/30 30/30 28/30 30/30 30/30 28/30
6.0 29/29 29/29 29/29 29/29 21/29 29/29 29/29 21/29
8.0 28/28 28/28 28/28 28/28 28/28 28/28 28/28 28/28
Section II
_[Success_- Excluded). 
(Total - Excluded)
1.5 27/27 27/27 27/27 25/25 21/27 21/21 0/0 0/0
2.0 29/29 29/29 29/29 29/29 25/29 28/28 0/0 0/0
2.5 29/29 29/29 29/29 29/29 27/29 25/25 5/5 4/4
3.0 29/29 29/29 29/29 29/29 28/29 27/27 15/15 13/13
3.5 30/30 30/30 30/30 30/30 28/29 23/23 26/26 20/23
4.0 30/30 30/30 30/30 30/30 27/29 23/23 27/27 19/19
6.0 29/29 29/29 29/29 29/29 21/21 21/21 29/29 16/16
8.0 28/28 28/28 28/28 28/28 13/13 19/19 28/28 8/8
1 8 0
Table 5.5 Effect of Different Values of a  on Individual and Joint Confidence Intervals 
Coverage for Parameter Estimates
Section III 
(Success - Excluded) 
Total
a
(h '1) A a B
Parameter 
P aA <*x % Joint
1.5 27/27 27/27 27/27 25/27 21/27 21/27 0/27* 0/27*
2.0 29/29 29/29 29/29 29/29 25/29 28/29 0/29* 0/29*
2.5 29/29 29/29 29/29 29/29 27/29 25/29 5/29* 4/29*
3.0 29/29 29/29 29/29 29/29 28/29 27/29 15/29 13/29
3.5 30/30 30/30 30/30 30/30 28/30 23/30 26/30 20/30
4.0 30/30 30/30 30/30 30/30 27/30 23/30 27/30 19/30
6.0 29/29 29/29 29/29 29/29 21/29 21/29 29/29 16/30
8.0 28/28 28/28 28/28 28/28 13/28 19/28 28/28 8/28*
* - p < 0.01
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(Fig. 5.6h). However, the parameters were estimated with similar efficiency 
when a  was varied between 2.0 and 4.0 h"^. The efficiency of parameters 
estimation with a  of 2.0 h"^ was significantly better than the efficiency of 
parameters estimation when a  was either 1.5 h' 1 or between 6.0 and 8.0 h '1.
Thus, A was efficiently estimated when a  was in the range of 1.5 and 4.0 
h"^, with the most efficient estimate obtained when a  was 1.5 h"^. a  was estimat­
ed with similar efficiency with the range of a  considered in this study. B and P 
were best estimated with a  in the range of 3.5 and 8.0 h"1 although the most 
efficient estimates of these parameters were obtained with a  of 6.0 and 8.0 h"*, 
respectively. While and were estimated with similar efficiency irrespective 
of the value of a, og was more efficiently estimated when a  was within the range 
of 2.5 to 8.0 h’l. The best estimate of Cg was obtained when a  was 8.0 h"^. All 
parameters were more efficiently estimated when a  was between 2.0 and 4.0 h"^, 
but the most efficient parameter estimates were obtained when a  was 2.0 h“ .^
In addition, the estimation of all parameters was associated with good 
individual and joint parameters confidence intervals coverage when catastrophic 
estimates were included (Table 5.5, Section I). However, when runs with "coeffi­
cients of variation" > 50% were excluded, poor coverage was obtained for eg 
when a  was between 1.5 and 2.5 h"^ (Table 5.5, Sections II & III). The joint 
confidence intervals coverage obtained was significantly lower than the expected 
value of 0.70 for a  between 1.5 and 2.5 h '1, and for a  of 8.0 h' 1 (Table 5.5, 
Section III).
The incidence of high correlation obtained for the correlation between B 
and a , p and a, and p and B when a  was 1.5 h' 1 was high. For all values of a  
high incidence of high pair-wise correlations was obtained between p and B, and 
for a  and A when a  was 6.0 h"* (Table 5.6).
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5.4.4 Varying A:B Ratio
When the ratio of A:B was varied between 1.0 and 40.0 (i.e. 1.0, 2.5, 5.0,
7.5,10.0, 30.0, and 40.0) and a  was 2.0 h'*, the number of successful NONMEM 
runs were 27, 29, 30, 30, 29, 29, 29, and 27. As in the previous experiments, op 
was excluded in the model and Fig. 5.7 shows the results as the A:B ratio varied.
All the estimates of A were minimally biased but relatively precise (Fig. 
5.7a). The most biased and least precise estimate was obtained for the A:B ratio 
of 1.0. Most estimates of a  were negatively biased. Apart from the estimate of 
this parameter obtained when the A:B ratio was 1.0 (SD of %PE = 26.2%) all 
other estimates were precise (Fig. 5.7b). All estimates of B and P were acceptably 
precise (Fig. 5.7 (c & d)). The estimates of B were significantly positively biased 
when the A:B ratio was 30.0 or 40.0. Also, greater bias was associated with 
estimates of p when the A:B ratio was 30.0 or 40.0. All estimates of c^, Oj^ , and 
were significantly positively biased (Fig. 5.7 (e - g)). With the exceptions of 
estimates of obtained for A:B ratios of 1.0 and 2.5, other estimates of this 
parameter were acceptably precise. The estimates of ca  were acceptably precise 
for A:B ratios of 20.0, 30.0, and 40.0, but all Cg estimates were imprecise. The 
greater the A:B ratio the greater the precision in the estimation of and Ga .
A was efficiently estimated when the A:B ratio was 30.0 (Fig. 5.8a), but 
this was not significantly better than that obtained with A:B ratio of 40 and be­
tween 2.5 and 20. However, this parameter was estimated with a significantly 
better efficiency with A:B ratio in the range of 2.5 and 40.0 than with A:B ratio 
of 1.0.
As with A, the most efficient estimate of a  was obtained when the A:B 
ratio was 30.0, and the least efficient estimate when the A:B ratio was 1.0 (Fig. 
5.8b). Estimates of a  obtained with A:B ratio of 30.0 were significantly better 
than that with A:B ratio of 1.0, 2.5, 7.5, or 10.0. a  was equally efficiently
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Fig. 5.8(a - d) aSummary of significant differences in the efficiency with which 
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Fig. 5.8(e - h) aSummary of significant differences in the efficiency with which 
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- Rank order of design numbers increasing from left to right.
Efficiency measured with design number
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estimated with A:B ratios of 5.0, 20.0, 30.0, and 40.0, or 5.0, 7.5,10.0, and 20.0, 
or between 2.5 and 10.0.
Unlike A and ot, B was most efficiently estimated when the A:B ratio was
1.0 (Fig. 5.8c) and this was significantly better than when the A:B ratio was 30.0 
or 40.0. The least efficient estimate of this parameter was obtained when the A:B 
ratio was 40.0.
P was best estimated when the A:B ratio was 2.5, and this was significant­
ly better than the estimates obtained when the ratio was 40.0 (Fig. 5.8d) which 
resulted in the least efficient estimate of this parameter.
aA and were best estimated when the A:B ratio was 20.0 (Fig. 5.8e) 
and 40.0 (Fig. 5.8f), respectively. These estimates were significantly better than 
when the A:B ratio was between 1.0 and 5.0. The least efficient estimates were 
obtained when the A:B ratio was 1.0. On the contrary, Cg was best estimated 
when the A:B ratio was 1.0 (Fig. 5.8g) and this was significantly better than when 
the A:B ratio was 30.0 and 40.0. The least efficient estimate of this parameter was 
obtained when the A:B ratio was 30.0.
All parameters were estimated with similar efficiency when the A:B ratio 
was in the range of 2.5 and 40.0 (Fig. 5.8h) and these were significantly better 
than when the A:B ratio was 1.0. The least efficient estimates of parameters 
overall were obtained when the A:B ratio was 1.0.
Consequently, A was efficiently estimated when the A:B ratio was in the 
range of 2.5 and 40.0, with the most efficient estimate when the A:B ratio was
30.0. Similarly, a  was most efficiently estimated when the A:B ratio was 30.0. 
However, the efficiency of a  estimation with this A:B ratio was similar to those 
obtained with A:B ratios of 5.0, 20.0, and 40.0. B was well estimated with A:B 
ratio in the range of 1.0 and 20.0. The most efficient estimate of this parameter 
was obtained when the A:B ratio was 1.0. p was efficiently estimated when the 
A:B ratio was between 1.0 and 30.0 with the most efficient estimate being when
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Table 5.7 Effect of Different A:B Ratios on Individual and Joint Confidence Intervals
Coverage for Parameter Estimates
Section I
Success
Total
A:B Parameter
Ratio A a B P aA <*x % Joint
1.0 27/27 27/27 27/27 27/27 27/27 27/27 27/27 27/27
2.5 29/29 29/29 29/29 29/29 29/29 29/29 29/29 29/29
5.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30 30/30
7.5 30/30 30/30 30/30 30/30 30/30 30/30 30/30 30/30
10.0 29/29 29/29 29/29 29/29 26/29 29/29 29/29 26/29
20.0 29/29 29/29 29/29 29/29 25/29 29/29 29/29 25/29
30.0 29/29 29/29 29/29 29/29 20/29 29/29 29/29 20/29
40.0 27/27 27/27 27/27 27/27 22/27 27/27 27/27 27/27
Section n
(Success - Excluded) 
(Totals Excluded)
1.0 26/26 24/24 26/26 26/26 11/11 6/6 14/14 0/0
2.5 29/29 29/29 29/29 29/29 24/24 1/1 26/26 0/0
5.0 30/30 30/30 30/30 30/30 30/30 10/10 14/14 3/3
7.5 30/30 30/30 30/30 30/30 29/29 17/17 16/16 8/8
10.0 29/29 29/29 29/29 29/29 26/29 19/19 7/7 4/4
20.0 29/29 29/29 29/29 29/29 25/29 28/28 0/0 0/0
30.0 29/29 29/29 28/28 29/29 20/29 28/28 1/1 1/1
40.0 27/27 27/27 27/27 26/26 22/27 26/26 1/1 1/1
1 9 0
Table 5.7 Effect of Different A:B Ratios on Individual and Joint Confidence Intervals
Coverage for Parameter Estimates
Section in 
(Success - Excluded) 
Total
A:B Parameter
Ratio A a B P aA % % Joint
1.0 26/27 24/27 26/27 26/27 11/27* 6/27* 14/27 0/27*
2.5 29/29 29/29 29/29 29/29 24/29 1/29* 26/29 0/29*
5.0 30/30 30/30 30/30 30/30 30/30 10/30* 14/30* 3/30*
7.5 30/30 30/30 30/30 30/30 29/30 17/30 16/30 8/30*
10.0 29/29 29/29 29/29 29/29 26/29 19/29 7/29*
ik
4/29
20.0 29/29 29/29 29/29 29/29 25/29 28/29 0/29* 0/29*
30.0 29/29 29/29 28/29 29/29 20/29 28/29 1/29* 1/29*
40.0 27/27 27/27 27/27 26/27 22/27 26/27 1/27* 1/27*
* - p < 0.01
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A:B ratio equalled 2.5. cr^ and were well estimated when the A:B ratio was in 
the range of 7.5 and 40.0. The best estimates of and aa  were obtained when 
the A:B ratio was 20.0 and 40.0, respectively. On the other hand, eg was well 
estimated when the A:B ratio was between 1.0 and 10.0, with the best estimate 
obtained when the A:B ratio was 1.0. The parameters when considered as a set 
were well estimated when the A:B ratio was between 2.5 and 40.0, with the best 
estimate obtained when the A:B ratio was 20.0.
Good individual and joint confidence intervals coverage was obtained 
with all A:B ratios when catastrophic runs were included (Table 5.7, Section I). 
When catastrophic runs were excluded to reveal the influence of standard errors 
on confidence intervals, poor coverage was obtained for of aa  when the A:B ratio 
was between 1.0 and 5.0. However, good coverage was obtained for eg at A:B 
ratios of 1.5, and 2.5. The confidence interval coverage for eg when the A:B ratio 
equalled 5.0 was significantly lower than the expected value of 0.95. On the other 
hand, good coverage was obtained for the estimation of c»a  when the A:B ratio 
was in the range of 7.5 and 40.0. The reverse was true for the coverage of in 
this range of A:B ratios. All values of the A:B ratio produced joint confidence 
intervals coverage which were significantly lower than the expected value of 0.70 
(Table 5.7, Section IE).
A high incidence of high correlation was obtained between B and a  with 
A:B ratios of 2.5, 5.0, 7.5, and 10.0, and for p and a  with an A:B ratio of 1.0. 
100% incidence of high correlation was obtained for p and B for all A:B ratios 
(Table 5.8). A lower incidence of high correlation between parameters was ob­
tained when the A:B ratio was either 20.0 or 40.0.
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Fig. 5.9(a - d) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the 
different number of sampling times in the a  phase of the plasma concentration - 
time curve and the total number of sampling times. Each vertical bar expresses 
the bias and precision of the population parameter estimate. Significant (p < 0.05) 
biases indicated by asterisks.
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the bias and precision of the population parameter estimate. Significant (p < 0.05) 
biases indicated by asterisks.
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5.4.5 Varying the Number of Samples in the a  Phase
Setting 3, 5, 7, and 12 sampling times in the a  phase of the plasma con­
centration - time curve, the number of successful NONMEM runs were 28, 28, 
29, and 25, respectively. As in the previous studies op was removed from the 
model. A and a  were associated with negative bias and good precision irrespec­
tive of the number of sampling times in the a  phase. The bias in A ranged from 
-0.2% (3 sampling times in the a  phase) to -2.3% (5 times in the a  phase) while 
the bias in a  ranged from -2.6% (3 times in the a  phase) to 4.0% (5 times in the a  
phase) (Fig. 5.9 (a & b)). Biased (mean %PE < 15%) but precise estimates of B 
and p were obtained with all schedules (Fig. 5.9 (c & d)). All estimates of 
and aa  were significantly positively biased but precise (Fig. 5.9(e & f)). 
estimates were acceptably precise. oa  estimates were precise for most of the 
schedules, except in the case where 3 time points were in the a  phase (SD of 
%PE = 25.9%). Cjj was associated with a significant positive bias when 3, 5, and 
7 sampling times were specified in the a  phase and all estimates were imprecise 
(Fig. 5.9 g).
A was estimated with equal efficiency for all sampling schedules, 
although the schedule with 7 time points in the a  phase had the lowest rank order 
(on average) of ^ ’s (Fig. 5.10a). a  was most efficiently estimated with 5 time 
points in the a  phase, but this was not significantly better than when 3 and 7 
sampling times were in the a  phase. However, it was significantly better than the 
design with 12 time points in specified in the a  phase (Fig. 5.10b).
B was best estimated with 7 time points in the a  phase (Fig. 5.10c) and 
this was significantly better than when 12 sampling times were in the a  phase. p 
was best estimated with 5 time points in the a  phase of the plasma concentration - 
time curve (Fig. 5.10d), and this was significantly better than when 12 time points
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were in the a  phase. The least efficient estimates of B and p were obtained with 
the latter sampling schedule.
was best estimated with 7 time points in the a  phase (Fig. 5.10e) and 
the estimates of this parameter with this design were significantly better than 
when 3 or 12 times were set in the a  phase. aa  and Gg were estimated with 
similar efficiency using the different designs (Fig. 5.10 f & g). However, the 
schedules with the lowest rank order (on average) of were the ones with 12 
and 3 sampling times in the a  phase for aa  and eg, respectively.
Overall, all parameters were best estimated with the sampling schedule in 
which 7 sampling times were specified in the a  phase (Fig. 5.1 Oh), but designs 
with 3 and 5 time points in the a  phase yielded similar results. The designs with 7 
and 5 times in the a  phase were significantly better than that with 12 time points.
All designs produced good individual parameters and joint confidence 
intervals coverage (Table 5.9, Section I). Also, examination of the impact of 
standard errors on confidence intervals coverage showed that all designs yielded 
coverage for Gq and joint coverage for parameter estimates which were signifi­
cantly lower than the expected values of 0.95 and 0.70, respectively (Table 5.9, 
Section HI).
In addition, the incidence of high correlation between B and a  when 3 
(39.3%) and 12 (25.0%) time points were in the a  phase was higher than the 
incidence for 5 (0%) and 7 (13.8%) sampling times in the a  phase (Table 5.10). 
Also, the design with 12 time points in the a  phase had an incidence of high 
correlation between a  and A of 32.1%. As in all the other studies previously 
described for this pharmacokinetic model, a high incidence (100%) of high corre­
la tion  betw een P and B was observed for all schedules.
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Table 5.9 Effect of Varying the Number of Sampling Times in the ot Phase on Individual
and Joint Confidence Intervals Coverage for Parameter Estimates
Section I
.Success,
Total
Number ofSampling Parameter
Times
a  phase Total
3 6
A
28/28
a
28/28
B
28/28
P
28/28
aA
23/28
<*x
28/28
%
28/28
Joint
23/28
5 8 28/28 28/28 28/28 28/28 26/28 28/28 28/28 26/28
7 10 29/29 29/29 29/29 29/29 25/29 29/29 29/29 25/29
12 15 25/25 25/25 25/25 25/25 20/25 25/25 25/25 20/25
3 6 28/28 28/28
Section II 
(Success - jixcluded). 
(Total ^Excluded)
28/28 28/28 23/28 27/27 9/9 8/9
5 8 28/28 28/28 28/28 28/28 26/28 24/24 8/8 6/6
7 10 29/29 29/29 29/29 29/29 25/29 28/28 0/0 0/0
12 15 25/25 25/25 25/25 24/25 20/25 18/18 1/1 1/1
3 6 28/28 28/28
Section IE 
(Success^ Excluded) 
Total
28/28 28/28 23/28 27/28 9/28* 8/28*
5 8 28/28 28/28 28/28 28/28 26/28 24/28 8/28* 6/28*
7 10 29/29 29/29 29/29 29/29 25/29 28/29 0/29* 0/29*
12 15 25/25 25/25 25/25 24/25 20/25 18/25 1/25* 1/25*
*-p<0.01
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Fig. 5.11 (a - d) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for estimated parameters. The horizontal axis represents the 
different number of sampling times in the p phase of the plasma concentration - 
time curve and the total number of sampling times. Each vertical bar expresses 
the bias and precision of the population parameter estimate. Significant (p < 0.05) 
biases indicated by asterisks.
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5.4.6 Varying the Number of Sampling Times in the P Phase
The schedules with 3, 6, and 8 sampling times in the p phase had 29, 28, 
and 25 successful NONMEM runs, respectively, when the sampling times in the p 
phase were varied. The estimates of A and a  were mostly significantly negatively 
biased but precise with the SD of %PE ranging from 3.8 to 5.8% (Fig. 5.11 (a & 
b)). B and p, on the other hand, were minimally biased and relatively precise (SD 
of %PE = 5.7 to 15.1%) (Fig. 5.11 (c & d)). oA and aa  estimates were signi­
ficantly positively biased, but acceptably precise (Fig. 5.11 (e & f)). eg was esti­
mated with a significant positive bias and poor precision (Fig. 5.11g). op was 
negatively biased and imprecise (Fig. 5.1 lh). The design with 3 time points in the 
p phase yielded the most biased estimate (mean %PE = 25.3%) and this was 
significant
No sampling schedule was significantly better than any other for the effi­
ciency with which A and a  was estimated (Fig. 5.12 (a & b)). However, the 
lowest rank orders (on average) of O ^’s were obtained with schedules having 6 
and 8 time points in the p phase for A and a, respectively.
B (Fig. 5.12b) and p (Fig. 5.12c) were most efficiently estimated with 8 
sampling times in the P phase. These estimates were significantly better than 
those obtained with other sampling schedules.
aA, (fc, and Og were estimated with similar efficiency with all designs 
(Fig. 5.12 (e - g)). While the best estimate of crA was obtained with 3 time points 
in the P phase, the best estimates of oa  and eg were obtained with 8 sampling 
times in the P phase. The most efficient estimate of op was obtained with 8 time 
points in the p phase (Fig. 5.12h), but this was only significantly better than when 
3 sampling times were in the p phase.
Overall, all sampling schedules did not differ in the efficiency in which
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Table 5.11 Effect of Varying the Number of Sampling Times in the p Phase on Individual 
and Joint Confidence Intervals Coverage for Parameter Estimates
Section I
Success.
Total
Number ofSampling Parameter
Times
P phase Total
A a B P aA * Joint
3 10 29/29 29/29 29/29 29/29 25/29 29/29 29/29 29/29 25/29
6 13 28/28 28/28 28/28 28/28 28/28 28/28 28/28 28/28 28/28
8 15 25/25 25/25 25/25 25/25 24/25 25/25 25/25 24/25 24/25
Section II
(Success - Excluded) 
(Total - Excluded!
3 10 29/29 29/29 29/29 29/29 25/29 28/28 0/0 0/0 0/0
6 13 28/28 28/28 28/28 28/28 26/26 23/23 11/11 5/5 8/8
8 15 25/25 25/25 25/25 25/25 23/24 19/19 9/9 11/11 6/6
Section HI
(Success_- Excluded) 
Total
3 10 29/29 29/29 29/29 29/29 25/29 28/29 0/29 0/29 0/29
6 13 28/28 28/28 28/28 28/28 26/28 23/28 11/28* 5/28* 0/28*
8 15 25/25 25/25 25/25 25/25 23/25 19/25
£
9/25 11/25* 0/25*
* - p < 0.01
2 0 7
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parameters were estimated (Fig. 5.12i). The schedule with 8 time points in the (3 
phase yielded estimates with the lowest rank order of d>r ’s, and the design with 3 
sampling times in the P phase yielded estimates with the highest rank order of 
Or*s, on average.
Consequently, all sampling schedules produced similarly efficient esti­
mates of A and a , and B and p were most efficiently estimated when 8 time 
points were in the p phase. While cr^, aa , and Cg were estimated with similar 
efficiency with the three sampling schedules studied, op was better estimated with 
6 or preferably 8 time points in the p phase. All designs produced parameter 
estimates with similar efficiency and not much could be gained by increasing the 
duration of sampling.
As with the other studies previously described, all sampling designs yield­
ed good confidence intervals coverage for individual and joint parameter esti­
mates when NONMEM runs with catastrophic estimates were included (Table 
5.11, Section I). When runs with catastrophic estimates were excluded to reveal 
the impact of standard errors on confidence intervals coverage, poor coverage 
was obtained for c^, op, and joint parameter estimates (Table 5.11, Section III). 
However, the coverage for op was slightly better when 8 time points were in the p 
phase compared to the designs with 6 and 3 sampling times in this phase of the 
concentration time curve (Table 5.11, Section HI).
The schedule with 8 sampling times in the p phase had 80.8%incidence of 
high correlation between a  and A, while incidences of 6.9% and 7.1% were 
obtained for the correlation between these parameters when 3 and 6 time points, 
respectively, were in the p phase (Table 5.12). Although the incidence of high 
correlation between P and a  was 13.8% (3 sampling times in the P phase) and 
3.6% (6 sampling times in the p phase) it was 0% when 8 time points were in the 
P phase. In addition, 100% incidence of high correlation between p and B was
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observed for all sampling schedules. Incidence of correlation of less than 11% 
was obtained for the correlation between p and a , Og and B for the designs 
having 3 and 6 sampling times in the p phase, but not the design with 8 time 
points in the P phase. The latter yielded 0% incidence for these pair-wise 
correlations. Also an incidence of 3.6% was obtained for the correlation between 
and A when 6 sampling times were specified in the p phase.
5.5 DISCUSSION
In the investigation of the effect of sample size on parameter estimation, 
the parameter values (A = 10000.0 IU/ml, a  = 2.0 h"*, B = 500 IU/ml, and p = 
0.2 h"l) and sampling strategy were chosen to mimic a real study which is report­
ed in detail in Chapter 7. With this sampling strategy, 70% of the data points were 
in the a  phase. This yielded precise estimates of A and a , irrespective of the 
sample size, as would be expected with the partitioning. The effect of the 
partitioning was observed in the estimation of B and p. Only the use of a sample 
size of 150 (15 animals per time point) gave estimates of these parameters which 
were precise. With this sample size, 45 data points were located in the p phase of 
the concentration - time curve compared with 30 and 18 for the 100 and 60 
sample sizes, respectively. The accuracy with which these parameters were 
estimated was not affected by sample size. Increase in the sample size led to an 
increase in the precision with which the variance parameters were estimated, as 
expected. In addition, the positive bias in the estimation of the variance param­
eters was probably a feature of the one observation per animal study design.
The estimation of the variance parameters (especially Og) was associated 
with large standard errors which led to poor individual and joint confidence 
intervals coverage when the runs with catastrophic estimates were excluded. The
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contribution of bias to this poor coverage was negligible since good coverage was 
obtained when the runs with catastrophic estimates were included. Given the 
pharmacokinetic model and design specifications considered, the appropriate 
sample size necessary for efficient estimation of population pharmacokinetic 
parameters is 150 (i.e. 15 observations per time point) or more. This was 
associated with a lower incidence of high correlation between parameters. 
Although parameters were better estimated with 150 observations than 100 
observations (i.e. 10 animals at each time point), the loss in estimation efficiency 
with the latter sample size was not very dramatic as seen in the individual and 
joint confidence intervals coverage when catastrophic runs were excluded (Table 
5.2, Section El). Model parameters were least efficiently estimated with a sample 
size of 60 and with this sample size, more parameters were highly correlated with 
each other (Table 5.4).
NONMEM estimation of A, a , B, and (3 was often associated with nega­
tive bias. This could be due to either the study design, or a feature of the program 
(i.e. estimation error since negative bias in the estimation of these parameters was 
also observed when oG was specified as 0%). Error in concentration measure­
ments had negligible influence on the estimation of model parameters. However, 
it did have an influence on the estimation of the variance parameters. When cG 
was greater than 10%, large biases were associated with the variance parameters. 
These were due to there being no information to allow the estimation of gg . Thus, 
the inter-animal variability estimated was a composite of inter- and intra- animal 
variability. Setting aG equal to 15% yielded the least efficient estimates of 
parameters. This specification of error in concentration measurements is the 
upper limit of error in concentration measurements generally acceptable in prac­
tice, and the need to minimise error in concentration measurements, especially 
with the one observation per animal study design cannot be over emphasised.
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The negative bias associated with A and a  observed in the study in which 
the efficiency of parameter estimation with a range of a  values was determined, 
is a feature of the NONMEM program as previously discussed. The almost un­
biased estimate of these parameters obtained when a  was 1.5 h"* was due to the 
fact that the slope of the a  phase of the concentration - time curve was less steep, 
hence more data points were located in the a  phase. Steeper slopes of the a  phase 
of the concentration - time curve, a consequence of higher a  values, yielded 
mostly efficient (unbiased and precise) estimates of B and p because more data 
points were partitioned into the P phase of the concentration - time curve (Fig. 
5.13). Similar conclusions were arrived at using the design numbers.
Thus, A was more efficiently estimated when a  was in the range of 1.5 
and 4.0 h"*, with the most efficient estimate obtained when a  was 1.5 h"*. Al­
though a  was estimated with similar efficiency irrespective of the value of a  
used, the best estimate was obtained when a  was 3.5 IT*. B and P were well 
estimated when a  was in the range of 3.5 and 8.0 h'*. Although the efficiency of 
cr^ and estimation was similar for a  values, the best estimates were obtained 
for and aa  when a  was 2.0 h“* and 4.0 h '*, respectively, Gg was better 
estimated when a  was in the range of 2.5 and 8.0 h'*. The relatively inefficient 
estimation of the variance parameters was due to the fact that there was no 
information in the data set on cre .
With the range of A:B ratios considered and a  of 2.0 h“*, efficient estima­
tion of A and a  was obtained with the higher A:B ratios. The greater the A:B 
ratio the more precise were the estimates of these parameters. Given that the slope 
of the a  phase of the concentration time curve remained constant irrespective of 
the A:B ratio , more data points were partitioned into the a  phase of the 
concentration time curve with higher A:B ratios (Fig. 5.14). Thus, A and a  were 
most efficiently estimated when the A:B ratio was 30.0. However, A was
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estimated with similar efficiency irrespective of the value of the A:B ratio, a , on 
the other hand, was better estimated when the A:B ratio was between 20.0 and
40.0.
B and p, however, were better estimated when the A:B ratio was low. B 
was best estimated when the A:B ratio was between 1.0 and 20.0 while p was 
best estimated when the A:B ratio was between 1.0 and 30.0. The most efficient 
estimates of these parameters were obtained when the A:B ratio was 1.0 and 2.5, 
respectively.
Good estimates of and ca  were obtained when the A:B ratio was in the 
range of 7.5 and 40.0 for the same reason advanced for the estimation of A and a.
was well estimated when the A:B ratio was in the range of 1.0 and 20.0, and 
the best estimate when the A:B ratio was lowest (1.0). Interpreting the results 
using bias and precision, and the design number approach led to the same conclu­
sions. All parameters were well estimated when the A:B ratio was in the range of
2.5 to 40.0 with the best estimates obtained when the A:B ratio was 20.0. It is 
worthy of note that fewer pair-wise high correlations were obtained when the A:B 
ratio was 20.0.
The poor confidence interval coverage observed for Og when the A:B 
ratios were high was due to large standard errors. There was no contribution of 
bias to this observation as seen in Table 5.11 (Section I & II). Similarly, the poor 
coverage observed for joint confidence intervals was due to large standard errors.
Although all schedules with the different specifications of sampling times 
in the a  phase produced estimates of A and a  that were negatively biased, some 
of which were significant, the mean %PE did not exceed 4%. All schedules 
produced precise estimates of A and a  with the SD of %PE ranging from 4.0 to 
5.9%. The difference in the efficiency with which these parameters were 
estimated lay in the contribution of the "standard error term" in the calculation of 
the design number. Thus, A was most efficiently estimated with 7 time points in
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the a  phase, while the design with 3 sampling times in the a  phase produced the 
least efficient estimate. As in the case of bias and precision where the %PE 
values were very close for all schedules, there were no significant differences 
when the design numbers for the different sampling schedules were compared. 
That the sampling schedule with 5 time points in the a  phase gave the most effi­
cient estimate of a , while the sampling schedule with 12 time points in the a  
phase gave the most inefficient estimate, was also due to the effect of the "stand­
ard error term". The design with 7 sampling times in the a  phase produced the 
least biased and most precise estimate of B, while the one with 5 time points 
produced the least biased estimate of p. The difference in the precision with 
which B and P were estimated with 5 and 7 time points in the a  phase was only 
1%. Thus, the most efficient estimates of B and P obtained with 7 and 5 sampling 
times in the a  phase, respectively, were due to the influence of bias. Although all 
designs produced estimates of B and p that were precise and not significantly 
biased, the efficiency with which these parameters were estimated with the 
schedule having 12 time points in the a  phase was significantly poorer than the 
rest. This was probably due to the fewer number of data points in the p phase 
which resulted in an estimate with a large standard error.
The positively biased estimates of variance parameters was a consequence 
of the one observation per animal study design. The least efficient estimates of 
and were obtained when 3 time points were in the a  phase. This design was 
associated with estimates which were the least precise and the most biased. On 
the other hand, the most efficient estimates of and oa  were obtained when 7 
and 12 time points, respectively, were in the a  phase. These schedules produced 
parameter estimates which were the most precise and least biased. Also, the 
"standard error term" in d>^ . for these parameters generated with these designs 
was the lowest when compared with the other designs, was least efficiently
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estimated when 12 sampling times were in the a  phase, and this design produced 
the most imprecise estimate. Although this sampling schedule produced the least 
biased estimate of Ojg, the inefficiency was due to the imprecision of the estimate 
of this parameter. The efficient estimation of op with 3 time points in the a  phase 
was due to the location of a greater number of data points in the p phase. Overall, 
model parameters and their variances were most efficiently estimated when 7 
time points were in the a  phase.
The schedule with 12 time points in the a  phase produced the least effi­
cient parameter estimates. This could be attributed to the greatest incidence of 
high correlation between parameters (Table 5.10). This inefficiency in parameter 
estimation was also associated with large "coefficient of variation". However, 
large "coefficient of variation" was responsible for poor confidence interval 
coverage for Og and joint parameter estimates for all sampling designs when 
catastrophic runs were excluded in the calculation of confidence intervals.
In the study in which the effect of altering the number of time points in 
the P phase on parameter estimation was investigated, the bias and precision 
obtained in the estimation of A and a  were similar for all sampling schedules; 
hence the lack of significant difference in the efficiency with which these parame­
ters were estimated. All schedules produced negatively biased estimates of these 
parameters. The design with 8 time points in the p phase produced the most 
precise estimates of B and p. Thus, the production of the most efficient estimates 
of B and p with this sampling strategy was due to the estimates being the most 
precise. The lack of significant differences in the efficiency with which c^, aa , 
and Cq were estimated by the different designs was due to estimates being biased 
and precise to a similar extent. On the other hand, the estimate of op was the least 
biased and imprecise when 8 time points were in the P phase. The bias produced 
in the estimation of this parameter with this schedule was less than one third of 
that when 3 sampling times were in the p phase. Thus, the most efficient estimate
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of op was obtained when 8 time points were in the P phase.
Although the sampling schedule with 8 time points in the p phase gave the 
most efficient parameter estimates when the overall design efficiency was consid­
ered, this was not significantly better than the other schedules. This may have 
been due to the pair-wise correlations between parameter estimates. Whereas the 
incidence of high correlation between a  and A was 6.9% for the design with 3 
sampling times in the p phase, and 7.1% for the design with 6 time points in the p 
phase, it was 80.8% when 8 time points were in the p phase. Alternatively, the 
incidence of high correlation between B and a , p and a, and A, and a, 
and B, Cjg and p was less than 14% for the design with 6 sampling times in the P 
phase. A similar incidence was obtained for the sampling design with 3 sampling 
times in the p phase, but the incidence of high correlation for vs. A, and Cp vs. 
P was zero. Except for the correlation of p and B, in which the incidence of high 
correlation was 100% for all sampling designs, the incidence of high correlation 
for other parameter pairs not previously discussed for the design with 8 time 
points in the p phase was zero. The instability in the estimates due to the pair­
wise correlations was reflected in the poor coverage observed with the joint 
confidence intervals for parameter estimates.
In all studies described, a high incidence (100%) of high correlation 
occurred between p and B. There were some occasions of high incidence of high 
correlation between a  and A, B and a, and a  and P . These must have contribut­
ed to inefficient parameter estimation in some study designs. This was reflected 
in wide confidence intervals such that, when estimates with "coefficient of varia­
tion" greater than 50% were excluded in the computation of confidence intervals, 
poor coverage was obtained for eg and joint parameter estimates. The large 
"coefficients of variation" could be inherent to the model or to the relative magni­
tudes of the parameters used. A high correlation reduces the desirability of obtain-
218
ing parameter estimates (Boxenbaum et al., 1974) and requires a reparameteriza­
tion of the model.
t
2 1 9
CHAPTER 6
REPARAMETERIZATION OF THE TWO COMPARTMENT MODEL
2 2 0
6.1 SUMMARY
A simulation study was carried out using the one observation per animal 
design to examine the impact of reparameterization of the two compartment 
model (IV bolus dose injection) on the efficiency with which model parameters 
were estimated. The parameters of the model were Cl, V^, and k2 j instead 
of A, a , B, and p. The efficiency of parameter estimation was determined by 
examining accuracy and precision, design number, single and joint confidence 
intervals for parameter estimates, and the correlation between parameter esti­
mates. Reparameterization led to the generation of more stable parameter esti­
mates, and relatively lower incidence of high correlation between parameters.
6.2 INTRODUCTION
The results of the studies reported in Chapter 5 showed that the estimation 
of parameters of the two compartment model described by Eq. (6.1) below can be 
problematic.
C(t) = A.exp(-a.t) + B.exp(-p.t) (6.1)
(Model I)
The instability in the estimation of some of the parameters was reflected in wide 
confidence intervals, and high correlation between parameter estimates. Conse­
quently, the model in Eq. (6.1) (Model I) was reparameterized in terms of Cl, V^,
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kj2» and k2j the following structural form:
C*j = [D j/V ^ a  - p)][a - k21)exp(-atj) + (k21 - P)exp(-Pij)] (6.2)
(Model II)
where a, P = l/2{kj2 + k2  ^+ kjQ ± [(k12 +k2j +kjo)2 ■ ^ 2 1 k 1 0 ^ ^ ^ ’ k 10
♦
= Clj/Viy  C j is the true drug concentration in the jth anim al, Dj, V ^, Clj are 
the dose, volume of the central compartment and clearance in the jth animal, 
respectively, and tj the corresponding sampling time. However, in the simulation 
a  and p were parameterized in terms of the microscopic rate constants k^2 and
k21-
The goal of this simulation study was to evaluate the impact of reparame­
terization of the two compartment open model with intravenous bolus dose 
administration on the estimation of population pharmacokinetic parameters using 
the one observation per animal design. Specifically, the efficiency with which 
these parameters were estimated was determined by examining the accuracy and 
precision, design number, single and joint confidence intervals for parameter 
estimates, and the incidence of high correlation between parameter estimates .
6.3 METHODS
6.3.1 SAMPLING DESIGN AND ANALYSIS
Using the following values of a: 2.0,4.0, 6.0, and 8.0 h"*; p, A and B 
values of 0.2 If*, 10000.0 and 500.0 IU/ml, respectively, used in Chapter 5, 
values of Cl, Vj, k j2 and k2j were computed and used in the simulation
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Table 6.1 Starting Values for Simulation on Reparameterization: Different a  Values
Parameter
a Cl V1 k 12 k21
(h-1) a/h) (1) (h'1) (h’1)
2.0 0.025 0.020 0.50 0.30
4.0 0.040 0.020 0.30 0.40
6.0 0.050 0.020 3.00 0.50
8.0 0.055 0.020 5.00 0.60
Table 6.2 Starting Values for Simulation on Reparameterization: Different A:B Ratios
Parameter
A:B Cl Vl k 12 k21
m 0) (h '1) (h"1)
1.0 0.070 0.200 0.75 1.00
10.0 0.040 0.035 0.70 0.35
20.0 0.025 0.020 0.50 0.30
30.0 0.020 0.012 0.40 0.25
40.0 0.016 0.010 0.30 0.20
2 2 3
(Table 6.1). The respective variances were selected to yield a coefficient of 
variation of 15% for all parameters. A 15% error was added in concentration 
measurements as previously described (see Chapter 2, Section 2.4).
An intravenous bolus dose of 200,000 IU was used, and animals were 
sampled over ten time points with 15 observations being made at each time point 
giving a sample size of 150. The sampling times used were 0.083, 0.25, 0.50, 
0.75, 1.0, 1.5, 2.0, 3.0, 4.0, and 6.0 h. As in Chapter 5 the first time point was 
fixed while others were sampled from a uniform range of 0.25 h. The simulation 
was carried out as previously described in Chapter 2 (Section 4) and 30 replicate
data sets were generated for each experiment.
1 1 
a  was then kept constant at 2.0 h-A and with p unchanged at 0.2 h , the
efficiency of parameter estimation with a range of A:B ratios was investigated.
The A:B ratios used were 1.0,10.0, 20.0, 30.0, and 40.0 (Table 6.2).
The chi-squared test was used to compare joint confidence intervals
coverage for parameter estimates obtained using the reparameterized model
(Model II) with those obtained with Model I in Chapter 5.
6.4 RESULTS
6.4.1 REPARAMETERIZATION WITH VARIATION IN a
6.4.1a Bias and Precision
In the results presented below < \i2 and c j^ l ar© n°t included since the 
estimates of these parameters were infinitesimal and their removal did not alter 
the NONMEM objective function or other parameters estimated. Fig. 6.1a shows
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Fig. 6.1 (a - d) Bias and precision in expressed as %PE (mean ± standard 
deviation, respectively) for (a) Cl, (b) V j, (c) k 12» and (d) k21. The horizontal 
axis represents the different values of a. Each vertical bar expresses the bias and 
precision of the population parameter estimate.
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226
(a) Estimation of Cl
6.0 2.0 4.0 8.0 a(h'x)
(b) Estimation of V j
2.0 4.0 6.0 8.0 a f l f 1)
(c) Estimation of k ^
6.0 4.0 2.0 8.0 a o r 1)
(d) Estimation of k2\
6.0 4.0 8.0 2.0 a(h_1)
Fig. 6.2(a - d) aSummary of significant differences in the efficiency with which 
parameters were estimated on reparameterization: effect of different values of a. 
- Rank order of design numbers increasing from left to right.
Efficiency measured with design number
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(e) Estimation of
4.0 2.0 6.0 8.0 a(h‘x)
(f) Estimation of Oyj
2.0 4.0 6.0 8.0 a f t '1)
(g) Overall Design Efficiency
4.0 6.0 2.0 8.0 o(h"X)
Fig. 6.2(e - g) aSummary of significant differences in the efficiency with which 
parameters were estimated on reparameterization: effect of different values of a. 
a - Rank order of design numbers increasing from left to right, 
b - All significantly different each other 
* Efficiency measured with design number
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that the estimates of Cl produced were very precise. The bias in the estimation of 
this parameter ranged from 0.19% (6.0 h"*) to 15.08% (8.0 h"*), with the most 
biased estimate obtained when a  was 8.0 h" *. The estimates of were unbiased 
and precise when a  was in the range of 2.0 and 6.0 h-*. When a  was as 8.0 h"*, 
the estimate of V j was biased and imprecise (Fig. 6.1b). The estimates of k ^  
were precise and not significantly biased (Fig. 6.1c). k.21 estimates were precise 
except when a  was 8.0 h"* (Fig. 6.Id). In addition, the biases in the estimation 
C q  and Oyj were significant. The greater the value of a, the greater the bias (Fig. 
6.1(e & f)). Imprecise estimates of were only obtained when a  was 8.0 h“*. 
Except when a  was 2.0 h" *, all estimates of Oyj were imprecise.
6.4.1b Design Number
With reparameterization, efficient estimates of Cl were obtained when a  
was in the range of 2.0 and 6.0 h"* (Fig. 6.2a) and these were significantly better 
than when a  was 8.0 If*. The most efficient estimate of Cl was obtained when a  
was 6.0 If* while the least efficient estimate was when a  was 8.0 If*.
Vj was efficiently estimated when a  was in the range of 2.0 and 4.0 h" * 
with the best estimate obtained when a  was 2.0 h“* (Fig. 6.2b). Estimates ob­
tained when a  was 2.0 h'* were significantly better than those when a  was in the 
range of 6.0 to 8.0 If*.
k j2 was niore efficiently estimated when a  was between 2.0 and 6.0 h '*, 
and results obtained when a  was in this range was significantly better than those 
obtained when a  was 8.0 If* (Fig. 6.2c). The most efficient estimates of this 
parameter were obtained when a  was 6.0 h"*.
More efficient estimates of k2 j were obtained when a  was in the range of
4.0 to 6.0 If* than when it was 2.0 h'*(Fig. 6.2d). The most efficient estimates
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were when a  was 6.0 h"*, and these were significantly better than when a  was 
either 2.0 or 8.0 h"*.
Estimates of obtained when a  was either 2.0 or 4.0 h“* were signifi­
cantly better than when a  was in the range of 6.0 to 8.0 h‘* (Fig. 6.2e). The best 
estimate Cjr-.j was obtained when a  was 4.0 IT* and the least efficient estimate 
when a  was 8.0 h-*. Oyj was best estimated when a  was 2.0 h“* (Fig. 6.2f) and 
this was significantly better than when a  was in the range of 4.0 to 8.0 h'*. The 
least efficient estimate of Oy^was obtained when a  was 8.0 h"*.
When the efficiency of estimation of all parameters was considered, effi­
cient estimates were obtained with a  in the range of 2.0 to 6.0 h“* (Fig. 6.2g). 
These estimates were significantly better than when a  was 8.0 h“*. The most 
efficient estimates were when a  was 4.0 h'* and the least efficient when a  was
8.0 If*. It should be noted that efficient estimates were obtained for parameters of 
Model I (see Chapter 5, Section 5.3.3) when a  was 2.0 h"  ^ and not greater than
4.0 h"1.
Thus, Cl was best estimated when a  was in the range of 2.0 to 6.0 h"*, 
and Vj when a  was between 2.0 to 4.0 h“*. The most efficient estimates of Cl 
and V j were obtained when a  was 6.0 and 2.0 h"*, respectively, and k 2 i 
were well estimated when a  was in the range of 2.0 to 6.0 h'^, and 4.0 to 6.0 h~ ,^ 
respectively. These micro transfer rate constants were best estimated when a  was
6.0 h"*. and Oyj were most efficiently estimated when a  was 4.0 and 2.0 h"*, 
respectively. However, c w a s  estimated with a similar efficiency when a  was 
either 4.0 or 2.0 h‘*. Considered as a set, all parameters were estimated with 
similar efficiency when a  was in the range of 2.0 and 6.0 h'* although the most 
efficient estimates were obtained when a  was 4.0 h"*.
2 3 0
Table 6.3 Effect of Reparameterization on Individual and Joint Confidence Intervals
Coverage for Parameter Estimates: Variation in a
Section I
Success
Total
a  Parameter
ci V l k12 k21 <fcl (tyl Joint
2.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
4.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
6.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
8.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
Section II
Success - Excluded 
Total - Excluded
a  Parameter
a Vl k 12 k21 <fcl °V1 Joint
2.0 30/30 30/30 30/30 30/30 29/29 30/30 29/29
4.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
6.0 30/30 30/30 30/30 30/30 28/28 30/30 28/28
8.0 30/30 30/30 30/30 30/30 16/16 30/30 16/16
Section in
Success
Total
^Excluded
a
a Vl k 12
Parameter 
k21 <£1 <Vl Joint
2.0 30/30 30/30 30/30 30/30 29/30 30/30 29/30
4.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
6.0 30/30 30/30 30/30 30/30 28/30 30/30 28/30
8.0 30/30 30/30 30/30 30/30 16/30 30/30 16/30
2 3 1
Table 6.4 Comparison of Joint Confidence Intervals Obtained with Models I and II: 
Effect of Different a  Values
Success - Excluded
Total
a  (If1) Model I Model H
2.0 0/29 29/30 p <  0.001
4.0 19/30 30/30 p <  0.001
6.0 16/30 28/30 p <  0.001
8.0 8/28 16/30 p < 0.05
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6.4.1c Individual and Joint Confidence Interval Estimates
After reparameterization, good confidence intervals coverage was ob­
tained for individual and joint parameter estimates with or without excluding 
NONMEM runs with "coefficient of variation" > 50% for a  of 2.0, 4.0, and 6.0 
h"^ (Table 6.3, Section I - HI). Unlike the 96% coverage (on average) for and 
joint parameter estimates obtained with a  in the range of 2.0 to 6.0 h"*, a value of 
53% was obtained when a  was 8.0 h"* (Table 6.3, Section III). However, this 
was not significantly different from the expected values of 0.95 and 0.74, respec­
tively.
6.4. Id Comparison of Joint Confidence Intervals Coverage for Parameter
Estimates Obtained with Models I and II
Table 6.4 gives the joint confidence intervals coverage for parameter 
estimates obtained using the two models. Reparameterization led to a significant 
improvement in the joint confidence intervals coverage for parameter estimates 
irrespective of the a  values.
6.4. le Correlation between Parameter Estimates
A notable incidence of high correlation of 40.0%, 66.7%, and 30.0% was 
obtained for the correlation between k.21 and Cl with a  equal to 2.0, 4.0 and 6.0 
h 'l ,  respectively. A 23.3% and 53.3% incidence of high correlation was obtained 
for the correlation between k.2\ and » and and V^, respectively, when a  
was 8.0 h’1 (Table 6.5).
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Fig. 6.3(a - d) Bias and precision in expressed as %PE (mean ± standard 
deviation, respectively) for (a) Cl, (b) V i, (c) kjo* and (d) k ^ i. The horizontal 
axis represents the different values of A:B ratios. Each vertical bar expresses the 
bias and precision of the population parameter estimate.
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(a) Estimation of Cl
30.0 20.0 10.0 40.0 1.0 A:B ratio
(b) Estimation of V j
20.0 30.0 10.0 40.0 1.0 A:B ratio
(c) Estimation of
10.0 20.0 30.0 40.0 1.0 A:B ratio
(d) Estimation of k2 j
10.0 20.0 30.0 40.0 1.0 A:B ratio
Fig. 6.4(a - d)a Summary of significant differences in the efficiency with which 
parameters were estimated on reparameterization: effect of varying A:B ratio.
- Rank order of design numbers increasing from left to right.
Efficiency measured with design number
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o<J *
(e) Estimation of
30.0 40.0 20.0 10.0 1.0 A:B ratio
(f) Estimation of Oy-j
1.0 10.0 20.0 30.0 40.0 A:B ratio
(g) Overall Design Efficiency
10.0 20.0 30.0 40.0 1.0 A:B ratio
Fig. 6.4(e - g)a Summary of significant differences in the efficiency with which 
parameters were estimated on reparameterization: effect of varying A:B ratio.
- Rank order of design numbers increasing from left to right 
Efficiency measured with design number
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6.4.2 REPARAMETERIZATION WITH VARIATION IN A:B RATIO
6.4.2a Bias and Precision
The estimation of Cl was associated with a significant negative bias irre­
spective of the A:B ratio (Fig. 6.3a). However, the least biased estimate was 
obtained when the A:B ratio was 20.0 ( mean %PE = 1.7%), and the most biased 
estimate when the A:B ratio was 1.0 (mean of %PE = 17.4%). The estimates of 
V j were mostly unbiased (Fig. 6.3b) and all estimates of Cl and V j were accept­
ably precise, k j j  and estimates were biased and mostly imprecise, but the 
estimates obtained when the A:B ratio was 10 or 20 were precise (Fig. 6.3(c & 
d)). Fig. 6.3(e & f) shows the estimates of and Oy^ to be significantly biased. 
Gy j was associated with acceptable precision, while c^.j was acceptably precise 
for most A:B ratios, except when the A:B ratio was 1.0. In this case the estimate 
of C£i was greatly biased and imprecise (Fig. 6.3f).
6.4.2b Design Number
Cl was efficiently estimated when the A:B ratio was between 10.0 and
40.0, and these were significantly better than when the A:B ratio was 1.0 (Fig. 
6.4a). The most efficient estimate of Cl was obtained when the A:B ratio was
30.0,
The most efficient estimate of Vj was obtained when the A:B ratio was
20.0, and this was significantly better than estimates for other A:B ratios (Fig. 
6.4b).
Good estimates of and k2 j were obtained when the A:B ratio was in 
the range of 10.0 to 30.0, with the most efficient estimate when the A:B ratio was
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10.0. These estimates were significantly better than those obtained when the A:B 
ratio was either 1.0 or 40.0. (Fig. 6.4 (c & d)).
When the A:B ratio was in the range of 20.0 to 40.0, better estimates of 
were obtained than when the A:B ratio was in the range of 1.0 and 10.0 (Fig. 
6.4e). The best estimates of were when the A:B ratio was 30.0. Estimates 
obtained when the A:B ratio was between 30.0 and 40.0 were significantly better 
than estimates obtained when the A:B ratio was in the range of 1.0 to 10.0.
Significantly better estimates of cy^ were obtained when the A:B ratio 
was in the range of 1.0 to 20.0 than when the ratio was 30.0 to 40.0 (Fig. 6.4f)
Parameters were well estimated when the A:B ratio was in the range of
10.0 to 30.0, but the estimates when the A:B ratio was between 10.0 and 20.0 
were significantly better than those for the A:B ratio of 1.0 or 40.0. The most 
efficient parameter estimates were obtained when the A:B ratio was 10.0. It 
should be recalled that the best parameter estimates using Model I (Chapter 5) 
were obtained when the A:B ratio was 20.0, but this result was not significantly 
better than when the A:B ratio was 2.5, 5.0, 7.5,10.0, 30.0, and 40.0.
Thus, Q  was efficiently estimated when the A:B ratio was in the range of
10.0 to 40.0, with the most efficient obtained when the A:B ratio was 30.0. Vj 
was most efficiently estimated when the A:B ratio was 20.0. Efficient estimates 
of k j2 and k2 \ were obtained when the A:B ratio was in the range of 10.0 to
30.0, with the most efficient estimates of these parameters when the A:B ratio 
was 10.0. C£i was most efficiently estimated when the A:B ratio was 30.0 al­
though these estimates were not significantly better than the estimates obtained 
when the A:B ratio was either 20.0 or 40.0. On the other hand, cy  ^  was better 
estimated when the A:B ratio was in the range of 1.0 to 20.0 than 30.0 to 40.0, 
with the best when the A:B ratio was 1.0. All parameters were well estimated 
when the A:B ratio was between 10.0 and 30.0 although the lowest rank order of 
d>r (on average) was obtained when the A:B ra tio  was 10.0.
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Table 6.6 Effect of Reparameterization on Individual and Joint Confidence Intervals
Coverage for Parameter Estimates: Variation in A:B Ratio
A:B
ci Vl k12
Section I 
Success,
Total
Parameter
k21 <fcl °V1 Joint
1.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
10.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
20.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
30.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
40.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
A:B
Cl Vl k12
Section II 
Success. - Excluded 
Total - Excluded 
Parameter
k21 <fcl °V1 Joint
1.0 30/30 30/30 22(22 20/20 27/27 30/30 20/20
10.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
20.0 30/30 30/30 30/30 30/30 29/29 30/30 29/29
30.0 29/29 30/30 30/30 30/30 30/30 30/30 29/29
40.0 30/30 30/30 30/30 21/21 29/29 30/30 20/20
A:B
a V1 k12
Section HI 
Success ^E_xcluded, 
Total 
Parameter
k21 <fcl °V1 Joint
1.0 30/30 30/30 22/30 20/30 27/30 30/30 20/30
10.0 30/30 30/30 30/30 30/30 30/30 30/30 30/30
20.0 30/30 30/30 30/30 30/30 29/30 30/30 29/30
30.0 29/30 30/30 30/30 30/30 30/30 30/30 29/30
40.0 30/30 30/30 30/30 21/30 29/30 30/30 20/30
2 4 1
Table 6.7 Comparison of Joint Confidence Intervals Obtained with Models I and D: 
Effect of Different A:B Ratios
Success - Excluded 
Total
A:B Ratio Model I Model H
1.0 0/27 20/30 p < 0.001
10.0 4/29 30/30 p <  0.001
20.0 0/29 29/30 p < 0.001
30.0 1/29 29/30 p < 0.001
40.0 1/27 20/30 p <  0.001
_______________
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6.4.2c Confidence Intervals for Individual and Joint Parameter Estimates
With reparameterization, good coverage was obtained for individual and 
joint confidence intervals for parameter estimates (Table 6.6, Section I). When 
runs with "coefficient of variation" greater than 50% were excluded, the 
coverage for k j2 and k2 \ was reduced when the A:B ratio was 1.0 and 40.0, 
respectively. With these A:B ratios, the joint coverage for parameter estimates 
was similarly reduced (Table 6.6, Section (II & III)). However, the coverage 
obtained with these A:B ratios was not significantly lower than the expected 
values of 0.95 and 0.74 for individual and joint parameter estimates, respectively.
6.4.2d Comparison of Joint Confidence Intervals Coverage for Parameter
Estimates Obtained with Models I and II
Reparameterization led to a statistically significant improvement in the 
joint coverage of parameter estimates irrespective of the value of the A:B ratio 
(Table 6.7). 62 to 93% improvement in coverage was observed as Model I was 
reparameterized to give Model n.
6.4.2e Correlation between Parameter Estimates
Incidence of high correlation was highest (93.3%) for k.21 and Cl when 
the A:B ratio was 1.0, and was 90.0% when the A:B ratio was 40.0. Comparative­
ly lower values were obtained when the A:B ratio was 10.0 (56.7%), 20.0 
(40.0%), and 30.0 (33.3%). In addition, incidence of high correlation of 46.7%,
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83.3%, and 23.3% for the pair-wise correlations of and Cl, and and 
GqY and V j, respectively, were obtained when the A:B ratio was 1.0 (Table 6.8).
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6.5 DISCUSSION
The highly precise nature with which Cl was estimated when a  ^ 4.0 h“* 
was due to the greater number of data points available in the elimination phase of 
the concentration - time curve. The greater the value of a, the steeper the slope of 
the distribution phase of the curve resulting in a fewer number of data points in 
this phase of the disposition curve (Fig. 6.5). However, the best estimate of Cl 
was obtained when a  was 6.0 h-* and not 8 h“* because of the bias with which 
this parameter was estimated when a  was 8.0 h"*. V j was estimated with least 
bias and greatest precision when a  was 2.0 h“* because more data points were 
located in the distribution phase of the plasma concentration - time curve, 
and k2 i were most efficiently estimated when a  was 6.0 h"*. The biases associat­
ed with the estimates of the variance parameters were due to the fact that the data 
contained no information on aG. When a  was 4.0 h"* the best estimate of was 
obtained. This estimate was associated with the highest precision. Oyj was most 
efficiently estimated when a  was 2.0 h"* for the same reason as V^. As a whole, 
the best parameter estimates were obtained when a  was in the range of 2.0 to 6.0 
h"l with the most efficient estimates obtained when a  was 4.0 h"^. This was 
probably a consequence of the even distribution of data points between the distri­
bution and elimination phases of the concentration - time curve.
The inefficiency with which parameters were estimated when a  was
8.0 h’* could be attributed to the correlation between parameter estimates since 
there were more cases of high correlation between parameters with this value of a, 
and this was reflected in the confidence intervals coverage. There were 14 
NONMEM runs with catastrophic estimates of C£j which led to a reduced joint 
confidence intervals coverage for all parameter estimates, and this was signifi­
cantly different from all others.
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However, when the joint confidence intervals coverages obtained after 
reparameterization (Model II) were compared with those obtained with Model I, 
significant improvements were obtained for all a  values. The incidence of high 
pair-wise correlations on reparameterization did not exceed 67% compared with 
100% obtained with Model I (Chapter 5, Section 5.4.3) for the same a  values. 
Thus, reparameterization led to a reduced incidence of high pair-wise correlations 
and stability in the estimates as reflected in the significant improvement in joint 
confidence intervals coverage for all parameter estimates. This improvement was 
associated with "coefficients of variation" < 50% for most parameter estimates.
When the A:B ratio was 20.0 or 30.0, efficient estimates of Cl were ob­
tained. The best estimate of Cl was when the A:B ratio was 30.0, due to the 
estimates being the least biased. The estimates obtained when the A:B ratio was
20.0 or 30.0 were equally precise. The most efficient (and most precise) estimate 
of V j was obtained when the A:B ratio was 20.0. The most efficient (least biased 
and most precise) estimates of the micro transfer rate constants were obtained 
when the A:B ratio was 10.0. The significant biases associated with the variance 
parameters were due to the lack of information about oG in the data sets. The best 
estimates of parameters as a whole, were obtained when the A:B ratio was 10.0, 
although these were not significantly better than when the A:B ratio was 20.0 or 
30.0. Inefficient parameter estimates were obtained when the A:B ratio was 1.0, 
and 40.0 with the most inefficient estimates obtained when the A:B ratio was 1.0.
The inefficiency of parameter estimation associated with the A:B ratios of
1.0 or 40.0 was associated with high pair-wise correlations. When the A:B ratio 
was 1.0, an incidence of high correlation of 93.3% and 83.3% was obtained for 
k2 i and Cl, k ^  and k j j ,  respectively. Also, parameter estimation when the A:B 
ratio was 40.0 was associated with a 90.0% incidence of high correlation between 
k2i and Cl. With these A:B ratios there were 10 NONMEM runs each with catas­
248
trophic estimates unlike the one NONMEM run each with catastrophic estimates 
obtained when the A:B ratio was 20.0 or 30.0, and none when the A:B ratio was 
10.0.
However, reparameterization with these A:B ratios led to significant 
improvements in joint confidence intervals for parameter estimates when com­
pared with results obtained with similar A:B ratios using Model I (Table 6.5). 
This improved coverage was due to the generation of parameter estimates with 
"coefficients of variation" mostly < 50%. Unlike the results obtained with Model 
I (Chapter 5) in which a 100% incidence of high correlation was obtained B and p 
irrespective of the A:B ratio, no such incidence was obtained with Model II. 
Thus, Model I reparameterized into Model II, resulted in a lower incidence of 
high pair-wise correlation between parameter estimates and more efficient estima­
tion.
Given that parameters were efficiently estimated when a  was in the range 
of 2.0 and 6.0 h’* and the A:B ratio was 20.0, and when the A:B ratio was be­
tween 10.0 to 30.0 when a  was 2.0 h"*, it is reasonable to suggest that parameters 
would be efficiently estimated when the A:B ratio was in the range of 10.0 to
30.0 and a  between 2.0 to 6.0 h"*.
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CHAPTER 7
PRECLINICAL PHARMACOKINETICS: AN APPLICATION OF 
THE POPULATION APPROACH
250
7.1 SUMMARY
Serum concentrations of a drug under development were obtained from an 
animal pharmacokinetic study using the one sample per animal design and 
analysed using the population data analysis program, NONMEM. A two com­
partment open model with IV administration was used as the basis of the analysis. 
Although sex and weight were not determinants of clearance (Cl), sex helped to 
explain the variability in the volume of the central compartment (V j). The aver­
age values of Cl and V j were: Cl(ml/min) = 0.40, Vj(ml/g)maje = 0.11, and 
Vj(ml/g)£emaje = V jmaie * 0.80. The variability in Cl and were 23.5 and 
23.2%, respectively.
7.2 INTRODUCTION
An estimation of the average value of pharmacokinetic parameters in a 
group of animals provides limited information if there is no good measure of the 
variability of each of the parameters. The traditional naive pooled data (NPD) 
approach used in the analysis of animal pharmacokinetic data does not provide 
this, nor can it assess the influence of physiology ( or pathology) on pharmacoki­
netics.The nonlinear mixed effects model (NONMEM) approach (Sheiner & 
Beal, 1979 - 1989) does, however, provide estimates of both the average values 
of pharmacokinetic parameters and their statistical distribution within a popula­
tion. Given the results of the simulation study described in Chapter 6, NONMEM 
was used to analyse data obtained during a preclinical pharmacokinetic study.
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Fig. 7.1 Weight distribution for rats: (a) female, (b) male
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Data were supplied by Ares Serono (Italy): serum concentrations of a drug under 
development were measured in rats after single intravenous bolus injections.
7.3 METHODS
7.3.1 Animals
60 serum concentrations were obtained from 60 rats. Demographic data 
included weight and sex: the distribution of weight according to sex is shown in 
Fig. 7.1 (a &b). Weight ranged from 139.0 to 192.0 g. The weight of female rats 
ranged from 139.0 to 171.0 g. and that of male rats, from 172.0 to 192.0 g.
7.3.2 Pharmacostatistical Models
A visual inspection of the data indicated that the disposition of the drug 
could, on average, be described by a two compartment open model (Fig. 7.2). 
The chi-squared test (p < 0.005) was used to examine the difference between the 
log likelihood values obtained from fitting the full (2 compartment) or reduced (1 
compartment) models (Sheiner et al., 1977). The model had the following 
structural form given in Eq. (7.1):
C*j = [Dj/Vy (a  - p)][a - k21)exp(-atj) + (k21 - p)exp(-ptj)] (7.1) 
where a, p = l/2{k^2 + k2  ^ + k^Q ± [(kj2 +k2j '  4^21^10^^*
, Clj are
the dose, volume of the central compartment and clearance in the jth animal, 
respectively, and tj the corresponding sampling time. In the analysis a  and P were
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- c i y v j j . c  j is the true drug concentration in the jth anim al, Dj, V y
parameterized in terms of the microscopic rate constants k ^  and ^ 21. A  bolus 
dose of 1.0M IU/kg was administered to each animal. The statistical model (see 
Chapter 2, Section 2.3.2) accounted for combined inter- and intra-animal 
variability.
7.3.3 Data Analysis
The data were analysed using the NPD approach and with NONMEM. For 
the NPD approach, the WLS estimation procedure (weight proportional to C ) 
was used to estimate the mean pharmacokinetic parameters from the average 
concentration - time data.
Using NONMEM, the influence of dem ographic factors (fixed 
effects(FE)) was tested by relating them to the pharmacokinetic parameters (P) 
using linear models of the type:
where P is the expected value of pharmacokinetic parameter (e.g., Cl or VI) in 
any animal, FE is an identifiable animal factor (e.g., weight), and 0  is a regres­
sion coefficient. When quantifying the influence of a discontinuous variable such 
as sex, the model was of the type:
P = 0(FE) (7.2)
P = 0(FE) if male
P = O(FE). 0 § ex if female
(7.3a)
(7.3b)
where 0 § ex effectively allows different slopes for males and females.
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Table 7.1 List of Models Tested and Log Likelihood Differences
Model No. C.f. OBJ LLD df P
(i) Clearance Models
©nurH 774.04
2. Cl = 0 j  * Wt 1 774.04 0 NA NA
3. Cl = ©! * 0  Sex 1 772.60 1.44 1 NS
4. Cl = 0 j  * Wt * 0  Sex 1 772.60 1.44 1 NS
(ii) Volume Models
5. Vj = © j 774.04
6. Vj = 0 2 * Wt 5 765.88 0 NA NA
7. Vj = 0 2 * 0 Sex 5 762.84 11.20 1 <0.005
8. Vj = 0 2 * Wt * ©gex 5 762.66 11.38 1 <0.005
c.f. - compared with model number 
OBJ - Objective function 
LLD - Log Likelihood Difference 
df - degree of freedom 
NA - Not Appropriate 
NS - Not Significant
©SeX = 1.0 if male and is estimated for females
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In the analysis, models that related weight and / or sex to Cl and Vj were 
tested (Table 7.1). These models were embedded in the two compartment phar­
macokinetic model. NONMEM estimated the values of 0  (equations (7.2) and 
(7.3)) and /  or other kinetic parameters ( if these were not specified as functions 
of demographic factors) simultaneously. Thus, the influence of these fixed effects 
was evaluated.
Theoretically, a data set could be analysed an infinite number of times 
with different regression models. Therefore, criteria were necessary to identify a 
useful analysis. One criterion was the value of the objective function which is 
normally calculated for each NONMEM run and is equal to -2 log likelihood. A 
difference in the objective function (log likelihood difference, LLD) between two 
NONMEM runs involving the use of two regression models (one of which was a 
restriction of the other; e.g., (a) a model which incorporated either Cl and V^ as a 
function of sex, and (b) a model which incorporated Cl or V j without any 
explanatory factor) of more than 8 indicated a significant improvement (p < 
0.005, assuming chi - square distribution) when the restricted model had one 
regression parameter less than the full model (Sheiner et al., 1977). Other criteria 
were: (1) a minimum correlation between parameters; (b) small standard errors of 
parameter estimates; (c) weighted residuals which were randomly scattered 
around zero when plotted against predicted concentration; and (d) decrease in the 
estimate of the inter-animal variances (see Chapter 2, Section 2.3.3). For non- 
hierarchical models, where all models had the same number of parameters, model 
comparison was based on the objective function, and other criteria enumerated 
above. An LLD greater than zero indicated an improvement and the one with the 
smaller OBJ described the data better. A summary of the models tested is 
presented in Table 7.1.
Estimates were obtained for (1) population means for Cl, V^, k^*  ^21 
and / or regression coefficients (0  in equations (4) and (5)), (2) the variance
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terms, (3) standard error of estimates, and (4) correlation matrix of the estimates.
7.4 RESULTS
An initial examination of NONMEM runs showed that the two compart­
ment model was superior to the one compartment model. The population pharma­
cokinetic parameter values obtained with the NPD approach were similar to the 
population parameter values obtained with NONMEM when no covariates were 
modelled (Table 7.2). However, with NONMEM, estimates of inter-animal 
variability in Cl and V ^  were obtained in addition to the average population 
parameters.
Modelling V ^  without regard to animal size with an additive model for 
variability, the effects of modelling basic drug clearance with demographic 
factors were examined. The first regression model (Model 1, Table 7.1) simply 
defined Cl in ml/min. without an effect of animal size. To this was added an 
influence of weight (g) as in Model 2 (Table 7.1). Model 2 did not give any 
improvement in the estimation of Cl as seen from the objective function (Table 
7.1). Thus, weight was not incorporated into the basic model for Cl.
Also, the inclusion of either sex (Model 3, Table 7.1), or sex and weight 
(Model 4, Table 7.1) in various regression models for clearance did not improve 
the value of the objective function (Table 7.1).
Using the basic Cl model, an additive model for variability, V j for the 
drug was initially modelled without regard to animal size (Model 5, Table 7.1), 
where ©2 equalled the volume of the central compartment in ml. To this was then 
added the influence of weight (g) (Model 6, Table 7.1). This was a significant 
improvement over V^ without regard to animal weight (Table 7.1).
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Table 7.2 Parameter Estimates (S.E)
NPD Approach 
Structural Model Parameters
a Vl ki2 k21
(ml/min) (ml) (miii'1) (min‘l)
0.42 16.68 0.01 0.006
(0.15) (5.20) (0.003) (0.005)
NONMEM Approach
0.41 15.80 0.01 0.005
(0.10) (3.30) (0.003) (0.004)
NONMEM Variance Estimates 
Cl (ml/min)2 Vj(ml)2 
0.54 21.70
(0.60) (16.6)
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Table 7.3 Parameter Estimates (S.E.)
(i) Structural Model Parameters
Male Female
Q  (ml/min) V { (ml/g) Cl (ml/min) V j (ml/g)
0.40 0.11 0.40 0.11*0.80
(0.03) (0.01) (0.03) (0.08)
k j2 (min"*) k2 i(min"l)
0.01 0.005
(0.002) (0.002)
(ii) Variance Estimates
Q  (mVmin)2 V j (ml/g)^
0.40 0.20
(0.22) (0.56)
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Fig. 7.3a Scatterplot of weighted residuals (upper axis) versus animal weight in 
grams (left axis) with volume of central compartment modelled as Model 5 
(without regard to animal size).
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Fig. 7.3b Scatterplot of weighted residuals (upper axis) versus animal weight in 
grams (left axis) with volume of central compartment modelled as Model 6 
(based on animal weight).
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A method of assessing the "goodness of fit" is to the examine the 
scatterplots of weighted residuals generated by NONMEM. Predicted concen­
trations more closely equal observed concentrations as accuracy improves and the 
weighted residuals approach zero. Fig. 7.3a is the scatterplot of weighted 
residuals vs. animal weight, with volume modelled as Model 5 (Table 7.1), i.e. 
not including to animal weight. The pattern of the weighted residuals when 
volume was modelled with regard to weight (Model 6 (Table 7.1), Fig. 7.3b) was 
not different from that with Model 5 although the former model yielded a lower 
objective function.
Including either sex (Model 7, Table 7.1), or weight and sex (Model 8 , 
Table 7.1) as factors to explain the variability  in V^ led to a significant 
improvement in the objective function (p < 0.005) with a small reduction in 
variability (from 29.4% for the simple model (Model 5, Table 7.1) to 23.2% for 
the full model (Model 8, Table 7.1). The variability in Cl was 23.5%. The final 
model which best described the data is that specified in Model 8, with ex­
pressed as a function of weight and sex.
The variances for and could not be estimated: removal of these 
variance terms from the model resulted in no change in the objective function or 
parameter estimates. Table 7.3 gives a summary of the parameter estimates.
7.5 DISCUSSION
The similarity in the estimates of model parameters obtained using the 
NPD and NONMEM approaches was not surprising since the NONMEM 
approach, like the NPD approach, is focussed on the estimation of average 
(population) pharmacokinetic parameters. However, NONMEM gave additional 
information about the distribution of these population parameters by providing
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estimates of variability.
Estimates of V^ were improved by considering the demographic factors. 
Thus, weight and sex contributed significantly to the explanation of variability in 
volume of the central compartment. It should be noted, however, that all female 
rats weighed less than their male counterparts (Fig. 7.1). When estimating V j for 
this drug, animal sex alone appears to allow some reasonable estimation.
In practice the development of most drugs is abandoned when large 
variability is observed in the population pharmacokinetics of the drug, without 
any effort to explain the variability . With the NONMEM program , the 
relationship between physiology and pharmacokinetics has been determined as an 
aid to explain the inter-animal variability observed in Cl and V j. The introduction 
of weight and sex in V ^  led to a reduction of the inter-animal variability in this 
parameter by approximately 6%. Other factors, as yet undetermined, may be 
affecting the pharmacokinetics of this drug. Vocci and Farber (1988) advocated 
the consideration of pharmacokinetic differences within species in interspecies 
scaling. With the inter-animal variability observed in a homogeneous population 
of rats, larger variations in response may be expected to occur in humans. The 
possibility of gender related drug response should be anticipated in man.
In conclusion, the NONMEM program has been used to obtain estimates 
of population pharmacokinetic parameters and their distributions for a drug under 
development in a group of rats. This analysis has taken into account the fact that 
samples came from a population with more variability than could be explained by 
simple experimental error. NONMEM has permitted some explanation of this 
variability in terms of sex, efficient partitioning between inter- and intra-animal 
variability would require an increase in the number of samples per animal.
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CHAPTER 8
PARAMETER ESTIMATION IN PHARMACOKINETIC STUDIES 
INVOLVING THE USE OF SMALL LABORATORY ANIMALS
2 6 5
8.1 SUMMARY
A simulation study was carried out to determine the impact of various 
design factors on the efficiency with which population pharmacokinetic 
parameters could be estimated in an animal pharmacokinetic study. A drug which 
exhibits monoexponential disposition characteristics when administered by an 
intravenous bolus injection was used for the study. The factors investigated were: 
(1) number of animals sampled at specified time points with one observation 
taken per animal, (2) error in observed concentration measurements, and (3) 
doubling the number of observations per animal with varying number of animals. 
Increasing the error in the concentration measurement led to a significant 
worsening of the efficiency with which variability was estimated. The one point 
per animal design yielded biased and imprecise estimates of inter-animal 
variability. The limitation of this design is discussed and the importance of 
sampling an animal at least twice for unbiased and precise parameter estimation is 
highlighted.
8.2 INTRODUCTION
In earlier chapters (Chapters 3 & 4) the effect of inter-animal variability 
and sampling designs on parameter estimation with the one compartment model 
were exam ined. In Chapters 5 to 7 param eter estim ation with the two 
compartment open model was examined. In this chapter the one compartment 
open model with IV bolus administration is reconsidered.
The results of simulation studies carried out to determine the impact of a
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num ber of design features on the effic iency  w ith w hich population  
pharmacokinetic parameters could be estimated in pharmacokinetic study 
involving the use of small laboratory animals are presented. The effects of the 
following design features: (a) number of animals sampled at specified time points 
with one observation taken per animal, (b) changing the error in observed 
concentration measurements, and (c) varying the total number of samples (i.e. 
doubling the number of samples per animal with or without halving the number 
of animals) on the estimation of population pharmacokinetic parameters were 
investigated.
8.3 METHODS
8.3.1 Sampling Design
The sampling design described in Chapter 2 (Section 2.4) was used in 
these studies. Briefly, there were ten sampling times (i.e. 5, 15, 30, 60, 90, 120, 
150, 180, 210, 240 minutes). The first two times were fixed , but the other points 
were sampled uniformly from a range of 15 minutes centred on the stated time.
In the simulation, the parameter values were as given in Chapter 2 
(Section 2.4). and Oy were sequentially set to give coefficients of variation of 
15%, 30%, 45%, and 60%, and cy was set to 15% (except in section (b) below).
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8.3.1a Varying the Number of Animals per Time Point
Each of j animals supplied one observation, and a different number of 
animals was used at each time point for different experiments. This design is 
denoted as the j * 1 design. Let the total number of animals used in each 
experiment be denoted by N ^, and the total number of observations, Ng. In the 
first set of experiments the effect of increasing the number of animals per time 
point (i.e increasing total sample size, Ng) on the efficiency with which 
parameters were estimated was investigated. There were nine sample sizes (20, 
30, 40, 50, 60, 70, 80,100, and 150) which involved the use of 2, 3, 4, 5, 6, 7, 8, 
10 and 15 animals, respectively, at each time point, and this yielded nine j * 1 
study designs.
8.3.1b Varying the Error in Concentration Measurements
The influence of specified  in tra - anim al variab ility  (or error in 
concentration measurement) on parameter estimation was studied for three cases: 
ae = 0, 15 and 30% with three j * 1 designs of Ng and = 30, 50, and 70. 
Inter- animal variability was set to 30%, i.e. c^ «j = 30%; (fy = 30%.
8.3.1c Keeping the Total Number of Observations Constant and Halving the
Total Number of Animals
The effect of keeping Ng constant while halving N ^  on parameter 
estimation was investigated by sampling each animal twice. The sampling 
regimen for this series of simulations involved dividing the ten sampling times 
into two independent blocks: the first five times (t j to t^), and the later five times
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Table 8.1 NONMEM Runs With Acceptable Estimates
Number of 
Animals Per 
Time -Point 15
Inter-Animal Variability(%) 
30 45 60
2 29 26 27 23
3 29 30 28 29
4 29 30 27 27
5 30 30 27 27
6 30 30 29 28
7 30 29 29 29
8 30 30 29 30
10 30 30 29 30
15 30 30 29 30
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(t^ to tjo>. Thus, each animal was sampled at, for example, the first times in each 
block (i.e. t j  and t^) or the second times in each block, etc. The study design in 
which each animal was sampled twice is denoted as j * 2. 15, 25, and 35 animals 
were used yielding three j * 2 designs with corresponding Ng of 30, 50, and 70, 
respectively. This allowed comparison with the j * 1 designs.
8.3. Id Doubling the Total Number of Observations without Changing the Total 
Number of Animals
The effect of keeping N ^  constant while doubling Ng was investigated 
using N ^ = 30, 50, and 70 animals. Each animal supplied two observations with 
resultant corresponding sample sizes of 60, 100, and 140 observations, 
respectively. Sampling was as described in the previous section.
8.4 RESULTS
8.4.1 Effect of Increasing the Number of Animals per Time Point
The outlier criteria outlined in Chapter 2 (Section 2.5.1) were applied to 
the data sets obtained. Table 8.1 is a summary of successful NONMEM runs used 
in the results presented below.
8.4.1a Bias and Precision
Fig. 8.1 (a - d) summarises the results when Gq  and Oy were 15%. As 
number of animals per time point increased, the precision of the estimates
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Fig. 8.1 Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for parameters. The horizontal axis represents the number of 
animals used at each time point. Each vertical expresses the bias and precision of 
the population parameter estimate. Only one observation was made on each 
animal. The inter-animal variability was set at 15%, and the error in concentration 
measurements was set at 15%. Significant (p < 0.05) biases are indicated by 
asterisks.
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Table 8.2 Mean of %PE (SD) and Nonzero Significance of the Parameters Estimates
from Simulated Data Sets for Different Study Designs (j * 1 Designs) at A
CV of 30% in Inter-Animal Variability
Number of 
Animals Per 
Time Point Cl
Parameter 
V e f t °V
2
sk
-6.70 -2.65 15.86* 21.6
(9.37) (11.69) (44.22) (51.8)
3 -1.10 -6.16* 13.77 23.99*
(7.57) (8.80) (41.27) (42.88)
4 -0.09 3k-7.73 %17.76 17.17*
(6.57) (8.36) (42.90) (46.41)
5 -1.91
3k-5.05 20.66* 27.47*
(6.95) (7.95) (44.55) (39.96)
6 -2.65*
3k-4.51 14.14* 27.04*
(3.49) (8.06) (26.65) (33.21)
7 -2.87*
3k-4.51 14.44* 24.20*
(5.28) (7.32) (22.17) (27.93)
8
j|c
-3.22 -4.41* 15.52* 22.78*
(4.64) (7.63) (19.08) (27.73)
10
9|c
-1.98 -5.54* 16.38* 22.78*
(3.41) (5.40) (17.18) (24.59)
15 -3.77*
3k-5.42 19.17* 31.20*
(3.45) (4.66) (17.30) (22.18)
*p < 0.05
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Table 8.3 Mean of %PE (SD) and Nonzero Significance of the Parameters Estimates
from Simulated Data Sets for Different Study Designs (j * 1 Designs) at A CV
of 45% in Inter-Animal Variability
Number of 
Animals Per 
Time Point Cl
Parameter
V °V
2 -6.55 -6.84 12.60 21.1
(16.74) (21.99) (63.60) (83.5)
3
jfc
-5.07 -10.13* 9.55 32.00*
(10.88) (17.41) (51.32) (60.30)
4 -2.04 -14.25* 15.81 23.0
(7.89) (13.88) (44.78) (65.10)
5 -4.16* -12.06* 15.09* 34.20*
(6.99) (11.19) (36.11) (59.90)
6
a|e
-6.65 -7.51* 23.98* 15.69*
(10.56) (10.51) (22.54) (34.00)
7
3k
-5.74 -6.84* 25.75* 17.31*
(7.00) (9.10) (27.59) (31.07)
8 -7.46*
3k-5.51 22.07* 23.27*
(7.84) (9.89) (22.44) (35.60)
10 -7.64* -5.90* 24.94*
$18.21
(5.27) (8.70) (21.62) (24.53)
15
3k-6.71 -7.66* 26.71* 13.64*
(5.69) (7.77) (21.79) (21.41)
*p < 0.05
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Table 8.4 Mean of %PE (SD) and Nonzero Significance of the Parameters Estimates
from Simulated Data Sets for Different Study Designs (j * 1 Designs)
at A CV of 60% in Inter-Animal Variability
Number of 
Animals Per 
Time Point Cl
Parameter
V °V
2 -12.72* -3.74 22.00* 17.7
(26.15) (24.91) (50.08) (92.3)
3 -3.16
$-13.81 29.90* 6.91
(17.13) (21.29) (69.0) (46.77)
4 0.13 -12.99* 15.59 18.14*
(11.93) (19.01) (46.07) (39.74)
5 -2.44 -13.58 23.60* 34.30*
(14.14) (22.12) (44.83) (66.20)
6 -5.22*
$-11.17 26.53* 1.98
(11.07) (10.68) (42.84) (27.41)
7
j|e
-7.56
%-8.11 22.43* 13.22
(10.00) (10.01) (28.75) (40.97)
8 -9.01*
$-6.58 19.77* 18.18*
(9.18) (8.17) (23.82) (37.75)
10
ale
-8.62
Hi-6.07 29.79* 14.48*
(7.68) (10.99) (20.07) (36.72)
15
]|c
-11.47 -7.61* 34.95* 9.05*
(6.02) (7.51) (22.59) (21.33)
*p < 0.05
2 7 4
(indicated by the reduction in the error bars) also increased. However, the 
estimates of Cl and V were negatively biased, irrespective of the number animals 
used. It was also of some interest to consider the magnitude of the SD of %PE for 
the various parameters, j * 1 designs yielded relatively precise estimates for the 
fixed effect parameters. Estimates of Gq  were acceptably precise when the 
number of animals at each time point was 5 or greater, but the estimates of CFy 
were acceptably precise only when the number of animals used at each time was 
10 or greater. The estim ates of inter-anim al variability  were, however, 
consistently positively biased and were relatively unaffected by increasing the 
number of animals.
When C q  and G y  were set at 30% the estimates of the fixed effect 
parameters were negatively biased, but precise (Table 8.2). As with the 15% 
inter-animal variability study, all estimates of and Gy were positively biased 
and mostly imprecise. Estimates of with acceptable precision were obtained 
when the number of animals used at each time point was 7 or greater while Gy 
estimates were acceptably precise when 10 animals or more were used at each 
time. As expected, the precision with which parameters were estimated increased 
as the number of animals per time point increased (i.e. precision increased with 
increased N<g).
With Gqy and e9ua  ^to 45%, negatively biased, but precise estimates 
were obtained for Cl and V (Table 8.3). The estimates of and Gy were 
positively biased and mostly imprecise as in the previous cases. Acceptably 
precise estimates of all parameters were obtained when >10 animals were used at 
each time point.
When Oq  and G y  were set to 60%, the estimates of Cl and V were 
negatively biased, but mostly precise (Table 8.4) as in the previous cases 
considered. Imprecise estimates of Cl were obtained with the 2 observations per 
time point design. Again, the estimates of and G y  were positively biased and
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Fig. 8.2a Bias (expressed as mean of %PE) in the estimation of Cl: three
dimensional plot of the influence of varying the number of animals sampled at
each time point and inter-animal variability on Cl estimation.
276
%PE *
-a
Fig. 8.2b Bias (expressed as mean of %PE) in the estimation of V: three
dimensional plot of die influence of varying the number of animals sampled at
each time point and inter-animal variability on V estimation.
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Fig. 8.2c Bias (expressed as mean of %PE) in the estimation of Oq : three
dimensional plot of the influence of varying the number of animals sampled at
each time point and inter-animal variability on c^j estimation.
278
Fig. 8 .2d Bias (expressed as mean of %PE) in the estimation of G y : three
dimensional plot of the influence of varying the number of animals sampled at
each time point and inter-animal variability on Gy estimation.
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mostly imprecise. Acceptably precise estimates of all parameters were obtained 
only when 15 animals were used at each time point.
These results are summarised in Fig. 8.2(a - d). The estimates of Cl 
obtained for each value of inter-animal variability were relatively stable. The 
mean of %PE ranged from -1.2 to -0.9% for Cq  and G y  equal to 15%, -6.7 to 
-0.1% for C£j and G y  set to 30%, -7.5 to -2.0% for G q  and G y  equal to 45%, and 
-12.7 to 0.1% for C£j and G y  set to 60% (Fig. 8.2a). Similarly the estimates of V 
were relatively stable with mean of %PE ranging from -1.6 to 0.2%, -14.3 to 
-5.5%, -7.7 to -2.7%, and -13.8 to -3.7% for inter-animal variabilities of 15, 30, 
45, and 60 %, respectively (Fig. 8.2b). Also, estimates were relatively stable 
with the difference between the most and least biased estimates for each level of 
variability not exceeding 12% (Fig. 8.2c). G y  estimates were less stable with the 
difference between the most and least biased estimates ranging from 8% for an 
inter-animal variability of 60% to 25% for an inter-animal variability of 15% 
(Fig. 8.2d). There was a tendency for the bias in the estimation of the fixed effect 
parameters to increase with the increase in the inter-animal variability as would 
be expected.
8.4. lb Design Number
When Gq[ and G y  were set to 15%, Cl was efficiently estimated when the 
number of animals used per time were between 3 and 15. However, Cl estimates 
obtained when the number of animals per time point were between 4 and 15 were 
significantly better than the estimates obtained when 2 animals were used per 
time point (Fig. 8.3a). As expected, the most efficient estimates were obtained 
when 15 animals were used per time point. V was significantly better estimated 
when 4 to 15 animals were used than 2 animals per time point (Fig. 8.3b). Again, 
the most efficient estimates were obtained with 15 animals per time point, and the
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(a) Estimation Cl
15 10 8 6 7  4 5  3 2 Animals per
time point
(b) Estimation of V
15 10 8 7  5 6 4 3 2  Animals per
time point
(c) Estimation of CHi
7 15 6 8 3 10 5 4 2  Animals per
time point
(d) Estimation of Oy
4 10 8 3 6 7  15 5 2 Animals per
time point
(e) Overall Design Efficiency 
15 10 8 7  6 5 4 3 2  Animals per
time point
Fig. 8.3 aSummary of significant differences in the efficiency with which 
parameters were estimated by varying the number of animals sampled at each 
time point with inter-animal variability set at 15%. 
a - Rank order of design numbers increasing from left to right.
* - Efficiency measured with design number.
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(a) Estimation Cl
10 7 6 15 5 8 4 3 2  Animals per
time point
(b) Estimation of V
15 10 7 8 5  6 3 4 2  Animals per
time point
(c) Estimation of q-n 
8 7 6 10 15 3 5 4 2  Animals per
time point
(d) Estimation of Oy 
4 7  10 8 15 3 5 6 2  Animals per
time point
(e) Overall Design Efficiency 
15 10 7 8 6 5 4 3 2  Animals per
time point
Fig. 8.4 aSummary of significant differences in the efficiency with which 
parameters were estimated by varying the number of animals sampled at each 
time point with inter-animal variability set at 30%. 
a - Rank order of design numbers increasing from left to right 
* - Efficiency measured with design number.
282
least efficient estimates with 2 animals.
At the 15% level of inter-animal variability, c^j (Fig. 8.3c) and O y  (Fig. 
8.3d) were inefficiently estimated with all j * 1 designs.
Overall, parameters were well estimated when the number of animals used 
at each time point was between 6 and 15 animals per time point (Fig. 8.3e). The 
use of between 5 to 8 animals per time yielded parameter estimates with similar 
efficiency. Parameter estimates obtained with 10 and 15 animals per time point 
were significantly better than those with 2 to 5 animals per time point. The best 
estimates of parameters was obtained with the 15 animals per time point design.
When C£j and Oy were set to 30%, Cl was more efficiently estimated with 
4 to 15 animals used at each time point than 2 animals (Fig. 8.4a). V was well 
efficiently estimated using either 3, or 5 to 15 animals per time (Fig. 8.4b). V 
estimates with 3 animals per time were only marginally better than those with 4 
animals. The difference lay in the bias term of d>-r  the estimates with 4 animals 
per time being more biased than those with 3 animals per time (Table 8.2). 
However, the results obtained using between 2 to 8 animals per time point were 
similar. Designs with 10 to 15 animals per time point yielded significantly better 
V estimates than those obtained with the design using 2 animals per time point. 
As with the 15% level of inter-animal variability, and Oy were poorly 
estimated with all designs (Fig. 8.4c & d). All parameters were well estimated 
when 6 to 15 animals were used per time point, and the estimates with 10 and 15 
animals per time point were significantly better than those with 2 to 5 animals per 
time (Fig. 8.4e). As expected, the least efficient estimates were obtained with the 
2 animals per time point design.
Cl was efficiently estimated with the use of 3 to 15 animals per time point 
when the inter-animal variability was 45% (Fig. 8.5a). V was well estimated with 
designs having 6 to 15 animals per time (Fig. 8.5b). Estimates obtained with 
designs having 8 to 15 animals per time point were significantly better than those
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(a) Estimation Cl
5 15 7 4 10 8 6 3 2  Animals per
time point
(b) Estimation of V
10 15 8 7  6 5 4 3 2  Animals per
time point
(c) Estimation of
8 10 15 6 7  3 5 4 2  Animals per
time point
(d) Estimation of Oy
15 7 4 10 6 8 5 2 3 Animals per
time point
(e) Overall Design Efficiency 
15 10 8 7  6 5 4 3 2  Animals per
time point
Fig. 8.5 aSummary of significant differences in the efficiency with which 
parameters were estimated by varying the number of animals sampled at each 
time point with inter-animal variability set at 45%. 
a - Rank order of design numbers increasing from left to right.
* - Efficiency measured with design number.
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(a) Estimation Cl
8 10 4 6 7  5 15 3 2 Animals per
time point
(b) Estimation of V
8 15 10 7 6 4  5 2 3 Animals per
time point
(c) Estimation of c^i 
6 8 7  5 10 15 4 2 3  Animals per
time point
(d) Estimation of
15 8 10 7 6 4 5  2 3  Animals per
time point
(e) Overall Design Efficiency 
15 8 10 7 6 5 4 3 2  Animals per
time point
Fig. 8.6 aSummary of significant differences in the efficiency with which 
parameters were estimated by varying the number of animals sampled at each 
time point with inter-animal variability set at 60%. 
a - Rank order of design numbers increasing from left to right.
* - Efficiency measured with design number.
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obtained with 2 to 5 animals per time point. C q  and Oy estimates were poorly 
estimated with all designs (Fig. 8.5c & d). Overall, parameters were better 
estimated with the use of 6 to 15 animals per time point (Fig. 8.5e). Estimates of 
similar efficiency were obtained with designs having 5 to 10 animals per time 
point. The most efficient estimates were obtained with the use of 15 animals at 
each time point. These estimates were significantly better than the estimates 
obtained with 2 to 5 animals per time point. Since the use of 6 to 15 animals at 
each time point produced parameter estimates with similar efficiency the use of 6 
animals per time in this type of study does not result in any significant loss in 
efficiency.
With and Oy equal to 60%, Cl was estimated with an equal efficiency 
with all the j * 1 designs (Fig. 8.6a). The designs with 6 to 15 animals per time 
point yielded more efficient estimates of V (Fig. 8.6b) than when 2 observations 
were used per time point. As with the previous results, and G y  were 
inefficiently estimated with all designs (Fig. 8.6 c & d). When considered as a set, 
all parameters were most efficiently estimated with 6 to 15 animals used at each 
time point (Fig 8.6e). Estimates obtained with 8 to 15 animals per time point were 
significantly better than those using 2 to 4 animals. Again, the use of 6 animals 
per time yielded equally efficient parameter estimates as 15.
8.4.1c Individual and Joint Confidence Intervals for Parameter Estimates
At the 15% level of inter-animal variability, good coverage was obtained 
for individual and joint parameter estimates when NONMEM runs with 
catastrophic estimates were included (Table 8.5, Section I). However, reduced 
coverage for joint parameter estimates was obtained with the use of 15 animals at 
each time point due to the bias associated with the estimation of the variance 
parameters. The influence of standard errors on confidence intervals coverage
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was only significant when 2 animals were used at each time point (Table 8.5, 
Section III).
Similarly, significantly reduced coverage for joint confidence intervals 
was obtained with the 2 observation per time point study design when the inter­
animal variability was set at 30% (Table 8.6, Section III). However, the joint 
coverage for parameter estimates was reduced (though not significantly lower 
than the expected value of 0.81) for designs with 3 to 5 animals per time point. 
When runs with catastrophic estimates were excluded in both the numerator and 
denominator during confidence intervals calculation, relatively good coverage 
was obtained for all study designs (Table 8.6, Section II), and the influence of 
bias was minimal (Table 8.6, Section I).
When the inter-animal variability was 45%, good coverage was obtained 
for individual and joint parameter estimates when catastrophic runs were included 
in the computation of confidence intervals coverage (Table 8.7, Section I). 
However, the coverage for the variance parameters and the joint coverage for 
parameter estimates were reduced when catastrophic runs were excluded in the 
numerator during the calculation of confidence intervals (Table 8.7, Section III). 
The reduced coverage obtained for and Oy using the 2 animals per time point 
design was significantly lower than the expected value of 0.95. Designs in which 
2 to 5 animals were used at each time point had joint coverage lower than the 
expected value of 0.81, due mostly to large standard errors.
Setting the inter-animal variability at 60% led to estimates whose 
confidence intervals coverage was good when NONMEM runs with "coefficient 
of variation" > 50% were included in the computation of the coverage (Table 8.8, 
Section I). However, reduced coverage was obtained for the variance parameters 
and the joint confidence intervals for parameter estimates when these NONMEM 
runs were excluded in the numerator during confidence intervals calculation 
(Table 8.8, Section IE). The coverage obtained for c^j (2 animals per time point)
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and G y  (2 and 3 animals per time point) and the joint confidence intervals for 
parameter estimates (2 to 5 animals per time point designs) was significantly 
lower than the expected value of 0.95 and 0.81, respectively (Table 8.8, Section 
ID).
Thus, as the inter-animal variability was increased, the coverage of 
interval estimates for the variance parameters and joint parameter estimates was 
reduced. At all levels of inter-animal variability, the joint coverage for parameter 
estimates was significantly lower than the expected value when 2 animals were 
used at each time point. On the other hand, significantly reduced coverage was 
only obtained for the joint confidence intervals at 45 and 60% level of inter­
animal variability with study designs having 3 to 5 animals per time point.
8.4. Id Incidence of High Pair-Wise Correlations
Greater than 0% incidence of high pair-wise correlation occurred between 
G y  and V, G y  and for most of the designs when the inter-animal variability 
was 15% (Table 8.9). The greatest incidence of 24.1% was obtained for the 
correlation between G y  and V with the 2 animals per time point design, and the 
incidence of high correlation between and Cl, and and V was 3.5 and 
10.3%, respectively, for the same design.
At the 30% level of inter-anim al variability the incidence of high 
correlation between G y  and V ranged from 3.3 (15 animals per time point) to 
21.4% (2 animals per time point) (Table 8.10). The incidence (> 0%) for the 
correlation between and V ranged from 3.3 (7 animals per time point) to 14.3 
(2 animals per time point). Also, the 2 animals per time point design yielded the 
highest incidence of correlation between V and Cl (3.6%), vs. Cl (3.6%), and 
Oy with (15.4%) (Table 8.10).
293
Ta
ble
 
8.1
0 
In
cid
en
ce
 
of 
Co
rr
ela
tio
n 
Va
lu
es
 A
sso
cia
ted
 
wi
th 
Pa
ra
m
ete
rs
 a
t 
30%
 
Va
ria
bi
lit
y 
in 
Cl 
and
 
V
in
00
VO
in
CO
cs
! o
§  1 i-H1
o
8
o
8
©
8
K 1 PI ©
O
o
o
o
o
o
! O
! 8
1 ^  1
o
8
o
8
o
8
33
0*0
0*0 oo
0*0
0*001
0*001
o
8
0001
33 i ° -I o
i
o
o
O
o
o
o
J
0001 96
.7
9
6
.7
0001
33
11
i ©  
i °
cq
CO
cq
CO
o
o
I ©
§i ^
o
8 96
.7 o
8
33
0*0 Oo
cq
CO
O
o
J
0*001 96
.7
8
6
.7
0001
33 1 §  ! ©
cq
CO
cq
CO
0*0
0001
o
8 vdOn
o
8
33
i ©
i °
0*0 cqCO
0*0
J
0001 96
.7
0
0
6
0001
33
0*0 cq
CO
o
o
0*0
9
6
.4
9
6
.4
8
5
.7
10
0.
0
33 vq
CO
vq
CO 14
.3
0*0
g !
g
1 n 0 > 0
1
>
>
>
£
>
P
>
t"*
VOOn
CO
CO
o
©
r-
voOs
CO
CO
CO
COON
r-
vd
vd00
CO
CO
CO
COOn
r-
vd
CO
CO00
i-*
vd
vq
00r-
O
o
o
o
o
o
o
o
r- vo 
vd vo* On On
CO Tf 
CO CO
o
o
vd00
CO
CO
o
d
vq
00
»-h m CS
294
b: 
L 
= 
Lo
w,
 C
or
re
lat
ion
 
co
ef
fic
ien
t 
< 
0.
75
Ta
ble
 
8.1
1 
In
cid
en
ce
 o
f 
Co
rre
lat
ion
 
Va
lue
s 
As
so
cia
ted
 
wi
th 
Pa
ra
m
ete
rs 
at 
45%
 
Va
ria
bil
ity
 
in 
Cl 
and
 
V
W-i
00
33
J
X
X
o O o O O o
8 8 8 8 8 81-H
O o o O O O
© o d o o o
o © VO o c-* o
8 8 VOOv 8 ON00 8
fH ▼H F^
o o tT O cn o
o o cn o of*H o
o o o O n o
8 8 cnO n 8 in 8fH
o o O n o rH o
o* o NO o S d
o VO o cn r**-
8fH
vd
ON
cn
O n 8 o\r - £
e
20
1 
&
I
VO
»n
cn
X
J
S3
J
S3
53
cs
o O n O
o cn VO o
o NO NO o
8fH vdO n VO*O n 8
o O
o cn cn o
o cn o o
8 £ 8fH 8
O o o
o cn o d
O n cn r - o
O n
O n’00 m'00 8
f-H r - cn O
o o
cn
O n*00 £ cs*00 *
r-
8
O ninr^
cs
00
cn
cn
vd
O n
n-h cn
s '
oo O
Pi 8
cs 
cs* cs
c n  O n
On 00 
00 00
t-* ^
©
o
©
NO On NO On o
d cn cn —H d
VO cs in On 00 cs
CS* in i«* 00 r-i in00On 00 00 00 r->
00 in cs 00
00 1—1 1—I cs’cs Tf
0C/3>
>
0  >  nC/3 C/3> >
0 > SM C/3 M> > >
«r <? &
295
b: 
L 
= 
Lo
w,
 C
or
rel
ati
on
 
co
ef
fic
ien
t 
< 
0.
75
Ta
ble
 
8.1
2 
In
cid
en
ce
 
of 
Co
rre
lat
ion
 
Va
lue
s 
As
so
cia
ted
 
wi
th 
Pa
ra
m
ete
rs 
at 
60%
 
Va
ria
bil
ity
 
in 
Cl 
and
 
V
in
OO
a
£
B
P
£CA
73
0
1
E9
55
VO
in
c n
X
K
S3
cs
o
©
o
o
o
o
o
8
O
o
r-
VO
ON
c n
c n
Ov
vo*
c n
c nOs
r*»
VO
o
£
c n  o  
«  2
o
o
00
o
8  
r * r  c n  
v o  c n  
00 ov
o c n p-*
o c n v d
o o o
8 8 8
o O o
o o o
9
6
.2 c ncs*
Ov 9
6
.2
00 00
c n r^* c n
vo VO p
cs*
Ov 8 Ov
Tp
K l>
c n o
Ov00 in vo
c n p" o
o
S ’
1—1
c n
00 VO vo
in
Ov
Ov*
P -
Ov
t" *
CS 00 00
8 8
o  o  
o  o
o
8
o
o
Tf
in
0000
o
o
00
in
Ov
r-
v dcs
o  r* 
o  v o  cs
in
Os 00
r-r-
cs
cs
cs
m
«n
VO
in
c n
cn
ooin
O
o
o  o  o
8 8 8
o  q o
ci 2  o
O  O  c n
8  8  Si
vo
v d
c n  v o  
c n  v d  r- O'
c n
H  c n
8  c n  v dg  ^  Ov
p
c n
vo vo H3 S §
o
o
Ov
0000
o
o
c n
oor-
Tf 1-H i—<cs
o >  G ► P
^ v w w ce> > ■ > > >
tP P & S’ t?-
296
b: 
L 
= 
Lo
w,
 C
or
rel
ati
on
 
co
ef
fic
ien
t 
< 
0.
75
When the inter-animal variability was 45%, the highest incidence of high 
pair-wise correlations was obtained when 2 observations were made at each time 
point (Table 8.11). A greater incidence of high correlation was obtained for the 
correlation between Oy and V for most study designs.
Similarly, a greater incidence of high pair-wise correlation was obtained 
for the correlation between Oy and V irrespective of the study design when the 
inter-animal variability was set at 60% (Table 8.12). More parameters were 
highly correlated with each other using the 2 animals per time point design than 
other designs.
Irrespective of the study design and the inter-animal variability, a greater 
incidence of high pair-wise correlation was obtained for Oy and V than any other 
parameter pair.
8.4.2 Effect of Varying the Error in Concentration Measurements
When 3 animals were used at each time point, there were 28, 29, and 27 
successful NONMEM runs with cG of 0, 15, and 30%, respectively. 30, 30, and 
28 successful runs were obtained for ce of 0, 15, and 30%, respectively when 5 
animals were measured at each time point, and with the 7 animals per time point 
design, 30, 29, and 28 successful NONMEM runs were obtained for ae of 0, 15, 
and 30%, respectively. The accuracy and precision of the fixed effect parameters 
were relatively unaffected by varying the error in concentration measurements. 
When cy was 15%, the estimates of inter-animal variability were less precise, as 
expected, and biased, and this trend was maintained for ae of 30%. Moreover, 
the estimates were significantly positively biased (Fig. 8.7 (a - d)). The bias in the 
estimation of inter-animal variability was unaffected by N§.
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Fig. 8.7(a & b) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for parameters. The horizontal panels show data obtained using 
= 0,15, and 30%. Only one observation was made on each animal. Each vertical 
expresses the bias and precision of the population parameter estimate. The inter- 
animal variability used was 30% (see methods). Significant (p < 0.05) biases are 
indicated by asterisks.
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Fig. 8.7(c & d) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for parameters. The horizontal panels show data obtained using au 
= 0,15, and 30%. Only one observation was made on each animal. Each vertical 
expresses the bias and precision of the population parameter estimate. The inter- 
animal variability used was 30% (see methods). Significant (p < 0.05) biases are 
indicated by asterisks.
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Fig. 8.8(a - c) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for parameters. The horizontal panels in each figure show results 
from different study designs. The first panel for each figure shows results with j *
1 designs which is used as a reference for comparing results obtained with the j *
2 designs (second panel, see methods). The j * 2 designs yielded total number of 
data points per data set equivalent to that obtained with the j * 1 designs but with 
the total number of animals halved. represents the total number of animals 
used for each study design and Nc, the sample size for each study design. o€ was 
set at 15%. Significant (p < 0.05) biases are indicated by asterisks.
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Fig. 8.8(d - f) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively) for parameters. The horizontal panels in each figure show results 
from different study designs. The first panel for each figure shows results with j *
1 designs which is used as a reference for comparing results obtained with the j *
2 designs (second panel, see methods). The j * 2 designs yielded total number of 
data points per data set equivalent to that obtained with the j * 1 designs but with 
the total number of animals halved. represents the total number of animals 
used for each study design and No, the sample size for each study design. oe  was 
set at 15%. Significant (p < 0.05) biases are indicated by asterisks.
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8.4.3 Effect of Keeping Ng Constant while Halving NA 
8.4.3a Bias and Precision
Ng was kept constant while the NA was reduced by a factor of 2 so that 
each animal supplied two concentration - time points (i.e., j * 2 designs) and NA 
equalled 15, 25, and 35, preserving the total number of data points (Ng). There 
were 14, 18, and 24 successful NONMEM runs for NA of 15, 25, and 35, 
respectively, compared to 29, 30, and 30 for the corresponding j * 1 designs. 
Most of the excluded NONMEM runs had spurious estimates of oe . The results 
for the j * 2 designs are shown in Fig. 8.8 (a - f) with the j * 1 designs included 
for reference. The estimation of the fixed effect parameters were relatively 
unaffected (Fig. 8.8a & b). The bias in the estimation of Oq  and Oy was 
significantly reduced (Fig. 8.8(d - f)) irrespective of Ng, but the precision of the 
estimates remained relatively unchanged. The relatively poorer precision for Gy 
obtained with NA of 35 (Ng = 70) as compared to 25 (Ng = 50) was due to the 
some estimates being at the ceiling of the cut off point for outliers. The bias in the 
estimation of ranged from -2.9% (NA = 35) to -13.7% (NA = 15), and the SD 
of %PE from 19.5% (Na  = 15) to 35.9% (NA = 35).
8.4.3b Incidence of High Pair-wise Correlations
A 100% incidence of high correlation was observed between ae and Cl 
irrespective of NA (Table 8.13). In addition, 13.3, 21.1, and 5.2% incidence of 
high correlation between and Oy was obtained for NA of 15, 25, and 35, 
respectively, while 40, 47.4, and 9.1% incidence was obtained with NA equal to 
15, 25, and 35, respectively, for the correlation between a6 and Oy. Parameter 
estimates were more highly correlated with each other when NA was 15 than 25 
or 35.
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Fig. 8.9(a - c) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively). The horizontal panels in each figure show results from different 
study designs. The first panel for each figure shows results with j * 1 designs 
which is used as a reference for comparing results obtained with the j * 2 designs 
(second panel, see methods). The j * 2 designs yielded total number of data points 
per data set twice that obtained with the j * 1 designs but with the total number of 
animals unchanged. N* represents the total number of animals used for each 
study design and Nc, the sample size for each design. a€ was set at 15%. 
Significant (p < 0.05) Diases are indicated by asterisks.
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Fig. 8.9(d - f) Bias and precision expressed as %PE (mean ± standard deviation, 
respectively). The horizontal panels in each figure show results from different 
study designs. The first panel for each figure shows results with j * 1 designs 
which is used as a reference for comparing results obtained with the j * 2 designs 
(second panel, see methods). The j * 2 designs yielded total number of data points 
per data set twice that obtained with the j * 1 designs but with the total number of 
animals unchanged. N* represents the total number of animals used for each 
study design and Nc, the sample size for each design. ae was set at 15%. 
Significant (p < 0.05)1)iases are indicated by asterisks.
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8.4.4 Doubling N§ without Changing NA
8.4.4a Bias and Precision
Again, each animal supplied 2 concentration - time points but NA 
equalled 30, 50, and 70 to keep the number of animals constant to allow 
comparison with the j * 1 designs. 16, 23, and 28 successful NONMEM runs 
were obtained with NA of 30, 50, and 70, respectively, compared to 30 (NA = 
30), 30 (NA = 50) and 30 (NA = 70) for j * 1 designs. The results presented 
herein are based on the successful runs. As in the previous study the accuracy 
with which the fixed effect parameters were estimated was relatively unaffected, 
but the precision was improved as expected (Fig. 8.9(a - c). The bias in the 
estimates of C£j and G y  was almost completely eliminated and the precision 
greatly improved (Fig. 8.9(d - f)). However, acceptably precise estimates of 
and G y  were only obtained with NA = 50 and 70 (i.e. Ng = 100 and 140, 
respectively).
In all the j * 2 designs the estimates of Ge were minimally biased, but 
acceptably precise. The mean of %PE ranged from -0.2% (NA = 70) to 6.0% (NA 
= 50), and the SD of %PE from 17.7% (NA = 70) to 24.6% (NA = 50). Spurious 
values of were responsible for the exclusion of most NONMEM runs.
8.4.4b Incidence of High Pair-wise Correlations
100% incidence of high correlation was obtained for the pair-wise 
correlation of a€ and Cl irrespective of NA (Table 8.13). Except for the 
correlation between cy and Gy in which the incidence of high correlation ranged 
from 6.3% (NA = 30) to 14.3% (NA = 70), and the correlation between Gy and V
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where the incidence was 6.3% for equal to 30, the incidence of all other pair­
wise correlations was less than 5.0%.
8.5 DISCUSSION
The fixed effect parameters were well estimated irrespective of the inter­
animal variability for most j * 1 designs. Inefficient estimates of Cl were obtained 
at the 60% level of inter-animal variability with the 2 animals per time point 
design. The accuracy of these estimates was relatively unaffected by increasing 
the number of animals sampled at each time. All inter-animal variability estimates 
were positively biased, and this highlights the difficulty when there is no 
inform ation on one of the components of variability  (in this case, aG ), 
emphasising the limitation of the one point per animal design. Estimates of 
variability associated with structural model parameters are considerably less 
precise, given a fixed number of experimental units, than are estimates of their 
means (Chapter 2, Section 2.5.3; Sheiner & Beal, 1981; Grasela et al., 1986). 
Some significant biases, associated with parameter estimates obtained with 
designs having a greater number of animals compared to the ones with fewer 
animals at each time point, were due to sample sizes being large enough to detect 
bias.
Since estimates were considered acceptably precise when the SD of %PE 
< 25%, the minimum number of animals required for reasonable estimation of 
population pharmacokinetic parameters with the one observation per animal 
design was 10 per time point if the inter-animal variability was between 15 and
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45%, and 15 when the inter-animal variability was 60%.
However, when the results were analysed using the design number 
approach in which the combined contributions of bias and precision are taken into 
account in determining the efficiency of parameter estimation, all parameters 
were estimated with similar efficiency when 6 to 15 animals were used per time 
point for all settings of and O y. Using this sampling strategy and the j * 1 
design, studies could be performed with at least 6 animals per time with no loss in 
the efficiency with which population parameters are estimated. This would result 
in savings in terms of the number of animals used and the time spent on such 
studies.
When the inter-animal variability was between 15 and 30%, Cl and V 
were efficiently estimated when 4 to 15 animals were used at each time point. 
Thus, as few as 4 animals per time could be used for the estimation of the fixed 
effect parameters with these settings of inter-animal variability, and O y were 
inefficiently estimated with all j * 1 designs due to a lack of information about 
ae .
When the inter-anim al variability was 45% and the estim ation of 
individual parameters were considered, Cl was well estimated using 3 to 15 
animals per time point while V was efficiently estimated with designs having 6 to 
15 animals per time point. As with previous levels of inter-animal variability 
considered, C£i and O y were inefficiently estimated.
With C£j (Oy) being 60%, the efficiency of Cl estimation was similar for 
all designs since the contributions of the bias and standard error terms in d>jr 
counter balanced each other, such that a comparison of the designs revealed 
nonsignificant differences. However, V was better estimated with designs in 
which 6 to 15 animals were used per time point. Thus, efficient estimation of Y 
would require more animals at each time point than Cl when the inter-animal 
variability is greater than 30%. Again, Cq  and O y were inefficiently estimated
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irrespective of the j * 1 design. The inefficiency with which the variance 
parameters were estimated was due to lack of information in the data sets on a€ 
as previously discussed.
Thus, the use of 6 to 15 animals at each time point in the estimation of 
population pharmacokinetic parameters would result in the production of 
reasonable estimates when the inter-animal variability is between 15 and 60%. 
Inefficient estimates were obtained with the 2 animals per time point design for 
all levels of inter-animal variability due to poor precision as seen, in the 
confidence intervals coverage for the variance parameters and joint parameter 
estimates when catastrophic runs were excluded. Poor precision was also 
responsible for significantly reduced coverage for joint confidence intervals when 
3 to 5 animals were measured at each time point with inter-animal variability set 
at 30 to 60%. The contribution of bias to the poor coverage (hence inefficient 
estimates) was minimal. However, bias was the major contributing factor to the 
reduced coverage obtained for G y  and joint confidence intervals for parameter 
estimates when 15 animals were used at each time point with the inter-animal 
variability set at 15%. Poorer estimation of the variance parameters could be due 
to higher incidence of pair-wise correlation involving these parameters.
When Ge was varied to examine its effect on the estimation of Gq  ^and 
G y , the magnitude of the bias in Cq and G y  increased with the magnitude of a£ , 
as expected, indicating that a substantial fraction of this bias was due to an error, 
i.e., the intra-animal error, which could not be partitioned. This finding confirms 
earlier observation by Graves et al. (1989). Using Monte Carlo simulation 
techniques, these authors generated data sets with error in concentration 
measurements without introducing inter-subject variability, and concluded that 
error in concentration measurements contributes significantly to large standard 
deviations associated with structural model parameters which could be interpreted
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as inter-individual variability in a real study situation.
Most NONMEM fixed effect parameter estimates derived from all studies 
with the j * 1 design showed a consistent significant negative bias. This was due 
to estimation error as negative biases in the estimation of these parameters were 
obtained even when a€ was set at 0%.
A trade - off between sample size and total number of animals (i.e., 
doubling the total number of observations (sampling an animal twice) while 
reducing the total number of animals sampled by half, produced a dramatic 
improvement in the estimation of inter-animal variability with a considerable 
reduction in bias. Accuracy was stable over the different population samples. The 
second sample practically eliminated bias and facilitated the partitioning of inter­
animal variability and residual error, by introducing information about oe . 
However, the estimates of c€ were unstable probably because of the correlation 
of ce with Cl and Oy. The correlation between ae and Oy was worse for N ^  
equal to 15 and 25.
Keeping N ^  constant as in the j * 1 designs while doubling N§ (j * 2 
designs) resulted in a significant improvement in the precision with which inter­
animal variability was estimated. This had no effect on the accuracy and precision 
of fixed effect parameters. The estimates of ae were more stable with significant 
high correlations occurring only between ce and Cl.
Doubling of the number of observations per animal results in savings in 
terms of the number of animals that are needed in this type of study. The j * 2 
design with N ^ equal to 30 animals yielded acceptably precise estimates of inter­
animal variability with no loss of efficiency. The use of this minimal number of 
animals with the j * 2 design and sampling strategy considered here would result 
in savings not only in animal number, but also in time and labour cost without 
sacrificing efficiency of parameter estimation.
The estimation of a set of population pharmacokinetic parameters
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provides limited information if there is no measure of the variability of each of 
the parameter estimates. Given the design specifications considered here, 
accuracy and precision in the estimation of inter-animal variability is significantly 
improved when the data set is enhanced by taking 2 observations per animal. In 
recent years, experimental methods have become available which permit serial 
blood sampling in small laboratory animals (Migdalof, 1976) . These sampling 
methods combined with modem approaches to population data analysis should 
lead to much more informative pharmacokinetic studies in small animals.
3 1 1
CHAPTER 9
GENERAL DISCUSSION AND CONCLUSION
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In pharmacokinetics, the rationale behind study design is the accurate and 
precise estimation of pharmacokinetic parameters. However, the overall objective 
of such studies is not only to learn about the average disposition of the drug in the 
study population, but also the interindividual variability. Indeed, the purpose of 
most animal pharmacokinetic studies is to estimate population parameters as a 
key step to quantifying individual animal response and population variability.
The traditional approaches (NPD and STS) to estimating population 
pharmacokinetic parameters in laboratory animals have been discussed in 
Chapters 1 and 2, and their limitations highlighted. The NPD approach provides 
no estimate of population variability, while the STS approach provides estimates 
of variability that are positively biased and requires a full concentration - time 
profile for each animal. On the other hand, NONMEM provides estimates of 
population param eters, their variances, and estim ated standard errors of 
parameters (Sheiner & Beal, 1981; 1983). The efficiency of this approach is the 
focus of this thesis.
In studies involving the use of inbred strains of small laboratory animals 
(e.g., rats or mice), in which each concentration - time point usually represents 
one animal, the NPD approach is the most common method of analysis (Loscher 
& Esenwein, 1978; Roberts & Renwick, 1989; Pritchard, Holmes, & Kirschman, 
1976). No estimate can be made of variability, although this may be up to 50% 
for some parameters (Lindstrom & Birkes, 1984; McArthur, 1988). Variability in 
the rate of oxidative metabolism of antipyrine by different inbred strains of rats 
has been reported, and Vocci and Farber (1988) advocated the consideration of 
variability within the same species in interspecies scaling. Thus, provision should 
be made for the estimation of variability inherent in the population sample in 
analysing data obtained by "destructive sampling". The NONMEM program was 
used in analysing data generated in the course of this thesis, and the majority of 
the data were simulated with the one observation per animal design.
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Pharmacokinetic data analysis is informative only if the data themselves 
are informative, and this can best be assured by appropriate experimental design. 
In designing experiments for efficient parameter estimation the following factors 
are taken into account: experimental error, number of samples taken, and the 
spacing of samples (Suverkrup, 1982).
In this thesis simulated data sets were used to investigate the effect of the 
various design features on the efficiency of parameter estimation using the one 
observation per animal design. Several methods were used to determine the 
efficiency of parameter estimation. The 99% individual and joint confidence 
intervals containing the true parameter 95% of the time for all parameters were 
introduced as aids to judging the efficiency with which individual and all 
parameters as a whole were estimated. The confidence intervals tables were 
constructed to reveal the influence of bias and standard error on parameter 
estimation.
In addition, the design number, a new statistic which combines the 
contributions of bias and precision in judging the efficiency of parameter 
estimation, was introduced to complement bias and precision, and the confidence 
intervals methods of analysis. The design number also allowed the efficiency with 
which all parameters of a model were estimated as a set to be judged. The 
incidence of high pair-wise correlations of parameter estimates was also taken 
into account in assessing the acceptability of estimates and the adequacy of model 
parameterization. Data were simulated using population parameters of a drug 
having the characteristics of avicin, a cytotoxic drug (McGovern et al., 1988), 
and assuming no covariance.
Using the one observation per animal design and assuming IV bolus 
injection with the monoexponential pharmacokinetic model, simulated data sets 
of different sample sizes (30 and 50) were employed to determine the influence of
314
inter-animal variability on parameter estimation (Chapter 3). The range of 
variability investigated was similar to that expected in real studies, and the 
traditional sampling strategy involving sampling animals at fixed times was used. 
Ten sampling times were specified between 5 and 240 min. using a simulated 
half-life (84 min.) of the drug (i.e., Cl and V of 1.3 ml/min. and 162.5 ml, 
respectively). It was observed that the fixed effect parameters (i.e., Cl and V) 
were precisely estimated at all combinations of inter-animal variability studied, 
but bias increased with increase in variability. These estimates were mostly 
negatively biased, and this was coupled with the overestimation of the variance 
parameters. The negative bias associated with the estimation of the fixed effect 
parameters was attributed to the nature of the NONMEM program (i.e. estimation 
error since negative bias was also observed in subsequent studies when oe was 
set at 0%). The overestimation of the variance parameters was attributed to the 
one observation per animal design since there was no information in the data set 
about ae .
The estimates of the fixed effect parameters were normally distributed 
while some of the variance parameters were nonnormal with right skewed 
distributions at large values of c^j and Oy (e.g., 60% * 60% combination). This 
right skewness was responsible for the good coverage of and Oy when the 
influence of standard errors was not considered. When the influence of standard 
errors was considered, poor coverage was obtained at high variability irrespective 
of sample size.
In studying the effect on parameter estimation of the spacing of sampling 
times with a fixed sample size (Chapter 4) using the two sample point design 
(one compartment model with IV bolus injection), efficient parameter estimation 
was obtained when the second sample was located at > 1.4 times the ty 2  ° f  the 
drug with the first sample obtained as early as possible (5 min.). When three or 
four samples were used, the exact location of the third or fourth sample was not
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critical to efficient parameter estimation. The fixed effect parameters were 
efficiently estimated with all designs. Irrespective of the design considered (i.e., 
two, three, or four sample points design), C q was efficiently estimated when the 
second, third, or fourth sample were located at > l-4 tj/2  ° f  the drug, Gy was 
poorly estimated with all sampling designs and this was attributable to lack of 
information about Ge in the simulated data sets. Metzler (1987) showed that 
NONMEM yielded poor estimates of volume, and although he did not estimate 
the variance parameters in his study, the poor estimates of Gy found in this work 
may be a feature of the NONMEM program.
Using the two compartment model (assuming IV bolus injection and 
sampling animals at set times), the efficiency of parameter estimation was 
examined over a range of parameter values with the model parameterized in terms 
of A, a , B, and p (Chapter 5). A and a  were efficiently estimated when a  was 
between 1.5 and 4.0 h"*, while B and p were efficiently estimated when a  was in 
the range 6.0 to 8.0 h"*. A and a, B and p were efficiently estimated at the higher 
(i.e. 20 to 40.0) and lower (i.e. 1.0 to 20.0) A:B ratios, respectively. The variance 
parameters were inefficiently estimated due to lack of information about ae . The 
parameters, considered as a set, were efficiently estimated when a  was in the 
range of 2.0 to 4.0 h"*, and the A:B ratio in the range 2.5 to 30.0. These results 
were attributed to the distribution of the data points between the distribution and 
elimination phases of the plasma concentration - time curve.
Also, A and a  were efficiently estimated when 3 to 12 and 3 to 7 times, 
respectively, were in the a  phase. However, a  was estimated with similar 
efficiency with designs having 3, 7, and 12 times in the a  phase. Inefficient 
estimates of B, and P were obtained when 12 times were in the a  phase because 
there were fewer samples in the p phase. Overall, designs with 5 to 7 times in the 
a  phase yielded efficient parameter estimates. However, the variance parameters
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were poorly estimated as a consequence of the one observation per animal design. 
The design with 12 times in the a  phase had greater incidences of high pair-wise 
correlations than other designs and, overall, yielded the least efficient estimates of 
parameters.
When the number of sampling times in the P phase was increased and the 
duration of sampling extended without altering the total number of samples, 
parameters were estimated with equal efficiency when the overall performance of 
the different sampling schedules (3, 6, and 8 times in the p phase) was examined. 
There was no loss in efficiency when the duration of sampling was reduced from 
10 h (8 times in P phase) to 6 h (3 times in the p phase). The schedule with 8 
times in the p phase was only significantly better than others in the estimation B 
and p.
However, most parameter estimates of the A, a , B, and P parameterization 
of the two compartment model were unstable due to greater incidences of high 
pair-wise correlations. Reparameterization of the model (Chapter 6) in terms of 
Cl, V, k j2» and ^ 21 rcsulted in more stable parameter estimates.
Observations made in a pharmacokinetic study are subject to two types of 
variability - biological variation (considered earlier) and errors in the analysis of 
samples. The influence of the latter on parameter estimation was also studied. 
Using both the one and two compartment open models with IV bolus injection, it 
was observed how the error in concentration measurements was added to the 
estimated inter-animal variability due to lack of knowledge about intra-animal 
variability. Thus, large inter-animal variability estimated in real studies involving 
the one observation per animal design could be misleading since it is actually a 
composite of inter- and intra-animal variability. Minimising experimental error is 
critical to efficient parameter estimation.
The 1986 Act on the protection of animals stipulates that use of animals 
for experimentation must be kept to the barest minimum, and, where possible,
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alternatives should be found. In the preclinical pharmacokinetic setting, the use of 
animals for accurate and precise estimation of population pharmacokinetic 
parameters is inescapable. However, a balance must be struck between minimal 
use of animals and efficient parameter estimation since the parameters so 
determined are used for extrapolation from one species to another, and more 
importantly man. Thus, the effect of sample size on parameter estimation was 
investigated with both one and two compartment open models. It was found that 
with the design specifications considered, the parameters of the one compartment 
model were estimated with equal efficiency when 6 to 15 animals were sampled 
destructively at each of ten time points (Chapter 8). Since there was no loss in 
efficiency when 6 animals are sampled per time (i.e., a sample size of 60), the 
costs involved in such studies could be greatly reduced. However, with serial 
micro-sampling of small laboratory animals, similar results could be obtained 
with at least 30 animals sampled twice with the same traditional sampling 
strategy. Sampling an animal at least twice allows the partitioning of inter- and 
intra-animal variability, almost eliminating bias in the estimation of the variance 
parameters. Using the two compartment model, 15 animals were required at each 
of ten time points for efficient parameter estimation. However, the loss in 
estimation efficiency with 10 animals sampled at each time point for ten time 
points was not dramatic with this model. The use of these numbers of animals 
with the design specifications considered in this thesis would strike a good 
balance between cost and good science.
In all studies reported in this thesis, most estimates of fixed effect 
parameters were associated with negative bias. This was due to estimation error 
since negative bias in these parameters was also observed in studies in which ae 
was set to 0%.
The design number was applied throughout the course of the thesis with
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the assumption that it was efficient although the determination of the power and 
efficiency of this statistic was outside the scope of this thesis. The rescaling of 
design numbers could, perhaps, be better done using the median, and this needs to 
be explored further.
The results of the simulation studies led to the application of NONMEM 
in the analysis of data obtained with the one observation per animal design for a 
drug under development (Chapter 7). The NONMEM analysis took into account 
that the samples came from a population with more variability than could be 
explained with experimental error. Parameter estimation without estimates of 
variability is of little value. NONMEM permitted the explanation of inter-animal 
variability in V j in terms of sex: efficient partitioning between inter- and intra­
animal variability would have required an increase in the number of samples per 
animal.
Thus, the influence of various design features on the efficiency of 
parameter estimation using the one observation per animal design has been 
investigated. Inefficient estimates of inter-animal variability are obtained with 
this design, but sampling an animal at least twice significantly improved the 
efficiency of parameter estimation. The fixed effect parameters, on the other 
hand, were efficiently estimated. The design number, individual and joint 
confidence intervals for parameter estimates, incidence of high pair-wise 
correlations in addition to bias and precision were found useful in judging the 
efficiency with which parameters were estimated individually or as a set.
3 1 9
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APPENDIX IA
PRED Subroutine for the 2 Compartment Model
SUBROUTINE PRED(ICALL,NEWIND,THETA,DATREC,INDXS,F,G,H)
C
C
C 2 COMP IV, 1ST DOSE, A, AL, B, BE 
C 
C 
C
DIMENSION THETA(4),DATREC(3),H(1),G(4),INDXS(1)
DOUBLE PRECISION THETA,F,G>H,T,EKT,XKE,EXPWCH,
+ A, AL,B,BE,E ALT ,EBET 
T=DATREC(2)
A=THETA(1)
AL=THETA(2)
B=THETA(3)
BE=THETA(4)
EALT=EXPWCH(-AL*T)
EBET=EXPWCH(-BE*T)
F=(A*EALT)+(B*EBET)
G(1)=EALT 
G(2)=-A*T*EALT 
G(3)=EBET 
C G(4)=-B*T*EBET 
C H(1)=F 
RETURN 
END
DOUBLE PRECISION FUNCTION EXPWCH(XX)
DOUBLE PRECISION XX 
IF(XX.LE.-50.) XX=-50.
IF(XX.GE.50.) XX=50.
EXPW CH=DEXP(XX)
RETURN
END
Note that G(4) was included in the subroutine when the effect of the number of 
sampling times in the p phase on parameter estimation was investigated.
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APPENDIX IB
PRED Subroutine for the Reparameterized 2 Compartment Model
SUBROUTINE PRED(IC ALL,NEWIND,THETA,D ATRECJNDXS ,F,G,H)
C
C 2COMP, IV, CL, VI, K12, K21 
C
DIMENSION THETA(4),D ATREC(3),INDXS (1 ),G(4),H( 1)
DOUBLE PRECISION THETA,G,H,F,CL,V1,K12,K21,
+DOSE,T,T21 ,Q,C 1 ,R,BE, AL,P,PP,C2,C3,C4,C5,C6, 
+C7,C8,A,B,DBE2,DBE1,DBE3,DBE4,DP1,DP2,DP3,DP4,
+DAL1,DAL2 JDAL3 J)AL4,DA 1 ,DA2,DA3,DA4,DB 1JDB2 JDB3,
+DB4,EA,EB,EALT,EBET,AT,BT
CL=THETA(1)
V1=THETA(2)
K12=THETA(3)
K21=THETA(4)
T=DATREC(2)
DOSE=200000.
T21=CIW1 
Q=K12+K21+T21 
C1=T21*K21 
R=DSQRT(Q*Q-4.*C 1)
BE=0.5*(Q-R)
AL=C1/BE
P=1./(CL*K21-V1*BE**2)
PP=P*P
C2=(K21 -BE)*BE
C3=2.0*V1*BE
C4=AL/BE
C5=(Cl-K21*BE)*DOSE
C6=K21 *P*DOSE
C7=C2*DOSE
C8=(K21-2*BE)*P*DOSE
A=DOSE*(Cl-BE*K21)*P
B=DOSE*C2*P
DBE2=0.5*(1.0-(Q-2.*K21)/R)/V1 
DBE1 =-T21 *DBE2 
DBE3=-BE/R 
DBE4=DBE3-0.5*T21/R 
DP1=PP*(BE**2-C3*DBE1)
DP2=PP*(C3*DBE2-K21)
DP3=PP*C3*DBE3
DP4=PP*(C3*DBE4-CL)
DAL1=-C1*BE/V1-C1*DBE1 
DAL2=AL/CL-C4*DBE2 
DAL3=-C4*DBE3 
D AL4=AL/K21 -C4*DBE4
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DA 1 =C5 *DP 1 -C1 *P*DOSE/V 1 - C6*DBE 1
DA2=C5*DP2+C6/V1-C6*DBE2
DA3=C5*DP3-C6*DBE3
D A4=C5 *DP4-C6*DBE4+P* (T21 -BE)*DOSE
DB1 =C7 *DP 1 +C8*DBE 1
DB2=C7*DP2+C8*DBE2
DB3=C7*DP3+C8*DBE3
DB4=C7*DP4+C8*DBE4+DOSE*P*BE
EA=AL*T
EB=BE*T
IF(EA.GE.50.) EA=50.
IF(EB.GE.50.) EB=50.
IF(EA.LE.-50.) EA=-50.
IF(EB.LE.-50.) EB=-50.
E ALT=EXP(-E A)
EBET=EXP(-EB)
AT=A*T
BT=B*T
F=A*EALT+B*EBET
G(1)=EALT*(DA1-AT*DAL1)+EBET*(DB1-BT*DBE1) 
G(2)=EALT*(DA2-AT*DAL2)+EBET*(DB2-BT*DBE2) 
C G(3)=EALT*(DA3-AT*DAL3)+EBET*(DB3-BT*DBE3) 
C G(4)=EALT*(DA4-AT*DAL4)+EBET*(DB4-BT*DBE4) 
C H(1)=F 
RETURN 
END
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APPENDIX IC
2 Compartment Model: PRED Subroutine for Modelling the 
Influence of Weight on Vj
SUBROUTINE PRED(ICALL,NE WIND,THETA,DATREC,INDXS,F,GJH)
C
C 2COMP. IV, CL,V1,K12,K21 
C
DIMENSION THETA(4),DATREC(4),INDXS(1),G(4),H(1)
DOUBLE PRECISION THETA,G,H,F,CL,V1,K12,K21,WT,
+DOSE,T,T21,Q,Cl,R,BE,AL,P,PP,C2,C3,C4,C5,C6,
+C7,C8ABJ)BE2J)BE1,DBE3DBE4,DP1J)P2,DP3J)P4,
+DAL1 ,DAL2 JDAL3 J)  AL4,D A 1 ,D A2,D A3,DA4,DB1JDB2 JDB3,
+DB4,EA,EBEALTEBET,AT,BT
CL=THETA(1)
K12=THETA(3)
K21=THETA(4)
T=DATREC(2)
WT=DATREC(4)
DOSE=WT*1000.
V1 =WT*THETA(2)
T21=CL/V1
Q=K12+K21+T21
C1=T21*K21
R=DSQRT(Q*Q-4.*C1)
BE=0.5*(Q-R)
AL=C1/BE
P= 1 ./(CL*K21 -V1 *BE**2)
PP=P*P
C2=(K21 -BE)*BE
C3=2.0*V1*BE
C4=AL/BE
C5=(Cl-K21*BE)*DOSE 
C6=K21 *P*DOSE 
C7=C2*DOSE 
C8=(K21-2.*BE)*P*DOSE 
A=DOSE*(C 1 -BE*K21) *P 
B=DOSE*C2*P
DBE2=0.5*(1.0-(Q-2.*K21)/R)/V1 
DBE1 =-T21 *DBE2 
DBE3=-BE/R 
DBE4=DBE3-0.5 *T21/R 
DP 1 =PP*(BE**2-C3*DBE 1)
DP2=PP* (C3 *DBE2-K21)
DP3=PP*C3*DBE3
DP4=PP*(C3*DBE4-CL)
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DAL 1 =-Cl *BE/V 1 -C1 *DBE 1
DAL2=AL/CL-C4*DBE2
DAL3=-C4*DBE3
DAL4=AL/K21-C4*DBE4
DA 1 =C5 *DP 1 -C1 *P*DOSE/V 1 -C6*DBE 1
DA2=C5*DP2+C6/V1-C6*DBE2
DA3=C5*DP3-C6*DBE3
D A4=C5 *DP4-C6*DBE4+P* (T21 -BE) *DOSE
DB1 =C7 *DP 1+C8 *DBE 1
DB2=C7*DP2+C8*DBE2
DB3=C7*DP3+C8*DBE3
DB4=C7 *DP4+C8 *DBE4+DOSE*P*BE
EA=AL*T
IF(EA.GE.50.) EA=50.
DF(EB.GE.50.) EB=50.
IF(EA.LE.-50.) EA=-50.
IF(EB.LE.-50.) EB=-50.
EALT=EXP(-EA)
EBET=EXP(-EB)
AT=A*T
BT=B*T
F=A*E ALT+B *EBET
G( 1 )=EALT* (DA 1 - AT*D AL1) +EBET* (DB 1 -BT*DBE 1) 
G(2)=EALT*(DA2-AT*DAL2)+EBET*(DB2-BT*DBE2) 
C G(3)=EALT*(DA3-AT*DAL3)+EBET*(DB3-BT*DBE3) 
C G(4)=EALT*(DA4-AT*DAL4)+EBET*(DB4-BT*DBE4) 
C H(1)=F 
RETURN 
END
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APPENDIX ID
2 Compartment Model: PRED Subroutine for Modelling the Influence 
of Sex and Weight on
SUBROUTINE PRED(IC ALL,NEWIND,THETA,D ATREC,INDXS ,F,G,H)
C
C 2COMP. IV, CL,V1,K12,K21 
C
DIMENSION THETA(5),DATREC(5),INDXS(1),G(2),H(1)
DOUBLE PRECISION THETA,GJI,F,CL,V1,K12,K21,WT, 
+DOSE,T,T21,Q,Cl,R,BE,AL,P,PP,C2,C3,C4,C5,C6,
+C7,C8,A,B»DBE2 JDBE1 ,DBE3,DBE4,DP1 JDP2,DP3,DP4,
+D AL1J )  AL2 JD AL3 ,D AL4,D A1J) A2JD A3 ,D A4JDB1JDB2 JDB 3,
+DB4,EA,EBJEALT3BET,AT,BT,SEX
CL=THETA(1)
V1=THETA(2)
K12=THETA(3)
K21=THETA(4)
T=DATREC(2)
WT=DATREC(4)
SEX=DATREC(5)
DOSE=WT*1000.
V1 =WT*THET A(2)
IF(SEX.GT. 1.0) V1 = V1 *THETA(5)
T21=CL/V1
Q=K12+K21+T21
C1=T21*K21
R=DSQRT(Q*Q-4.*C1)
BE=0.5*(Q-R)
AL=C1/BE
P=1./(CL*K21-V1*BE**2)
PP=P*P
C2=(K21-BE)*BE
C3=2.0*V1*BE
C4=AL/BE
C5=(Cl-K21*BE)*DOSE 
C6=K21 *P*DOSE 
C7=C2*DOSE 
C8=(K21-2.*BE)*P*DOSE 
A=DOSE*(Cl-BE*K21)*P
TJ— T V ^ Q P * P 9 * P
DBE2=0.5*(1.0-(Q-2.*K21)/R)/V1 
DBE1 =-T21 *DBE2 
DBE3=-BE/R 
DBE4=DBE3-0.5*T21/R 
DP1=PP*(BE**2-C3*DBE1)
DP2=PP*(C3*DBE2-K21)
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DP3=PP*C3*DBE3
DP4=PP*(C3*DBE4-CL)
DAL1=-C1*BE/V1-C1*DBE1
DAL2=AL/CL-C4*DBE2
DAL3=-C4*DBE3
D AL4=AL/K21 -C4*DBE4
DA 1 =C5 *DP 1 -C1 *P*DOSE/V 1 -C6*DBE 1
D A2=C5 *DP2+C6/V 1 -C6*DBE2
D A3=C5 *DP3-C6*DBE3
D A4=C5 *DP4-C6*DBE4+P* (T21 -BE) *DOSE
DB 1 =C7*DP1 +C8*DBE 1
DB2=C7*DP2+C8*DBE2
DB3=C7*DP3+C8*DBE3
DB4=C7*DP4+C8*DBE4+DOSE*P*BE
EA=AL*T
EB=BE*T
IF(EA.GE.50.) EA=50.
IF(EB.GE.50.) EB=50.
IF(EA.LE.-50.) EA=-50.
IF(EB.LE.-50.) EB=-50.
EALT=EXP(-EA)
EBET=EXP(-EB)
AT=A*T
BT=B*T
F=A*EALT+B*EBET
G( 1 )=EALT*(D A1 - AT*D AL1 )+EBET* (DB 1 -BT*DBE 1) 
G(2)=EALT*(DA2-AT*DAL2)+EBET*(DB2-BT*DBE2) 
C G(3)=EALT*(DA3-AT*DAL3)+EBET*(DB3-BT*DBE3) 
C G(4)=EALT*(DA4-AT*DAL4)+EBET*(DB4-BT*DBE4) 
C H(1)=F 
RETURN 
END
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APPENDIX IIA
Simulation Program Used to Investigate the Effect of Sample 
Size and Inter-animal Variability on Parameter Estimation with 
the 1 Compartment Model
C 1 S T  TWO TIMES F I X E D ,  REST RANDOMLY W IT HI N 3 0  MINS
C SAMPLING AT SET TIMES
C
PROGRAM DATA2
C
C CHAN 2 0  -  I N I T I A L  STAR TING  VALUES
C CHAN 3 0  -  NONMEM DATA F I L E
C CHAN 4 0  -  M IN IT A B  DATA F I L E
C
INTEGER RAN,GEN,BASE
COMMON / M I R N G / R A N ( 1 0 ) , G E N ( 1 0 ) , NW RD,B ASE ,M MOD ,F BA SE ,F MOD  
D IM EN SI O N T ( 2 0 )
C
C CLBAR = POPN CL VBAR = POPN VD
C SDCL = POPN SD CL SDV =  POPN SD VD
C SDC =  PROP ERROR I N  CONC DOSE =  DOSE
C NT =  NO OF TIMES NR =  NO OF R A T S / T I M E
C NSTART =  RANDOM SEEDS
C
R E A D ( 2 0 , * )  NSTART
R M A X = 2 . 0 * * 1 5 - 1 . 0
MAXINT=RMAX
CALL R A N S E T ( M A X I N T ,N S T A R T )
R E A D ( 2 0 , * )  C L B A R , S D C L , V B A R , S D V , S D C , D O S E , N T , N R  
R E A D ( 2 0 , * )  ( T ( I ) , 1 = 1 , NT)
DO 5 0 0  1 = 1 , NT 
DO 1 0 0  J = 1 , NR 
5 CALL NGAUSS ( C L , R N , C L B A R , S D C L )
I F  ( C L . L E . 0 . 0 )  GOTO 5  
1 0  CALL NGAUSS (V ,  RN,  VBAR,  SDV)
I F  ( V . L E . 0 . 0 )  GOTO 1 0
K E = C L / V
D V = D O S E / V
CALL URAND ( T l )
I F ( I . E Q . 1 . O R . I . E Q . 2 )  GO TO 3 0  
R E = 1 5  
R M = - 7 . 5  
GO TO 3 5  
3 0  R E = 0  
RM=0
3 5  T l =  T 1 * R E  + T ( I ) + RM 
EKET=EXPWCH( - K E  * T 1 )
C 1=DV*EK ET
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SDC1=SDC*C1
CALL NGAUSS ( C C , R N , C l , S D C 1 )
C1= CC
I F ( C l . L T . 0 . 1 . O R . C l . G T . 5 0 . 0 )  GO TO 5  
NN= ( ( 1 - 1 ) *NR) + J  
R I = F L O A T  (NN)
W R I T E ( 3 0 , 2 0 )  R I , T l , C l  
W R I T E ( 4 0 , 2 5 )  R I , C L , V , T l , C l  
1 0 0  CONTINUE  
5 0 0  CONTINUE  
2 0  FORMAT ( 3 F 8 . 2 )
2 5  FORMAT ( 5 F 8 . 2 )
STOP
END
FUNCTION EXPWCH(XX)
I F ( X X . L E . - 5 0 . )  X X = - 5 0 .
I F  ( X X . G E . 5 0 . )  X X = 5 0 .
EXPWCH=EXP(XX)
RETURN
END
SUBROUTINE R A N S E T ( M A X I N T , N S T R T )
COMMON / M I R N G / N R A N ( 1 0 ) , N G E N ( 1 0 ) , NW RD ,NBAS E,M MOD, FNBAS E,F MOD
M A X I = M A X I N T /4
I B = 0
N B A S E = 1
9 9  I F ( N B A S E . G T . M A X I ) G O  TO 1 0 0  
NBA SE= NBA SE * 4 
I B = I B + 1  
GO TO 9 9
1 0 0  N B A S E = 2 * * I B  
FNBA SE= NBA SE  
N W R D = 4 7 / I B + 1  
N R E M = 4 7 - I B * ( N W R D - 1 )
MMOD= 2  * *NREM 
FMOD=MMOD
DO 1 0 1  N = l , 1 0  
N R A N ( N ) = 0
1 0 1  N G E N ( N ) = 0  
N G E N ( 1 ) = 5
DO 2 0 0  1 = 1 , 1 4
NCARRY=0
DO 1 9 0  N = 1 , NWRD
N G E N ( N ) = N G E N ( N ) * 5 + N C A R R Y
NCARRY=0
IF(NGEN(N).LT.NBASE)GO TO 1 9 0  
N CARRY=NGEN(N)/NBASE 
NGEN(N)=NGEN(N)-NBASE *NCARRY 
1 9 0  CONTINUE 
2 0 0  CONTINUE
N S TART=N S TRT
I F ( N S T A R T . L E . 0 ) N S T A R T = 2 0 0 1  
N S T A R T = 2 * ( N S T A R T / 2 ) + 1  
DO 3 0 0  N = 1 , NWRD 
NTE MP= NST AR T/ NBA SE  
N R A N ( N ) = N S  TART-NTEMP * NBASE
3 2 9
3 0 0  NSTART=NTEMP  
RETURN 
END
SUBROUTINE URAND(FRAN)
COMMON / M I R N G / N R A N ( 1 0 ) , N G E N ( 1 0 ) , NWRD, N B A S E , MMOD, F N B A S E , FMOD 
D IM E N SI O N  N S U M ( I O )
DO 3 0  I S = 1 , NWRD 
3 0  N S U M ( I S ) = 0
DO 1 I G = 1 , NWRD 
N 2 = N W R D -I G + 1  
DO 1 I R = 1 , N 2  
I S = I R + I G - 1
NPROD=NRAN(IR)*NGEN(IG)
NHPROD=NPROD/NBASE - 
LPROD=NPROD-NHPROD * NBASE  
N S U M ( I S ) = N S U M ( I S ) +LPROD
I F ( I S . L T . N W R D ) N S U M ( I S + 1 ) = N S U M ( I S + 1 ) +NHPROD 
1 CONTINUE  
N2 =NW RD-1  
DO 5 I S = 1 , N2  
N CARRY=N S U M ( I S ) / N B A S E  
N S U M ( I S ) = N S U M ( I S ) - N C A R R Y  * NBASE  
N S U M ( I S + 1 ) = N S U M ( I S + 1 ) + N C A R R Y  
5 CONTINUE
NSUM(NWRD)=NSUM(NWRD)-MMOD*(NSUM(NWRD)/MMOD)
DO 2 0  I S = 1 , NWRD 
2 0  N R A N ( I S ) = N S U M ( I S )
FRAN =N S UM ( 1 )
DO 1 0  I S = 2 , NWRD 
1 0  F R A N = F R A N / F N B A S E + N S U M ( I S )
FRAN=FRAN/FMOD
RETURN
END
SUBROUTINE N G A U S S ( X , R N , A M , S D )
COMMON / M I R N G / N R A N ( 1 0 ) , N G E N ( 1 0 ) , NWRD,NBAS E,M MOD, FNBAS E,F MOD  
I F ( S D . N E . 0 . 0 ) GO TO 3 0  
X=AM 
RETURN 
3 0  S U M = 0 . 0
DO 2 0  1 = 1 , 1 0 0  
CALL URAND(R)
2 0  SUM=SUM+R
R N = ( S U M - 5 0 . ) / S Q R T ( 2 5 . / 3 . )
X=RN*SD+AM
RETURN
END
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APPENDIX I IB
Simulation Program for Investigating the Effect of Arrangement 
of Concentrations in Time
ONLY TIME 1 I S  F I X E D  
PROGRAM DATA1
CHAN 2 0  -  I N I T I A L  START ING VALUES  
CHAN 3 0  -  NONMEM DATA F I L E  
CHAN 4 0  -  M I N IT A B  DATA F I L E
INTEGER RAN,GEN,BASE
COMMON / M I R N G / R A N ( 1 0 ) , G E N ( 1 0 ) , NWRD ,B ASE ,M MOD ,FBA SE ,FM OD  
D IM EN SI O N T ( 2 0 )
CLBAR =  POPN CL VBAR =  POPN VD
SDCL =  POPN SD CL SDV =  POPN SD VD
SDC = PROP ERROR I N  CONC DOSE =  DOSE 
NT =  NO OF TIMES NR = NO OF R A T S / T I M E
NSTART =  RANDOM SEEDS
R E A D ( 2 0 , * )  NSTART
R M A X = 2 . 0 * * 1 5 - 1 . 0
MAXINT=RMAX
CALL RANSET(MAXINT,NSTART)
R E A D ( 2 0 , * )  C L B A R , S D C L , V B A R , S D V , S D C , D O S E , N T , NR  
R E A D ( 2 0 , * )  ( T ( I ) , 1 = 1 , NT)
DO 5 0 0  1 = 1 , NT 
DO 1 0 0  J = 1 , NR 
5  CALL NGAUSS ( C L , R N , C L B A R , S D C L )
I F  ( C L . L E . 0 . 0 )  GOTO 5  
1 0  CALL NGAUSS (V ,  RN,  VBAR,  SDV)
I F  ( V . L E . 0 . 0 )  GOTO 1 0
K E = C L / V
DV=DOSE/V
CALL URAND (Tl)
I F  ( I . E Q . 1 )  GO TO 3 0  
R E = 1 5  
R M = - 7 . 5  
GO TO 3 5  
3 0  R E = 0  
RM=0
3 5  T l =  T 1 * R E  + T ( I )  + RM 
E K E T = E X P W C H (- K E * T 1 )
C1=D V*EK ET
S D C 1 = S D C * C 1
3 3 1
CALL NGAUSS ( C C , R N , C l , S D C 1 )
C1=C C
I F ( C l . L T . 0 . 1 . O R . C l . G T . 5 0 . 0 )  GOTO 5  
NN= ( ( 1 - 1 ) *NR) +J 
R I = F L O A T  (NN)
W R I T E ( 3 0 , 2 0 )  R I , T l , C l  
W R I T E ( 4 0 , 2 5 )  R I , C L , V , T l , C l  
1 0 0  CONTINUE  
5 0 0  CONTINUE  
2 0  FORMAT ( 3 F 8 . 2 )
2 5  FORMAT ( 5 F 8 . 2 )
STOP
END
FUNCTION EXPWCH(XX)
I F ( X X . L E . - 5 0 . )  X X = - 5 0 .
I F ( X X . G E . 5 0 . )  X X = 5 0 .
EXPWCH=EXP(XX)
RETURN
END
SUBROUTINE RANSET(MAXINT,NSTRT)
COMMON / M I R N G / N R A N ( 1 0 ) , N G E N ( 1 0 ) , NWRD,NBASE, MMOD,FN BAS E,F MOD
M A X I = M A X I N T /4
I B = 0
N B A S E = 1
9 9  I F  ( N B A S E . G T . M A X I ) G O  TO 1 0 0  
NBASE=NBASE  * 4 
I B = I B + 1  
GO TO 9 9
1 0 0  N B A S E = 2 * * I B  
FNB AS E= NB ASE  
N W R D = 4 7 / I B + 1  
N R E M = 4 7 - I B * ( N W R D - 1 )
MMOD= 2  * *NREM 
FMOD=MMOD
DO 1 0 1  N = l , 1 0  
N R A N ( N ) = 0
1 0 1  N G E N ( N ) = 0  
N G E N ( 1 ) = 5
DO 2 0 0  1 = 1 , 1 4
NCARRY= 0
DO 1 9 0  N = 1 , NWRD
N G E N ( N ) = N G E N ( N ) * 5 + N C A R R Y
NCARRY=0
I F ( N G E N ( N ) . L T . N B A S E ) G O  TO 1 9 0  
N C A R R Y = N G E N ( N ) / N B A S E  
N G E N ( N ) = N G E N ( N ) - N B A S E  *NCARRY 
1 9 0  CONTINUE  
2 0 0  CONTINUE
NSTART=NSTRT
I F ( N S T A R T . L E . 0 ) N S T A R T = 2 0 0 1  
N S T A R T = 2 * ( N S T A R T / 2 ) + 1  
DO 3 0 0  N = 1 , NWRD 
NTE MP=N ST ART/ NB ASE  
N R A N ( N ) = N  S TART-NTEMP *NBASE  
3 0 0  NSTART=NTEMP
3 3 2
RETURN
END
SUBROUTINE URAND(FRAN)
COMMON / M I R N G / N R A N ( 1 0 ) , N G E N ( 1 0 ) , NWRD, N B A S E , MMOD, F N B A S E , FMOD 
DIM E N SI O N  N S U M ( 1 0 )
DO 3 0  I S = 1 , NWRD 
3 0  N S U M ( I S ) = 0
DO 1 I G = 1 , NWRD 
N 2 = N W R D - I G + 1  
DO 1 I R = 1 , N 2  
I S = I R + I G - 1
N P R O D = N R A N ( I R ) * N G E N ( I G )
NHPROD=NPROD/NBASE  
LPROD=NPROD-NHPROD*NBASE  
N S U M ( I S ) = N S U M ( I S ) + L P R O D
I F ( I S . L T . N W R D ) N S U M ( I S + 1 ) = N S U M ( I S + 1 ) + N H P R O D  
1 CONTINUE  
N 2 =NW RD-1  
DO 5 I S = 1 , N 2  
NCARRY=NSUM ( I S )  / N B A S E  
NSUM ( I S )  =NSUM ( I S )  -NCARRY*NBAS E  
N S U M ( I S + 1 ) = N S U M ( I S + 1 ) + N C A R R Y  
5  CONTINUE
NSUM(NWRD)=NSUM(NWRD)-MMOD*(NSUM(NWRD)/MMOD)
DO 2 0  I S = 1 , NWRD 
2 0  N R A N ( I S ) = N S U M ( I S )
FR AN=NSU M( 1 )
DO 1 0  I S = 2 , NWRD 
1 0  F R A N = F R A N / F N B A S E + N S U M ( I S )
FRAN=FRAN/FMOD
RETURN
END
SUBROUTINE N G A U S S ( X , R N , A M , S D )
COMMON / M I R N G / N R A N ( 1 0 ) , N G E N ( 1 0 ) , NWRD, N B A S E , MMOD, F N B A S E , FMOD 
I F ( S D . N E . 0 . 0 ) GO TO 3 0  
X=AM 
RETURN 
3 0  S U M = 0 . 0
DO 2 0  1 = 1 , 1 0 0  
CALL URAND(R)
2 0  SUM=SUM+R
R N = ( S U M - 5 0 . ) / S Q R T ( 2 5 . / 3 . )
X=RN*SD+AM
RETURN
END
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APPENDIX IIC
Simulation Pro9ram Used to Investigate the Effect of Sampling 
An Animal Twice on Parameter Estimation
THIS ASSUMES 10 TIMES
1ST TWO FIXED, REST RANDOMLY WITHIN 30MINS
THE VALUE PREVIOUSLY THE NO OF ANIMALS/TIME 
IS NOW THE NO OF ANIMALS/BLOCK 
EACH BLOCK HAS CONC TAKEN AT A DIFFERENT 
PAIR OF TIMES
I.E. 1 & 6, 2 & 7, 3 & 8, 4 & 9, 5 & 10
PROGRAM DATA3
CHAN 20 - INITIAL STARTING VALUES 
CHAN 30 - NONMEM DATA FILE 
CHAN 40 - MINITAB DATA FILE
INTEGER RAN,GEN,BASE
COMMON /MIRNG/RAN(10),GEN(10),NWRD,BASE,MMOD,FBASE,FMOD 
DIMENSION T (20)
CLBAR = POPN CL VBAR = POPN VD
SDCL = POPN SD CL SDV = POPN SD VD
SDC = PROP ERROR IN CONC DOSE = DOSE 
NT = NO OF TIMES NR = NO OF RATS/TIME
NSTART = RANDOM SEEDS
READ(20,*) NSTART 
RMAX=2.0**15-1.0 
MAXINT=RMAX
CALL RANSET(MAXINT,NSTART)
READ(20,*) CLBAR,SDCL,VBAR,SDV,SDC,DOSE,NT,NR 
READ(20,*) (T(I),1=1,NT)
NBL=NT/2 
DO 500 1=1,NBL 
DO 100 J=1,NR 
5 CALL NGAUSS (CL,RN,CLBAR,SDCL)
IF (CL.LE.0.0) GOTO 5 
10 CALL NGAUSS (V,RN,VBAR,SDV)
IF (V.LE.0.0) GOTO 10
KE=CL/V
DV=DOSE/V
CALL URAND (Tl)
IF(I .E Q .1.OR.I .EQ .2) GO TO 30
RE=15
RM=-7.5
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GO TO 35 
30 RE=0 
RM=0
35 Tl= T1*RE + T(I) + RM 
EKET=EXPWCH(-KE*T1)
C1=DV*EKET
SDC1=SDC*C1
CALL NGAUSS (CC,RN,Cl,SDC1)
C1=CC
IF (Cl.LT.0.1.OR.Cl.GT.50.0) GO TO 5 
11=1+5
CALL URAND (T2)
IF (II.EQ.1.OR.II.EQ.2) GO TO 300 
RE=15 
RM=-7.5 
GO TO 305 
300 RE=0 
RM=0
305 T2= T2*RE + T(II) + RM 
EKET=EXPWCH(-KE*T2)
C2=DV*EKET
SDC2=SDC*C2
CALL NGAUSS (CC,RN,C2,SDC2)
C2=CC
IF(C2.LT.0.1.OR.C2.GT.50.0) GO TO 5 
NN=((1-1)*NBL)+J 
RI=FLOAT (NN)
WRITE(30,20) RI,Tl,Cl,RI,T2,C2 
WRITE(40,25) RI,CL,V,Tl,Cl,T2,C2 
100 CONTINUE 
500 CONTINUE 
20 FORMAT (3F8.2,/,3F8.2)
25 FORMAT (7F8.2)
STOP
END
FUNCTION EXPWCH(XX)
IF (XX.LE.-50.) XX=-50.
IF(XX.GE.50.) XX=50.
EXPWCH=EXP(XX)
RETURN
END
SUBROUTINE RANSET(MAXINT,NSTRT)
COMMON /MIRNG/NRAN(10),NGEN(10),NWRD,NBASE,MMOD,FNBASE,FMOD
MAXI=MAXINT/4
IB=0
NBASE=1
99 IF(NBASE.GT.MAXI)GO TO 100 
NBASE=NBASE * 4 
IB=IB+1 
GO TO 99 
100 NBASE=2**IB 
FNBASE=NBASE 
NWRD=47/IB+1 
NREM=47-IB*(NWRD-1)
MMOD=2 * *NREM
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FMOD=MMOD 
DO 101 N=1,10 
NRAN(N)=0 
101 NGEN(N)=0 
NGEN(1)=5 
DO 200 1=1,14 
NCARRY=0 
DO 190 N=1,NWRD 
NGEN (N)=NGEN(N)*5+NCARRY 
NCARRY=0
IF (NGEN (N) .LT.NBASE)GO TO 190 
NCARRY=NGEN(N)/NBASE 
NGEN(N)=NGEN(N)-NBASE*NCARRY 
190 CONTINUE 
200 CONTINUE
NSTART=NSTRT
IF(NSTART.LE.0)NSTART=2001 
NSTART=2*(NSTART/2)+1 
DO 300 N=1,NWRD 
NTEMP =N S TART/NBASE 
NRAN(N)=NSTART-NTEMP*NBASE 
300 NSTART=NTEMP 
RETURN 
END
SUBROUTINE URAND(FRAN)
COMMON /MIRNG/NRAN(10),NGEN(10)/NWRD,NBASE,MMOD,FNBASE/FMOD 
DIMENSION NSUM(10)
DO 30 IS=1,NWRD 
30 NSUM(IS)=0
DO 1 IG=1,NWRD 
N2=NWRD-IG+1 
DO 1 IR=1,N2 
IS=IR+IG-1
NPROD=NRAN(IR)*NGEN(IG)
NHPROD=NPROD/NBASE 
LPROD=NPROD-NHPROD*NBASE 
NSUM(IS)=NSUM(IS)+LPROD
IF(IS.LT.NWRD)NSUM(IS+1)=NSUM(IS+1)+NHPROD 
1 CONTINUE 
N2=NWRD-1 
DO 5 IS=1,N2 
NCARRY=NSUM (IS) /NBASE 
NSUM (IS) =NSUM (IS) -NCARRY*NBASE 
NSUM(IS+1)=NSUM(IS+1)+NCARRY 
5 CONTINUE
NSUM(NWRD)=NSUM(NWRD)-MMOD*(NSUM(NWRD)/MMOD)
DO 20 IS=1,NWRD 
20 NRAN(IS)=NSUM(IS)
FRAN=NSUM(1)
DO 10 IS=2,NWRD 
10 FRAN=FRAN/FNBASE+NSUM(IS)
FRAN=FRAN/FMOD
RETURN
END
SUBROUTINE NGAUSS(X,RN,AM,SD)
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COMMON /MIRNG/NRAN(10),NGEN(10),NWRD,NBASE,MMOD,FNBASE,FMOD 
IF(SD.NE.0.0)GO TO 30 
X=AM 
RETURN 
30 SUM=0.0
DO 20 1=1,100 
CALL URAND(R)
20 SUM=SUM+R
RN=(SUM-50.)/SQRT(25./3.)
X=RN*SD+AM
RETURN
END
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APPENDIX IID
Simulation Program for the 2 Compartment Model
C SAMPLING AT SET TIMES
C
PROGRAM DATA4
C
C CHAN 20 - INITIAL STARTING VALUES
C CHAN 30 - NONMEM DATA FILE
C CHAN 40 - MINITAB DATA FILE
C
INTEGER RAN,GEN,BASE
COMMON /MIRNG/RAN(10),GEN(10),NWRD,BASE,MMOD,FBASE,FMOD 
DIMENSION T (20)
C
C ABAR=POPN A BBAR=POPN B ALBAR=POPN AL
C SDA=POPN SD A SDB=POPN SD B SDAL=POPN SD AL
C BEBAR=POPN BE SDBE=POPN SD BE
C SDC = PROP ERROR IN CONC DOSE = DOSE
C NT = NO OF TIMES NR = NO OF RATS/TIME
C NSTART = RANDOM SEEDS
C
READ(20,*) NSTART 
RMAX=2,0**15-1.0 
MAXINT=RMAX
CALL RANSET(MAXINT,NSTART)
READ(20,*) ABAR,SDA,ALBAR,SDAL,BBAR,SDB,BEBAR,SDBE,SDC, 
+DOSE,NT,NR 
READ(20,*) (T(I),1=1,NT)
DO 500 1=1,NT 
DO 100 J=1,NR 
5 CALL NGAUSS (A,RN,ABAR,SDA)
IF (A.LE.0.0) GO TO 5 
10 CALL NGAUSS (AL,RN,ALBAR,SDAL)
IF (AL.LE.0.0) GO TO 10 
15 CALL NGAUSS (B,RN,BBAR,SDB)
IF (B.LE.0.0) GO TO 15 
30 CALL NGAUSS(BE,RN,BEBAR,SDBE)
IF (BE.LE.0.0) GO TO 30 
CALL URAND(Tl)
IF(I .E Q .1.OR.I .EQ .2) GO TO 35 
RE=0.25 
RM=-0.125 
GO TO 40 
35 RE=0 
RM=0
40 Tl= T1*RE + T(I) + RM 
EALT=EXPWCH(-AL*T1)
EBET=EXPWCH(-BE * T1)
C1=A*EALT+B*EBET
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SDC1=SDC*C1
CALL NGAUSS (CC,RN,Cl,SDC1)
C1=CC
IF(Cl.LT.10.0.OR.Cl.GT.20000.0) GO TO 5 
NN= ((I—1)*NR) +J 
RI=FLOAT (NN)
WRITE(30,20) RI,Tl,Cl 
WRITE(40,25) RI,A,AL,B,BE,Tl,Cl 
100 CONTINUE 
500 CONTINUE 
20 FORMAT (3F10.2)
25 FORMAT (7F10.2)
STOP
END
FUNCTION EXPWCH(XX)
IF(XX.LE.-50.) XX=-50.
IF(XX.GE.50.) XX=50.
EXPWCH=EXP(XX)
RETURN
END
SUBROUTINE RANSET(MAXINT,NSTRT)
COMMON /MIRNG/NRAN(10),NGEN(10),NWRD,NBASE,MMOD,FNBASE,FMOD
MAXI=MAXINT/4
IB=0
NBASE=1
99 IF(NBASE.GT.MAXI)GO TO 100 
NBAS E=NBAS E * 4 
IB=IB+1 
GO TO 99
100 NBASE=2**IB 
FNBASE=NBASE 
NWRD=47/IB+1 
NREM=47-IB*(NWRD-1)
MMOD=2 * *NREM 
FMOD=MMOD
DO 101 N=l,10 
NRAN(N)=0
101 NGEN(N)=0 
NGEN(1)=5
DO 200 1=1,14
NCARRY=0
DO 190 N=1,NWRD
NGEN(N)=NGEN(N)*5+NCARRY
NCARRY=0
IF(NGEN(N).LT.NBASE)GO TO 190 •
NCARRY=NGEN(N)/NBASE 
NGEN(N)=NGEN(N)-NBASE*NCARRY 
190 CONTINUE 
200 CONTINUE
NSTART=NSTRT
IF(NSTART.LE.0)NSTART=2001
NSTART=2*(NSTART/2)+1
DO 300 N=1,NWRD
NTEMP=NSTART/NBASE
NRAN(N)=NSTART-NTEMP*NBASE
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300 NSTART=NTEMP 
RETURN 
END
SUBROUTINE URAND(FRAN)
COMMON /MIRNG/NRAN(10),NGEN(10),NWRD,NBASE,MMOD,FNBASE,FMOD 
DIMENSION NSUM(10)
DO 30 IS=1/NWRD 
30 NSUM(IS)=0
DO 1 IG=1,NWRD 
N2=NWRD-IG+1 
DO 1 IR=1,N2 
IS=IR+IG-1
NPROD=NRAN(IR)*NGEN(IG)
NHPROD=NPROD/NBASE 
LPROD=NPROD-NHPROD*NBASE 
NSUM(IS)=NSUM(IS)+LPROD
IF(IS.LT.NWRD)NSUM(IS+1)=NSUM(IS+1)+NHPROD 
1 CONTINUE 
N2=NWRD-1 
DO 5 IS=1,N2 
NCARRY=NSUM(IS)/NBASE 
NSUM(IS)=NSUM(IS)-NCARRY*NBASE 
NSUM(IS+1)=NSUM(IS+1)+NCARRY 
5 CONTINUE
NSUM(NWRD)=NSUM(NWRD)-MMOD*(NSUM(NWRD)/MMOD)
DO 20 IS=1,NWRD 
20 NRAN(IS)=NSUM(IS)
FRAN=NSUM(1)
DO 10 IS=2,NWRD 
10 FRAN=FRAN/FNBASE+NSUM(IS)
FRAN=FRAN/FMOD
RETURN
END
SUBROUTINE NGAUSS(X,RN,AM,SD)
COMMON /MIRNG/NRAN(10),NGEN(10),NWRD,NBASE,MMOD,FNBASE,FMOD 
IF(SD.NE.0.0)GO TO 30 
X=AM 
RETURN 
30 SUM=0.0
DO 20 1=1,100 
CALL URAND(R)
20 SUM=SUM+R
RN=(SUM-50.)/SQRT(25./3.)
X=RN*SD+AM
RETURN
END
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APPENDIX IIE
Simulation Program for the Reparameterized 2 Compartment Model
C SAMPLING AT SET TIMES
C
PROGRAM DATA9
C
C CHAN 20 - INITIAL STARTING VALUES
C CHAN 30 - NONMEM DATA FILE
C CHAN 40 - MINITAB DATA FILE
C
INTEGER RAN,GEN,BASE
COMMON /MIRNG/RAN(10),GEN(10),NWRD,BASE,MMOD,FBASE,FMOD
DIMENSION T (20)
C
C CLBAR=POPN CL VlBAR=POPN VI P12BAR=POPN P12
C SDCL=POPN SD CL SDV1=P0PN SD VI SDP12=POPN SD P12
C P21BAR=POPN P21 SDP21=POPN SD P21
C SDC = PROP ERROR IN CONC DOSE = DOSE
C NT = NO OF TIMES NR = NO OF RATS/TIME
C NSTART = RANDOM SEEDS
C
READ(20,*) NSTART
RMAX=2.0**15-1.0
MAXINT=RMAX
CALL RANSET(MAXINT,NSTART)
READ(20,*) CLBAR,SDCL,V1BAR,SDV1,P12BAR,SDP12,P21BAR,SDP21, 
+SDC,DOSE,NT,NR 
READ(20,*) (T (I),1=1,NT)
DO 500 1=1,NT 
DO 100 J=1,NR 
5 CALL NGAUSS (CL,RN,CLBAR,SDCL)
IF (CL.LE.0.0) GO TO 5 
10 CALL NGAUSS (VI,RN,V1BAR,SDV1)
IF (V1.LE.0.0) GO TO 10 
15 CALL NGAUSS (P12,RN,P12BAR,SDP12)
IF (P12.LE.0.0) GO TO 15 
30 CALL NGAUSS(P21,RN,P21BAR,SDP21)
IF (P21.LE.0.0) GO TO 30 
CALL URAND(Tl)
IF(I .E Q .1.OR.I .E Q .2) GO TO 35 
RE=0.25 
RM=-0.125 
GO TO 40 
35 RE=0 
RM=0
40 Tl= T1*RE + T(I) + RM 
P=P12+P21+CL/V1 
Q=SQRT(P**2-4.*P21*CL/V1)
A=(DOSE/VI)*(0.5*(P/Q+l)-P21/Q)
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B=(DOSE/VI)*(P21/Q-0.5*(P/Q-1.0) )
EALT=EXPWCH(-0.5*(P+Q)*T1)
EBET=EXPWCH(-0.5*(P-Q)*T1)
F=A*EALT+B*EBET
C1=A*EALT+B*EBET
SDC1=SDC*C1
CALL NGAUSS (CC,RN,Cl,SDC1)
C1=CC
IF (Cl.LT.10.0.OR.Cl.GT.20000.0) GO TO 5 
NN= ( (I — 1)*NR) +J 
RI=FLOAT (NN)
WRITE(30,20) RI,Tl/Cl 
WRITE(40,25) RI,CL,VI,P12,P21,Tl,Cl 
100 CONTINUE 
500 CONTINUE 
20 FORMAT (3F10.2)
25 FORMAT (7F10.2)
STOP
END
FUNCTION EXPWCH(XX)
IF(XX.LE.-50.) XX=-50.
IF(XX.GE.50.) XX=50.
EXPWCH=EXP(XX)
RETURN
END
SUBROUTINE RANSET(MAXINT,NSTRT)
COMMON /MIRNG/NRAN(10),NGEN(10),NWRD,NBASE,MMOD,FNBASE,FMOD
MAXI=MAXINT/4
IB=0
NBASE=1
99 IF(NBASE.GT.MAXI)GO TO 100 
NBASE=NBASE * 4 
IB=IB+1 
GO TO 99
100 NBASE=2**IB 
FNBASE=NBASE 
NWRD=47/IB+1 
NREM=47-IB*(NWRD-1)
MMOD=2 * *NREM 
FMOD=MMOD
DO 101 N=1,10 
NRAN(N)=0
101 NGEN(N)=0 
NGEN(1)=5
DO 200 1=1,14
NCARRY=0
DO 190 N=1,NWRD
NGEN(N)=NGEN(N)*5+NCARRY
NCARRY=0
IF(NGEN(N).LT.NBASE)GO TO 190 
NCARRY=NGEN(N)/NBASE 
NGEN(N)=NGEN(N)-NBASE*NCARRY 
190 CONTINUE 
200 CONTINUE
N S TART=N S TRT
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IF(NSTART.LE.0)NSTART=2001 
NSTART=2*(NSTART/2)+1 
DO 300 N=1,NWRD 
NTEMP=NS TART/NBASE 
NRAN(N)=NS TART-NTEMP *NBASE 
300 NSTART=NTEMP 
RETURN 
END
SUBROUTINE URAND(FRAN)
COMMON /MIRNG/NRAN(10),NGEN(10)/NWRD/NBASE,MMOD,FNBASE,FMOD 
DIMENSION NSUM(10)
DO 30 IS=1,NWRD 
30 NSUM(IS)=0
DO 1 IG=1,NWRD 
N2=NWRD-IG+1 
DO 1 IR=1,N2 
IS=IR+IG-1
NPROD=NRAN(IR)*NGEN(IG)
NHPROD=NPROD/NBASE 
LPROD=NPROD-NHPROD*NBASE 
NSUM(IS)=NSUM(IS)+LPROD
IF(IS.LT.NWRD)NSUM(IS+1)=NSUM(IS+1)+NHPROD 
1 CONTINUE 
N2=NWRD-1 
DO 5 IS=1/N2 
NCARRY=NSUM(IS)/NBASE 
NSUM(IS)=NSUM(IS)-NCARRY*NBASE 
NSUM(IS+1)=NSUM(IS+1)+NCARRY 
5 CONTINUE
NSUM(NWRD)=NSUM(NWRD)-MMOD*(NSUM(NWRD)/MMOD)
DO 20 IS=1,NWRD 
20 NRAN(IS)=NSUM(IS)
FRAN=NSUM(1)
DO 10 IS=2,NWRD 
10 FRAN=FRAN/FNBASE+NSUM(IS)
FRAN=FRAN/FMOD
RETURN
END
SUBROUTINE NGAUSS ( X , RN,AM,SD)
COMMON /MIRNG/NRAN(10)/NGEN(10),NWRD,NBASEtMMODtFNBASE,FMOD 
IF(SD.N E .0.0)GO TO 30 
X=AM 
RETURN 
30 SUM=0.0
DO 20 1=1/100 
CALL URAND(R)
20 SUM=SUM+R
RN=(SUM-50.)/SQRT(25./3.)
X=RN*SD+AM
RETURN
END
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